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1.1 Haematopoiesis 
The human blood consists of many different kinds of blood cells. There are the red 
blood cells (erythrocytes) and the white blood cells (leukocytes), further subdivided 
into blood cells like lymphocytes, granulocytes, monocytes etc. Those cell types 
have all different purposes ranging from transportation, wound healing or support of 
the immune system. The erythrocytes are for transportation and carry the oxygen or 
carbon dioxide through the blood stream. White blood cells or leukocytes include 
various cell types divided into four sub groups. Group one are the granulocytes 
containing neutrophils, eosinophils and basophils which destroy invading bacteria or 
parasites, secrete histamine and play a role in modulating allergic inflammation 
reactions. Group two consists of the monocytes which infiltrate the blood vessel 
surrounding tissue and differentiate to macrophages to fight pathogens or destroy 
damaged cells. The third group are the lymphocytes which consist of B-cells, mainly 
antibody producers, T-cells which play an important role in inflammation and 
regulating other immune cells. The last cell type in this group is the natural killer cell 
(NK-cell). NK cells kill virus infected cells and have been reported to kill gastric 
tumour cells (Miller, 2001). There are also thrombocytes in the blood which are 
small cell fragments produced by megakaryocytes in the bone marrow. On the other 
hand they support wound healing and coagulation. 
All of these blood cells are derived from pluripotent haematopoietic stem cells (HSC) 
in the bone marrow. Pluripotent stem cells create progenitor cells with a 
predetermined fate (Figure 1-1). 
HSCs are generated by a process called haematopoiesis and have been classified 
depending on their capacity to self-renew. In the beginning there are long-term self 
renewing HSCs which generate then other more short living HSCs resulting in 
pluripotent progenitors without self-renewal capacity (Reya et al., 2001).  
HSCs occupy niches in the bone marrow. A niche is a microenvironment which 
consists of supporting cells providing necessary cytokines for self renewal and 
differentiation ability (Yin and Li, 2006). 
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The differentiation process of a HSC can result in a myeloid or a lymphoid 
progenitor cell. Following the lineage determination a series of differentiation steps 
leads first to the progenitor cell and then to a precursor cell. Progenitor cells still 
divide at a high rate, although numbers of cell divisions are limited. Continued 
differentiation of the precursors finally produces the fully differentiated and mature 
blood cell (Alberts, 2002). 
 In summary it can be stated that the haematopoiesis of HSCs is a delicate and a 
critical sequence of incidents with highly and tightly regulated processes. These 
processes are proliferation, maturation and differentiation. The tight regulation is 
necessary as for example many leukocytes are very short living and need to be 
replaced constantly. The half life of neutrophils in the peripheral blood for example 
lies between 8 and 10 hours which means there have to be ensured strictly controlled 
mechanisms for proper differentiation during the 10 to 14 days of their maturation. 
This maintains a constant level of neutrophils in the peripheral blood (Speck, 2001). 
Disruption of this process can lead to a disordered form of haematopoiesis called 
leukaemia, the cancer of the blood. 
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Figure 1-1 Overview of haematopoiesis 
An overview of the haematopoiesis; Self-renewing haematopoietic stem cells produce 
common lymphoid (CLP) or common myeloid (CMP) progenitors which then differentiate 
into the different subtypes. (adapted from www.bloodlines.stemcells.com)  
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1.2 Leukaemia 
Leukaemia [greek: λευχαιµία; λευκος (leukos): white and αίµα (aima) blood] is a 
disease of the blood. Characteristic for the disease is an abnormal increase of 
leukocytes and their precursors the leukoblasts in bone marrow and blood. Further 
characteristics are the ability of self renewal and impaired ability in haematopoietic 
differentiation (Speck, 2001). Leukaemia is classified in two major subgroups, the 
acute form and the chronic form of leukaemia. 
Characteristic for the chronic leukaemias is the massive production of relatively 
mature but malignant leukoblasts and the disease is commonly diagnosed in adults. 
While acute forms have to be treated immediately, chronic forms can be monitored 
for some time before treatment to reach the highest efficiency of the therapy. Due to 
the slow progression of the chronic form of leukaemia it is difficult to diagnosis them 
in early stages. But once diagnosed it is possible to monitor the disease and apply the 
right form of therapy at its most effective time. The ten years event-free-survival lies 
currently between 55 and 70 percent. Nevertheless new forms of treatment are 
currently under investigation. For example a new agent, called imatinib (Gleevec ©, 
Novartis) has been primarily developed for treatment of t(9;22) BCR/ABL positive 
CML (Table 1) and is currently being monitored in clinical trials. Imatinib is an 
inhibitor of the ABL kinase. Actual studies show a 5 year event-free survival of 
about 90 % (Fausel, 2007). 
This work is focused on acute forms of leukaemia where a rapid production and 
bloodstream infiltration with immature blood cells is characteristic for this 
progressive disease. In acute leukaemia the lymphoblasts inundate the bone marrow 
and the blood thereby displacing healthy cells. Other infiltrated organs are liver, 
spleen and lymph nodes. As consequence, the function of the blood system is 
severely disturbed which if left untreated leads to death within several weeks or 
months. While chronic forms of leukaemia are generally detected in adults, acute 
form, especially acute lymphoblastic leukaemia is also often diagnosed in young 
people and infants (Figure 1-2). 
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To further determine the type of leukaemia a second classification is necessary. It is 
important to know the lineage of cells from where the leukaemia appears. On the one 
hand it can be the lymphoid lineage, affecting mainly B and T cells or on the other, it 
can be the myeloid lineage, affecting e.g. granulocytes and monocytes. 
The combination of this classification gives four major types of leukaemia. (Table 1) 
 
Table 1 The four major types of leukaemia 
LINEAGE/FORM Acute Chronic 
Lymphoid Acute lymphoblastic 
leukaemia 
Chronic lymphoblastic 
leukaemia 
Myeloid Acute myeloid leukaemia Chronic myeloid leukaemia 
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Figure 1-2 Age specific incidence of leukaemia in the US 
This SEER statistics show the incidence of leukaemia in the US between 1997 and 2001. 
While acute leukaemias (ALL, AML) do also occur in young patients, chronic leukaemias 
are diagnosed in adults only. Of note is the ALL peak between the age of 1 and 5, a hallmark 
of this form of leukaemia. (www.cancer.gov)  
 
 
1.3 The leukaemic stem cell 
One so far unanswered question in leukaemia is whether there is one single 
malignant cell, the so called leukaemic stem cell (LSC), that is responsible for the 
onset of leukaemia or if every cell is able to initiate leukaemia. Over the past years 
several cancer stem cell models have been proposed and more and more data keeps 
the discussion alive.  
For AML a few stem cell models have been established in the past. The first 
appearance of an AML model is based on pioneering work from the lab of John Dick 
in the early 1990’s. It has been shown that xenotransplantations of a rare 
Age specific incidence of leukaemia (USA 1997-2001) 
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subpopulation of human AML cells with similar immunophenotype characteristics of 
human HSC could successfully be engrafted in immunodeficient SCID mice 
(Lapidot et al., 1994). From that point on more experiments led to the formulation of 
two leukemic heterogeneity models, the stochastic model and the tumour hierarchy 
model (Figure 1-3). The hierarchy model suggests that the development of a 
leukaemic stem cell is probably induced by a mutation which transforms a HSC into 
a LCS. In xenotransplantation experiments leukaemic stem cells were detected with 
variable leukaemia initiation potential. Those leukaemic cells are named after their 
ability to induce leukaemia in immunodeficient SCID mice (SCID-leukaemia 
initiating cells, SL-IC). Three different types are described. The short-term SL-IC 
does induce leukaemia in a recipient but is not able to sustain the leukaemia in 
secondary recipients. Long-term SC-ILs can initiate leukaemia in the first recipient 
and harvested cells from that individual will induce leukaemia in serial 
transplantations. The third SC-IL type is the quiescent long-term SC-IL which induce 
leukaemia not in the primary recipient but in following recipient cohorts (Dick, 
2008). 
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Figure 1-3 The leukaemic stem cell hierarchy 
AML organised in a hierarchy. Short-term SCID-leukaemia initiating cells (ST-SL-IC) in 
green are only able to induce leukaemia in their first recipient. Long-term SCID-leukaemia 
initiating cells (LT-SL-IC) are able to sustain their leukaemia initiating ability in multiple 
transplantations. Quiescent LT-SL-ICs remain silent in the first recipient but may get active 
in second or further instance. Picture adapted from Dick., Blood 2008 (Dick, 2008). 
 
On the other hand there is the stochastic model of tumour heterogeneity. This 
basically says that every malignant cell has a low but equal ability of forming a 
tumour. The heterogeneity within the cell subpopulation is necessary to initiate the 
malignancy. Isolated subgroups lack this ability (Wang and Dick, 2005). 
Other questions are where the leukaemic cell of origin comes from or what the initial 
event for transforming a haematopoietic stem cell into a self renewing immortal 
malignant cell is. Is there more than one event necessary? Currently two models are 
discussed for the initiation and progression of leukaemia. The first model suggests 
that in the normal HSC pool a single cell gets a hit. This hit then causes a genetic 
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mutation which leads to the malignant transformation and expansion of the affected 
cell. During the now deregulated maturation process, additional mutations can occur 
and cause further severe disruptions mainly blocking the differentiation program and 
inducing uncontrolled proliferation. These mutations lead then to the infiltration of 
immature progenitor cells into the blood stream and in the end to the most prominent 
leukaemic phenotype.  
The second model suggests a two-hit incident (Greaves, 2005). The first hit a HSC 
receives does not initiate expansion but immortalises the affected cell. The cell still 
differentiates but during early differentiation a second hit initiates expansion and 
blocks further differentiation steps. Additionally this transformation event(s) trigger 
the self-renewal program in order to generate LSCs. In the early stages of 
differentiation the self renewal programs are still deactivated, but the earlier the 
malignant transformation takes place, the easier for the cell to restart the self renewal 
program. Without activation of the self-renewal program it is likely that the 
committed progenitor due to the limited life span will die or undergo terminal 
differentiation (Wang and Dick, 2005). When the cell overcomes this differentiation 
bottleneck it is already transformed into the malignant LSC the expansion is 
uncontrollable. 
A third hypothesis was formulated in the early 70s. The Knudson hypothesis stated 
that multiple mutations within the DNA of a malignant cell lead to the cancerous 
phenotype although his hypothesis is based on Retinoblastoma studies (Knudson, 
1971). However his hypothesis could also be applied to the leukaemic background 
and would concord with the two-hit hypothesis. 
In contrast for ALL no such model exists. Many research groups set up 
transplantation experiments with different subsets of leukaemic lymphoblasts but 
results are conflicting as the recent controversial discussion in Blood shows 
(Heidenreich and Vormoor, 2009). Within this dispute the results of Cox et al. (Cox 
et al., 2009) are discussed compared to results by le Viseur et al. (le Viseur et al., 
2008). Each research group used different subsets of lymphoblasts deriving from 
human ALL patients for their transplantations in immunodeficient mice but showed 
heterogeneous success rates. The discussion is also based on methods and technical 
issues as well as the minimal necessary cell number to induce leukaemia. One 
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important point in the discussion is the choice of the mouse model. In the debate it 
was mentioned, that studies for rare leukaemic stem cells used more conventional 
irradiated NOD/scid mice whereas a wider variety of LSC populations were studies 
in newer genetically altered mouse strains like NSG (NOD/scid gamma) or NK cell 
depleted NOD/scid mice. In his recent review, Vormoor even asked the question 
whether the stem cell concept for ALL is dead (Vormoor, 2009). The answer can 
only be found in additional experiments. There are many publications from 
experiments which show that not all xenotransplanted ALL cells cause leukaemia 
(Uckun et al., 1998, Kong et al., 2008). Again others used different subsets of sorted 
leukaemic blasts to induce leukaemia in mice (le Viseur et al., 2008). 
The contribution of rearranged oncogenes involving the MLL gene (MLL/AF4 t(4;11) 
(Krivtsov et al., 2008), MLL/AF9 t(9;11) (Chen et al., 2008)or MLL/ENL t(11;19) 
(Bach et al., 2010)) led to a malignant transformation of haematopoietic progenitor 
cells and created AML as well as ALL phenotypes in transplanted mice. A recent 
publication showed for the translocation t(4;11) that also the AF4/MLL fusion 
product is able to induce ALL in mice (Bursen et al., 2010). Thus developing or 
creating a LSC is dependent on chromosomal changes within the cell. The successful 
engraftment of the malignant haematopoietic progenitor cells showed stem cell 
abilities like self renewal and rapid expansion of blasts. 
The in utero detection of translocation events (Greaves, 2005) and the later onset of 
the leukaemia strongly suggests the two-hit model in accordance with the multiple-
hit hypothesis of Knudson (Knudson, 1971). 
Ultimately knowledge about the mechanisms which cause leukaemia are still unclear. 
It may depend on the state of differentiation or if there are different subsets, at which 
time point the leukaemic hit occurs, the number of necessary hits or which mutations 
are involved. Clearly more experiments are necessary to answer these questions or to 
support one of the LSC hypotheses in ALL.  
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1.4 Acute leukaemia 
1.4.1 Acute myeloid leukaemia 
This form of leukaemia is the most common form of myeloid neoplasm in adults 
accounting for ~25 % of leukaemia. In children it accounts for 15 – 20 % (Deschler 
and Lubbert, 2006). The systemic haematologic disease arises from the clonal 
proliferation of myeloid precursors characterised by a block of differentiation, an 
abnormal high rate of proliferation and a decrease rate in apoptosis. Apoptosis is 
programmed cell death which is initiated from a cell itself in response to a variety of 
stimuli and often the trigger for this suicide mechanism derives from a failure in the 
repair mechanisms of the genetic material of the cell. Once this cell death mechanism 
does not work properly it gives rise to abnormal proliferation of the blood cells and is 
therefore one reason for causing leukaemia. 
The incidence of AML in adults is between 3 to 5 per 100,000 cases per year 
representing about 3 % of all malignant diseases. The median age of adult patients is 
68 years, although the incidence of people over 65 years lies at 17 of 100,000 
compared to an incidence of 1.8 of 100,000 cases considering people under 65 years 
(Deschler et al., 2006) (NCI – SEERS database). 
In 1976 AML was morphologically classified by introducing the French-American-
British (FAB) classification (Bennett et al., 1976) (Table 2). The FAB classification 
is based on cytohistochemistry of bone marrow cells dependent on morphological 
and cytochemical characterisation of the leukoblasts which allows a classification 
into eight subgroups (M0-M7). The majority of AML cases are de novo diseases, 
meaning they occur without obvious reason. However, one has to distinguish 
between these diseases and secondary AML cases where specific risk factors can be 
identified. An increased incidence of AML was found in patients after exposure to 
radioactive material, benzene and cytostatics (Infante and White, 1983). Especially 
after treatment with intensive combined chemotherapies the onset of therapy-induced 
AML (t-AML) became clear. Mainly, treatment with alkylic compounds leads within 
2 to 7 years to a t-AML. Those t-AMLs often show cytogenetic changes like 
aneuploidies, like monosomy 5 or 7, which have a poor prognosis. t-AML can occur 
after exposition to topoisomerase-II inhibitors within a shorter time period of 1 to 5 
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years which is then characterised by a translocation involving the mixed lineage 
leukaemia (MLL) gene (Estey and Dohner, 2006). 
 
 
Table 2 The FAB classification of AML 
The French-American-British (FAB) Classification of AML 
Class Definition Frequency 
M0 Acute myeloid leukaemia with minimal 
differentiation 
2-5 % 
M1 Acute myeloid leukaemia without maturation 10-15 % 
M2 Acute myeloid leukaemia with maturation 25-30 % 
M3 Acute promyelocytic leukaemia 10-15 % 
M4 Acute myelomonocytic leukaemia 25-30 % 
M5 Acute monocytic leukaemia 10-15 % 
M6 Acute erythroleukaemia 3-4 % 
M7 Acute megakaryocytic leukaemia 1 % 
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1.4.2 Acute lymphoblastic leukaemia 
Acute lymphoblastic leukaemia (ALL) is the most common leukaemia in children 
and young adolescents. There is a peak age of developing this disease between 2 and 
5 years (Pui et al., 2008) as well as a gradual increase from the age of 45 on 
(www.cancer.gov, Figure 1-2). Acute lymphoblastic leukaemia in children is the 
major type of leukaemia with about 80 % to 85 % of all leukaemia cases 
(Chowdhury and Brady, 2008, Shah et al., 2008). Depending on the disease subtype, 
with current forms of treatment the chances of curing the disease are fairly high 
although a range from 10 % to 90 % demonstrates the biological diversity of the 
disease (Greaves, 2002). In an actual case study of the Berlin-Frankfurt-Muenster 
group (BFM group) the estimated 6 year event free survival of children with ALL 
was 80 % (ALL-BFM 95) (Moricke et al., 2008). However, children with AML have 
only a cure rate of about 45 % (Pui et al., 2004b). In recent years, a growing number 
of methods to investigate malignant haematopoietic cells on a molecular level have 
been used to further characterise and define subsets of leukaemia dependent on 
chromosomal and genetic abnormalities. 
Acute lymphoblastic leukaemia is caused by haematopoietic precursors which are 
committed to differentiate into B or T cells. Those then malignant cells carry 
chromosomal mutations which allow them to self renew unlimited and at the same 
time they stop any further differentiation.  
In terms of prognosis, age is also exceptionally important. Children between the age 
of 1 and 9 have a better prognosis than either adolescents (10 years and over) or 
infants (younger than one year) (Pui et al., 2001). The five year event free survival 
(EFS) rate for the former is 88 %, adolescents between 10 and 15 years is estimated 
at 73 % (Vitale et al., 2006, Kinlen, 2004). Older adolescents have a 69 % 5 year 
EFS and infants only 44 % (Kinlen, 2004).  
In addition biological factors also play a role for prognosis and outcome of a patient. 
An important prognostic marker is the occurrence of cytogenetic or chromosomal 
aberrations like translocations. This results in good prognosis for patients with 
hyperdiploidy (more than 50 chromosomes) or the fusion gene TEL/AML1 t(12,21) 
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(p13,q22). On the other hand patients with BCR/ABL t(9;22) or MLL/AF4 t(4;11) 
have a very poor prognosis. Five year EFS for hyperdiploidy was estimated at 91 %, 
89 % for TEL/AML1  and only 37 % for BCR/ABL – positive patients as well as only 
32 % of the MLL/AF4 diagnosed ones (Greaves, 2006). 
1.4.3 Diagnosis and treatment of acute leukaemia 
The first method of diagnosis is a complete blood count. This will give the first 
indication for leukaemic development. It is normally followed by characterisation of 
the immunophenotype by FACS analysis. From this result conclusions can be drawn 
about the presents of immature blasts in the blood and also which type of cell is 
affected like B cell or T cell ALL and classification of AML by WHO standards 
(Vardiman et al., 2002). Further morphological investigations are done to classify 
AML according to the FAB classification system. Molecular diagnostic examinations 
of the malignant cells reveal often cytogenetic aberrations which, due to global trials 
and microarray studies, have led to individual therapy. Molecular diagnostics include 
fluorescent in situ hybridisation (FISH) analysis for detection of chromosomal 
aberrations like reoccurring translocations, inversions or loss of chromosomal 
segments. More senstitive methods like PCR or DNA sequencing are needed to 
detect mutations which have been associated with the onset of certain type of 
leukaemia. For example a commonly mutated gene has been detected in FLT3, a 
tyrosine kinase receptor, which has been reported to be constitutively active in AML 
(Reilly, 2003). All those examinations make it possible to risk assess the patients and 
set up the therapy according to the risk group. 
According to the type of leukaemia and age of the patient, patients are risk assessed. 
This risk assessment determines the risk of the patient relapsing after therapy. This 
gives the clinician the opportunity to choose the therapy conditions according to the 
patient. Low to standard risk patients therefore need a less intensive therapy with less 
side effects than a patient with high or even very high risk of relapse. 
Treatment of AML has two goals. The first is to induce the remission of the 
malignant cells, while the second is to maintain the remission. For induction of 
remission two drug types are used namely standard dose of cytarabine (AraC) and 
anthracycline drugs, like daunorubicin (Tallman et al., 2005) (Table 3). A successful 
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induction of remission is defined by complete remission (CR) of leukaemic cells in 
the blood and a presents of less than 5 % blasts in the bone marrow. In adults 
remission rates of 60 – 70 % are currently achieved. Within a few weeks normal 
bone marrow cells will start to build new blood cells. To prevent a relapse further 
treatment is needed. Those therapies are normally multiple treatments with high 
doses of AraC (Mayer et al., 1994). Although good results have been achieved so far 
by induction and consolidaton therapy still 50 – 70 % of patients are expected to 
relapse within 4 years. The chances of success of a CR after relapse are associated 
with the time of CR after the primary therapy. Generally if CR lasts for one year or 
less, chances of a secondary CR are between 10 – 15 %. If primary therapy achieved 
a time of CR for more than one year, chances of a second CR raise to 40 – 60 % 
(Robak and Wierzbowska, 2009). Currently allogenic stem cell transplantation has 
been the most effective therapy for AML patients in first or subsequent remission 
(Vicente et al., 2007). Several new therapeutic approaches for AML therapy are 
currently being investigated in clinical studies. A new drug called gemtuzumab 
ozogamicin is an anti-CD33 monoclonal antibody conjugated with calicheamicin 
which breaks DNA double strands (Hamann et al., 2002a, Hamann et al., 2002b, Pui 
et al., 2008). In combination with standard therapy this agent showed promising 
results (Feldman et al., 2005). Further agents currently used in trials are 
hypomethylating agents like azacytidin (Vidaza ®), new nucleoside analogous like 
Clofarabine which inhibit ribonucleotide reductase and DNA polymerase leading to 
apoptosis or tyrosine kinase (FMS-like tyrosine kinase 3 FLT3) inhibitors like 
tandutinib which inhibit tyrosine phosphorylation and thereby induce apoptosis 
(Robak and Wierzbowska, 2009). 
Therapy for acute lymphoblastic leukaemia normally consists of an induction therapy 
to achieve remission of the immature leukaemic cells in the blood and bone marrow. 
This is followed by an intensification therapy with the goal to remove residual 
leukaemic cells. Subsequently there a continuation therapy follows to further remove 
any residual malignant cells and to minimise the risk of relapse. An exception is 
made with mature B cell ALL that needs to be treated with a short term intensive 
chemotherapy including high doses of methotrexate, cytarabine and 
cyclophosphamide (Patte et al., 2001).  
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For standard risk patients the induction therapy is carried out by applying at least 
three different chemotherapy drugs. Current treatment protocols suggest a 
combination with a glucocorticoid like prednisone or dexamethasone, vincristine and 
asparaginase or anthracycline. To patients with a higher risk of relapse a fourth or 
even more drugs are applied. The final goal is to achieve 100% remission of 
malignant haematopoietic cells in the blood system although it is known that this 
could be hard to achieve. The actual clinical remission currently reach is between 96 
and 99 % in children and 78 – 93 % in adults (Pui and Evans, 2006). 
 
Table 3 Chemotherapeutic drugs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemotherapeutic drug 
 
Effect 
Methotrexate Inhibits metabolism of folic acid, thereby inhibiting all purine synthesis 
Cytarabine DNA damage and DNA and RNA polymerase inhibition 
Cyclophosphamide Causes DNA crosslinks and leads to 
apoptosis 
Glucocorticoid 
(Prednisone, 
Dexamethasone) 
induction of apoptosis by binding to 
the glucocorticoid receptor in sensitive 
lymphoblasts 
Vincristine Interferes with tubulin and causes cell 
cycle arrest. 
L-asparaginase Serum depletion of asparagine, inhibiting protein synthesis 
Anthracycline 
(Doxorubicin, 
Daunorubicin) 
inhibits RNA and DNA synthesis; 
inhibits topoisomerase II; creates free 
oxygen radicals that damage DNA and 
cell membrane 
6-mercaptopurine 
purine analogue; inhibits purine 
nucleotide synthesis, thereby altering 
RNA and DNA synthesis 
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In the following consolidation phase there is no standard therapy for the second 
treatment phase. Post-remission treatments with combinations of corticosteroids, 
vincristine, methotrexate and mercaptopurine have so far given good results. Also 
here the pheno- and genotype of the leukaemic cells are linked to the outcome of the 
therapy. The most radical treatment is allogeneic stem cell transplantation. Especially 
in the group of high risk patients this form of treatment shows the most benefit for 
the patient. For so far unknown reasons even after the consolidation therapy the risk 
of relapse still remains (Pui et al., 2008).  
The subsequent continuation therapy should further minimise the risk of relapse as 
remaining cells are quiescent, chemotherapy resistant and self renewing dormant 
LSCs. Although 60 % of childhood cases can be treated within 12 months the chance 
of relapse is still present. The maintenance therapy continues for 2 to 3 further years. 
In different randomised trials a therapy with mercaptopurine turned out to be the 
most favourable drug as other drugs had unacceptable rates of side effects mainly 
liver defects or even an increased risk of death during remission (Pui et al., 2008). 
A new treatment protocol for infants was introduced in the Interfant-99 trial. 482 
patients between 0 and 12 months diagnosed with ALL have entered the trial. For the 
induction phase four drugs have been administered, dexamethasone, vincristine, 
daunorubicin and L-asparaginase. Following the induction phase the consolidation 
phase, called MARAM, was initiated. MARAM consisted of 6-mercaptopurine, 
methotrexate, leucovorin rescue, prednisone, cytarabine and L-asparaginase. After 
the MARAM phase the OCTADD phase has been initiated with a combination of 
dexamethasone, 6-thioguanine, vincristine, daunorubicin, cytarabin, prednisone and 
cyclophosphamide. Following these treatment phases intensification phases or 
maintenance phases then follow. If a donor was available some high-risk patients 
received bone-marrow transplantation. For the outcome of the study 445 patients in 
complete remission have been analysed. 163 patients had relapsed from which 146 
died during relapse treatment. This resulted in an overall survival rate of 55.3 % 
which was better compared to other treatment protocols like the BFM (48 % survival) 
or CCG-1953 (45 %). In this study MLL rearrangement and age younger than 6 
months were strong indicators for poor outcome. Their 4-year event free survival was 
below 40 %. Especially for this group of patients new forms of treatment are 
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necessary (Pieters et al., 2007, van der Linden et al., 2009, Van der Velden et al., 
2009) 
1.5 The molecular genetics of childhood ALL 
Acute lymphoblastic leukaemia (ALL) is the most common form of malignancy in 
childhood representing about 25 % of all cases. The B cell precursor ALL is the most 
common form of ALL in children (Armstrong and Look, 2005). Chromosomal 
abnormalities are a hallmark of ALL but also give insight into the molecular biology 
behind the disease. Cytogenetic anomalies in acute lymphoblastic leukaemia occur 
with different frequencies in children and adults. Figure 1-4 gives an overview of 
current cytogenetic anomalies in childhood ALL. 25 % of ALL positive diagnosed 
children show in cytogenetic examinations a so called hyperdiploidy, which means 
more than 46 chromosomes (Paulsson and Johansson, 2009). Gene expression 
studies demonstrated, that ALL with hyperdiploidy represent a separate subset of B-
precursor ALL. Although being a subset, further analyses did not show any specific 
genes involved in the development of hyperdiploid pre-B All. Recently, the first 
evidence of a specific gene mutation was found within the receptor tyrosine kinase 
FLT3 gene in about 20 % of the investigated hyperdiploid pre-B ALL cases 
(Armstrong et al., 2004). This finding is important as it would be the first gene 
associated with hyperdiploid ALL and this kinase would be a good target for therapy. 
As patients with hyperdiploid ALL have a very good prognosis, the addition of FLT3 
inhibitory treatment may further improve patient outcome. The loss of chromosomes, 
called hypodiploidy, is a marker for poor prognosis and is diagnosed in ca. 1 % of 
childhood ALL patients. One big group of abnormalities is the chromosomal 
rearrangement or translocation group. The reciprocal translocation, which is the 
common form of translocation in leukaemia, is the exchange of chromosomal 
material. This translocation event often creates two fusion genes, which then lead to 
abnormal function of the involved genes. The most frequent diagnosed translocation 
is t(12;21) (p13;q22) fusing the genes TEL and AML1. This translocation cannot be 
diagnosed by normal karyotyping but with molecular techniques this translocation is 
found in 22 % childhood ALL cases. Interestingly this translocation can be found in 
the blood of newborn babies up to 5 to 10 years before the leukaemia development 
(Greaves and Wiemels, 2003). The mechanisms of leukaemogenesis induction by 
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TEL/AML1 are still not fully understood. TEL and AML1 have been shown to be key 
players in normal haematopoiesis, thus suggesting that the TEL/AML1 fusion protein 
severely disrupts haematopoietic development (Wang et al., 1997). As mentioned 
before the expression of TEL/AML1 has a good prognosis and the 5-year event free 
survival rate is around 90 % not depending on the age and leukocyte count. This 
means that these patients are candidates for a less-intensive therapy 
Translocations involving the MLL gene are diagnosed in about 8 % of childhood 
ALL cases and will be described in section 1.6. 
Figure 1-4 Cytogenetic aberrations in childhood ALL 
The picture represents an overview of cytogenetic abnormalities in Childhood ALL for 
patients between 1 and 18 years. The coloured names represent cytogenetic aberrations in T-
ALL, all other abnormalities are diagnosed in B-ALL. Adopted from Pui et al, 2004 (Pui et 
al., 2004a) 
 
1.5.1 Infant ALL 
Infants younger than one year with acute lymphoblastic leukaemia represent a 
subgroup of childhood ALLs as their characteristics and also prognosis differ from 
that of patients older than one year. At diagnosis, infants with ALL often present 
high risk leukaemia features like CD10 negativity, an immature pro-B phenotype and 
Hypodiploidy <45 
chromosomes
1.0% Hyperdiploidy >50 
chromosomes
25.0%
TEL-AML1 
t(12;21)
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MYC t(8;14), 
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5.0%MLL-ENL t(11;19)0.3%
TLX1 10q24
0.7%
TAL1 1p32
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LYL1 19p13
1.5%
TLX3 5q35
2.5%
MLL 
rearrangements 
t(4;11), t(11,19),
t(9;11)
8.0%
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3.0%
Others
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a high leukocyte count (Bhojwani et al., 2009). A genetic hallmark of infant ALL is 
translocation involving the MLL gene which is diagnosed in about 80 % of all infant 
ALL cases. This translocation is a marker for a very aggressive form of leukaemia 
with a poor prognosis. Infants with MLL rearranged ALL treated according to the 
Interfant-99 protocol had an estimated 4 year survival rate of about 40 % (Pieters et 
al., 2007). 
An interesting characteristic of childhood ALL and especially infant ALL is the in 
utero origins of the disease. Greaves and colleagues (Greaves, 2005) investigated 
Guthrie blood spots of diagnosed ALL patients for leukaemia associated 
chromosomal anomalies. In infant ALL patients the translocation t(4;11) coding for 
the MLL/AF4 and AF4/MLL fusion gene was found in nearly 100 % of the 
investigated cases. Other chromosomal anomalies like the t(12;21) TEL/AML1 in 
childhood ALL or t(8;21) AML1/ETO in childhood AML were also found but only in 
75% and 50% respectively. As the disease for some patients did not show at birth but 
years later this supports the two-hit model of leukaemogenesis as secondary events 
are needed to accomplish the transition to AML or ALL. Also this would fit into the 
hierarchy model of leukaemia as the immortalised cells, leukaemic stem cells, stay 
quiescent until an event occurs that results in development of the malignancy. In case 
of t(4;11) already present in an ALL at birth, this would suggest that the second hit 
also occurs prenatal which indicates the rapid development of t(4;11) positive ALL. 
This second hit could be the contribution of both derivates of the t(4;11) 
translocation. Each of the derivates has been shown to induce leukaemia in mouse 
models, but together show highest transforming potential (Bursen et al., 2010, 
Gaussmann et al., 2007, Krivtsov et al., 2008). 
1.6 MLL rearrangements 
 
For MLL more than 100 translocation partners have been identified with about 64 
characterised at the molecular level. The most common reciprocal translocation in 
ALL is the fusion of the MLL gene to the gene AF4 creating the translocation 
t(4;11)(q31;q23) (66% of all cases), followed by ENL t(11;19) (q23;p13.3) (~15%) 
and AF9 t(9;11)(p22;q23)(~8.5%). 
 22 
 
MLL translocations play also a role in acute myeloblastic leukaemia (AML). Most 
common fusion partners here are AF9 t(9;11)(p22;q23) (~30%), ELL 
t(11;19)(q23;p13.1), AF10 ins(10;11)(p12;q23q13) and AF6 t(6;11)(q27;q23) (~10% 
each) (Meyer et al., 2009). 
In various knockout experiments it was demonstrated that MLL needs a fusion 
partner to form an active oncogene while truncated versions of the wild type gene did 
not lead to leukaemogenesis (Li et al., 2005). 
As illustrated in figure 1-5 MLL has several important domains for modifying 
genetic regulation processes. 
 
 
Figure 1-5 The MLL wild type and fusion protein 
The schematic shows an overview of the main domains of the MLL wild type protein. These 
are: 
AT-H, AT-hooks; MT/RD, DNA methyltransferase homology/repression domain; BCR, 
breakpoint cluster region; PHD, plant homeodomain; AD, transcriptional activation domain; 
SET, histone methyltransferase domain. Arrow indicates Taspase 1 cleavage site. Proteins 
that interact with those important domains are noted below the domain (Popovic and 
Zeleznik-Le, 2005). 
 
 
The breakpoint cluster region (BCR) genetically lies between exon 5 and 11 in the 
MLL gene. It spans over 8.3 kb and indicates that the chromosomal rearrangement 
reallocates three important domains namely the plant homeodomain, the 
transcriptional activation domain and the histone methyltransferase domain (SET). 
More and more evidence shows, that especially the rearrangement of the SET 
domain has an important impact on the leukaemic cell. It seems that by the 
displacement of the SET domain, the whole epigenetic phenotype of the cell changes. 
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The exact mechanisms of leukaemogenesis caused by MLL translocations are not 
fully understood so far. The common finding is the involvement of the N-terminus of 
the MLL protein fused to a partner protein. Those partner proteins do not show any 
common characteristics. Rowley hypothesised in 1992 (Rowley, 1992) that the 
der(11), meaning the fusion gene coding for the N-terminal part of an MLL fusion, is 
the key oncogene for the onset of leukaemia. Previous studies demonstrated the 
potential of fusion genes to disrupt the development of stem and precursor cells 
(Cleary, 1991). 
In animal models the oncogenic potential of MLL fusions has already been studied. 
In the year 2000, two independent groups reported (DiMartino et al., 2000, Lavau et 
al., 2000) the oncogenic characteristic of MLL-ELL transfected primary myeloid 
progenitors and the ability of those transformed progenitors in mice to develop acute 
myeloid leukaemia. It is still not clear whether the N-terminal MLL part is sufficient 
for the leukaemic transformation or if the fusion partner is necessary. It has been 
shown for fusion proteins like MLL/AF9 (Hemenway et al., 2001) or MLL/AF10 
(DiMartino et al., 2002) that MLL and its fusion partner are necessary of the 
transformation. On the contrary Martin published in 2003 (Martin et al., 2003) the 
transformation ability of a truncated form of the MLL wild type gene. Investigations 
showed upregulation of HOXA7, HOXA9 and MEIS1, which is a common 
observation in acute leukaemia. Despite those two models, the role of MLL fusion 
proteins and their contribution to leukaemogenesis still remain unanswered. The 
general question is whether a fusion partner in necessary to cause leukaemia or MLL 
alone is necessary to cause the malignant transformation. 
1.7 The translocation t(4;11) 
The reciprocal translocation t(4;11) creating the fusion genes MLL/AF4 and 
AF4/MLL is detected in about 66 % of ALL cases with MLL gene fusions (Meyer et 
al., 2009) but remains very rare in AML. In about 80 % of infants with ALL MLL 
fusions are detected and in over 50 % of MLL involved translocations, AF4 is the 
fusion partner gene. An important group of leukaemias connected with MLL 
translocations is the group of therapy induced secondary leukaemias. Especially after 
treatment with topoisomerase II inhibitors like etoposide, the occurrence of MLL 
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translocations is detected in about 25 % of treated adults (Pedersen-Bjergaard et al., 
1998). 
In patients with the translocation t(4;11), the fusion gene MLL/AF4 is always 
detected. In a study published in 2007 Kowarz and colleagues report that the 
reciprocal counterpart AF4/MLL was only detected in 80 % of all studied t(4;11) 
positive cases (Kowarz et al., 2007). The remaining 20 % showed complex 
translocation events involving more than two genes like the three way translocation 
resulting in der(1) PBX1/MLL, der(4) AF4/PBX1 and der(11) MLL/AF4 or loss of 
the N-terminal part of the der(4) resulting in MLL/AF4 and ∆MLL.  
 
1.8 The genes MLL and AF4 
Like the HOX genes themselves also two groups of HOX regulators have been 
detected in Drosophila melanogaster. The genes of the polycomb group (pcG) have 
been identified as HOX gene expression inhibitors while genes of the trithorax group 
(trxG) act as activators for HOX genes (Grimaud et al., 2006). In recent years the 
mechanisms of gene expression regulation by those protein groups has been 
investigated. Both pcG and trxG proteins seem to be epigenetic gene regulators 
meaning that they alter transcription by changing the methylation status of histones 
and the resulting alteration of chromatin structure in the gene’s promoter region 
(Simon and Tamkun, 2002). The histone methyltransferase MLL is the human 
homologue to Drosophila melanogaster trithorax and a member of the Su(var)9-3, 
Enhancer of Zeste and trithorax (SET) family (Gu et al., 1992, Djabali et al., 1993). 
The MLL gene codes for a multiple domains consisting protein with 3969 amino 
acids and a molecular weight of ~430 kDa. Important domains are 3 AT-hook DNA 
binding domains, a DNA methyltransferase homology domain (DNMT), a central 
zinc finger plant homeodomain (PHD) as well as a highly conserved SET domain, 
which has the catalytic histone methyltransferase activity. The MLL protein has been 
identified to control the gene expression of several HOX transcription factors, 
including HOXA7, HOXA9 and HOXA10 (Ernst et al., 2004b, Nakamura et al., 
2002). In mll knockout mice it was shown that mll is essential for the correct 
initiation of the hox genes during embryonic development. Mll knockout lead to 
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lethal disruptions during mouse haematopoiesis (Ernst et al., 2004a, Ernst et al., 
2004b, Hess et al., 1997). 
Functional studies in human cells revealed that MLL in cooperation with other 
cofactors formed a stable super complex called SET1 to transfer methyl groups to 
lysine K4 of the histone H3 (H3K4) (Terranova et al., 2006, Nakamura et al., 2002). 
The double or triple methylation of H3K4 within the promoter region of the MLL 
target genes facilitates the transcriptional status of those promoters (Bernstein et al., 
2002, Santos-Rosa et al., 2003).  Direct promoter activation by binding and 
methylation of H3K4 was demonstrated for HOXA9 in the human cell line HeLa and 
hoxc8 in murine fibroblast cells (Milne et al., 2002, Nakamura et al., 2002). However, 
within the MLL complex other proteins have been identified which have the ability 
to modify histone methylation. The cofactor WDR5 has been shown to modify 
methylation of H3K4 (Wysocka et al., 2005). 
Not only methylation but also acetylation activity has been identified for the MLL 
complex. A factor called MOF has been identified that is able to transfer acetyl 
groups to lysine K16 of histone H4 (Dou et al., 2005). The interaction of MLL with 
the tumour suppressor MENIN was also described as being very important 
(Yokoyama et al., 2004). A N-terminal Menin binding motif (MBM) enables the 
interaction of MENIN and MLL which allows recruitment of lens epithelium derived 
growth factor (LEDGF), a transcription factor essential for MLL mediated gene 
expression (Yokoyama and Cleary, 2008). 
To function properly MLL has to be posttranslational cleaved which is catalysed by 
TASPASE1, a threonine-aspartase (Hsieh et al., 2003a). The cleaved products 
(MLLC and MLLN) will then reassociate and build the central part of the MLL 
complex (Hsieh et al., 2003b, Yokoyama et al., 2002). Taspase1 knockout mice have 
shown to be viable but show a significant lower histone H3K4 methylation status 
(Takeda et al., 2006). This leads to the assumption that MLL plays a very important 
role in general gene transcription regulation. This is backed up by the findings of 
Nakamura (Nakamura et al., 2002) who showed a connection between RNA 
modifying proteins as well as components of the RNA-polymerase II transcription 
machinery and MLL. Binding of MLL has been detected in about 40 % of all genes 
of which about 90 % show RNA-polymerase II binding (Guenther et al., 2005). 
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The gene AF4 (ALL-1 fused gene on chromosome 4) has been identified as MLL 
fusion parter in 1992 (Gu et al., 1992). AF4 is a generally expressed gene (Frestedt et 
al., 1996) of 300 kb length and belongs to the ALF gene family. The mRNA is 10.5 
kb and is comprised of 23 exons coding for a 131 kDa protein localised in the 
nucleus. Five functional domains have been identified in the AF4 protein. From N-
terminal to C-terminal these are a N-terminal homology domain (NHD), a conserved 
domain of the ALF protein family (ALF), a proline –serine rich region (pSer), a 
nuclear localisation sequence (NLS) and a C-terminal homology domain (CHD). The 
function of AF4 is still under investigation. It is know that it can bind DNA and has 
transcription initiating characteristics so AF4 is assumed to be a transcription factor 
(Ma and Staudt, 1996, Prasad et al., 1995). 
AF4 has also been described as a critical factor for lymphocyte development. Isnard 
and colleagues investigated murine af4 knockout models and described a defect in 
the differentiation of B and T lymphocytes (Isnard et al., 2000). Furthermore this 
leads to the assumption that AF4 translocations promote oncogenic development of 
haematopoietic cells. This has been investigated by Bursen and colleagues as they 
transfected murine embryonic fibroblasts (MEF) with AF4 wild type and AF4/MLL 
constructs clearly demonstrated a growth transforming ability and hence oncogenic 
potential (Bursen et al., 2004). 
An important study to reveal AF4 function was published in 2007 by Bitoun, Oliver 
and Davies (Bitoun et al., 2007), here illustrated in figure 1-6. They demonstrate the 
involvement of AF4 in a protein complex containing RNA-polymerase II (Pol II). In 
this study it was demonstrated that AF4 has an important impact on the transcription 
activity of Pol II by enabling transcriptional elongation. AF4 together with the 
ENL/AF9 complex binds to the kinase p-TEFb and associates with the Pol II 
complex. P-TEFb then phosphorylates Pol II inhibitors thereby initiating 
transcription. AF4/ENL/AF9 are also phosphorylated, bind to Pol II and recruit AF10 
and DOT1L. This enables methylation of histone H3 lysine K79 causing chromatin 
remodelling. A negative feedback mechanism has also been described. The 
phosphorylation of AF4 lowers its transactivation activity furthermore 
phosphorylation of ENL/AF9 leads to their degradation by a so far unknown 
mechanism. pAF4 then detaches from the complex and is mediated via the E3 
ubiquitin ligase SIAH  to 26S proteasomal degradation (Bursen et al., 2004). 
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Figure 1-6 The role of the AF4 protein complex 
The three stages of RNA polymerase II transcriptional elongation and chromatin remodelling 
mediated by AF4. The figure shows (A) the pre-initiation complex with Pol II being 
inhibited by NELF and DSIF. By binding to ENL/AF9 and P-TEFb AF4 mediates (B) the 
activation of Pol II by degradation of the inhibitory factors. Furthermore AF4-ENL/AF9 bind 
to the Pol II complex and recruit AF10 and DOT1L enabling H3K79 methylation. 
Phosphorylation of AF4 and ENL/AF9 by P-TEFb (C) initiates degradation of ENL/AF9 by 
an unknown mechanism and proteasomal degradation of AF4 via SIAH ubiquitin ligases. 
Amended from (Bitoun et al., 2007) 
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1.9 The fusion proteins MLL/AF4 (der11) und AF4/MLL(der4) 
The protein MLL/AF4 (der (11); figure 1-7) is the fusion product of the MLL N-
terminus with three domains (AT-Hook, DNA MT and two sub-nuclear localisation 
signal (SNL) domains) and the C-terminus of AF4 with four domains (ALF 
homology domain, pSer domain, NLS domain and CHD domain). In functional 
studies with MLL/AF4 it was shown, that the fusion protein did not have an effect on 
HOX gene expression (Bertrand et al., 2003). However, over expression of the fusion 
gene did implicate a role in the cell cycle and apoptosis. Interestingly affected cells 
showed a diminished proliferation and a G1 phase cell cycle arrest but also were 
more resistant to apoptosis mediating stimuli (Caslini et al., 2004, Gaussmann et al., 
2007). In 2005 Thomas and colleagues published that siRNA mediated knockdown 
of MLL/AF4 in t(4;11) positive cell lines led to an increasing apoptosis rate (Thomas 
et al., 2005). 
A more novel discovery is the influence of MLL/AF4 on the regulation of 
microRNAs. MicroRNAs have been reported to regulate gene expression by 
inhibiting the translation of mRNA or mediating degradation of the transcript 
(Novina and Sharp, 2004, Meister and Tuschl, 2004). Nakamura and colleagues 
report in 2007, that MLL fusion proteins target Drosha, a protein complex that is 
important for microRNA processing (Nakamura et al., 2007). In a recent publication 
the research team around Popovic discovered that the over expression of microRNA 
mir196b in bone marrow precursors leads to increasing proliferation and 
survivability as well as to an inhibition of differentiation (Popovic et al., 2009). 
 
Three mouse models have been developed to perform in vivo studies to reveal the 
potential of MLL/AF4 to develop ALL or AML. In 2006 Metzler and colleagues 
published a study where they created knock in mice by using the cre-loxP 
recombinase system. Affected mice developed a B cell lymphoma but neither ALL 
or AML phenotype (Metzler et al., 2006). In the same year Chen and colleagues 
published an attempt to induce leukaemia by generating mice expressing a mll-AF4 
construct. Although the mice developed haematopoietic malignancies, mostly B-Cell 
lymphomas, no leukaemic phenotype was induced (Chen et al., 2006). Another 
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attempt to create a mouse model that develops ALL or AML upon MLL/AF4 
expression was published in 2008. In this model the C-terminal part of AF4 was 
successfully been cloned into the endogenous murine mll gene thereby expression 
was controlled by the endogenous mll promoter. This approach successfully created 
mice which developed AML or ALL. Furthermore this study demonstrated the 
importance of the H3K79 methylation for maintaining the leukaemic phenotype 
(Krivtsov et al., 2008). 
Another important study was published in 2008 by Guenther and colleagues. They 
investigated using microarray studies and ChIP on chip studies the effect of 
MLL/AF4 expression on global gene regulation. It was shown, that the chromatin 
structure in genes targeted by MLL/AF4 was heavily influenced by altered histone 
modification by trithorax group proteins and DOT1 methylases (Guenther et al., 
2008). 
 
The role of AF4/MLL (der (4); figure 1-7) in leukaemogenesis is still widely 
unknown. AF4/MLL consists of the NHD and ALF domain from the AF4 part and 
the BD, PHD, TAD, SET domain and the FYRN and FYRC interaction domains, 
furthermore the cleavage site for taspase 1. Two recent publications have 
investigated the fusion protein AF4/MLL and its role in leukaemia. So far it is known 
that AF4/MLL unlike the AF4 wild type is not subject to proteasomal degradation 
and thus accumulates in AF4/MLL positive cells. This is very likely the reason for 
the oncogenic effects and growth stimulation of cells (Bursen et al., 2004, 
Gaussmann et al., 2007). 
Cotransfected cells with AF4/MLL and MLL/AF4 demonstrated the highest growth 
rate and also the highest resistance against apoptosis. Also two genes which are 
described as stem cell genes Oct4 and Nanog showed an increase expression rate 
upon coexpression of both fusion genes. The combination of both stem cell genes has 
been described for the maintenance of pluripotency and self-renewal of embryonic 
stem cells (Gaussmann et al., 2007). To what degree this contributes to the leukaemic 
phenotype still has to be investigated. 
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Figure 1-7 AF4/MLL der(4) and MLL/AF4 der(11) 
The picture shows a schema of der(4) AF4/MLL and der(11) MLL/AF4. Numbers show the 
amino acids; der(4): NHD N-terminal homology domain, ALF ALF protein family 
homology domain, P PHD zincfinger domain, BD bromodomain, FYRN/FYRC internal 
interaction domain, TAD transactivation domain, SET Histone methyltransferase domain; 
the two lines next to TAD are the taspase cleavage site; der(11) AT AT hook, MT DNA 
methyltransferase domain, pSer proline-serine rich domain, NLS nuclear localisation 
sequence, CHD C-terminal homology domain; taken from (Bursen et al., 2004) 
 
1.10 The HOX genes 
With the discovery of the homeobox sequence, a DNA region of highly conserved 
homology in various species, a milestone was set.  
Firstly those homeobox containing genes (or HOX genes) were discovered in flies 
(Drosophila melanogaster) but homologues have also been found in mammalians. 
The homeobox genes are well studied in mice and humans. In humans a total of 39 
HOX genes are clustered in four complexes distributed on four different 
chromosomes. These clusters are named HoxA located on chromosome 7, HoxB on 
chromosome 17, HoxC on chromosome 12 and HoxD on chromosome 2. Sequence 
similarities in the homeobox motive of the 39 HOX genes makes it possible to group 
those genes in 13 paralogous groups, where paralogous means that a gene has a copy 
located on another locus within the same genome. But none of the HOX clusters has 
the full set of 13 HOX genes (Figure 1-8). 
Investigations have shown that HOX genes are regulated by their epigenetic status 
and they are regulated by their own state of expression. For example the HoxA 
cluster is regulated by a cascade which means that each HOX gene activates the 
expression of the next one while it causes repression of the previous HOX gene. 
HOX genes are developmental genes. In flies and mice they tightly regulate the 
segment structure of the embryo and determine the body axis. In vivo knockout 
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experiments have demonstrated severe developmental changes proving the 
importance of the HOX genes. 
The role of the HOX genes in the haematopoiesis and leukaemogenesis has also been 
in the focus of research. HOX genes, especially of the A, B and C cluster seem to be 
expressed in haematopoietic stem cells and immature progenitor cells while being 
less expressed at later differentiation states. In HOX over expression and knockout 
experiments in mice (characterized in Figure 1-8) results show that HOX genes play 
a crucial role in HSC self renewal as well as a block in lymphoblast development. 
Further investigations demonstrated that HOX genes have the potential to cause or at 
least influence the onset of myeloproliferative disorders and leukaemia. 
In Drosophila melanogaster one of the key regulator of HOX genes are the genes of 
the trithorax group. The human homologue of those trithorax genes are the mixed 
lineage leukaemia (MLL) genes. In MLL -/- double knockout experiments affected 
embryonic bodies were not capable to form haematopoietic populations. This defect 
could be overcome by over expression of HOX genes A9 and A10 furthermore by B3 
and B4. (Ernst et al., 2004b). The discovery of two major co-factors for HOX 
proteins gave more insight into the complex regulation mechanism of HOX in 
development. PBX1 and MEIS1 directly interact with the HOX transcription factors 
and are important for the DNA binding efficiency of the HOX proteins. It has been 
shown, that MEIS1 and PBX1 can enhance HOX binding specificity and affinity 
(Shen et al., 1997). Further MEIS1 in combination with PBX1 has been shown to 
increase transforming ability of MLL fusion gene transfected cells (Wong et al., 
2007, Wang et al., 2006). Knockout experiments for both PBX1 and MEIS1 have 
demonstrated their important role in development and self renewal potential of HSCs. 
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Figure 1-8 Overview of the Hox cluster in human 
This figure demonstrates the simplified structure of the human Hox clusters (HoxA, HoxB, 
HoxC and HoxD) compared to the Drosophila melanogaster Hox complex on the top. 
Homologe genes are shown in the same colour. This picture also shows, that no Hox cluster 
contains all 13 HOX genes. Different effects on hematopoiesis are also shown. Red arrows 
indicated over expression of the Hox gene, while brackets show knockout mouse 
experiments. (Argiropoulos and Humphries, 2007) 
 
Various research groups have concentrated their work on the correlation of the 
altered HOX gene expression profile and pro-leukaemogenic MLL rearrangements. 
As described before, MLL rearrangements have been detected in ALL and AML 
cases alike. In all studied cases of leukaemias with a MLL rearrangement a 
dysregulated HOX profile was detected. In addition to HOX, dysregulation of MEIS1 
is a frequent observation in haematopoietic malignancies. Elevation of HOXA9 
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expression levels for example is strongly correlated with a poor prognosis in acute 
myeloid leukaemia (AML). Further studies showed that especially HOXA9 is 
essential for the survival of MLL rearranged acute leukaemias (Faber et al., 2009). 
Over expression of MLL fusion genes in mice showed upregulation of certain 
members of the clustered HOX genes, especially HOXA9.  
But also the posterior HOXA genes HOXA7 and HOXA10 have a prominent 
leukaemogenic potential. 
In a series of lymphoblastic leukaemias an elevated HOX gene expression profile, 
especially of the HOXA cluster, was monitored. In a recent publication (Bach et al., 
2010) the oncogenic potential of every gene within the HOXA cluster was 
investigated. As expected by the authors HOXA7, HOXA9 and HOXA10 were 
demonstrated to have the ability to cause leukaemogenesis. A new finding was that 
also anterior HOXA genes like HOXA1, HOXA4 and HOXA6 were also able to 
transform haematopoietic cells. The transforming potential was not as potent as of 
the posterior HOXA genes, but it was shown, that those specific anterior HOXA genes 
have transforming ability. Apart from HOXA5, all other genes of the HOXA cluster 
had an effect on haematopoiesis, be it either transformation into a malignant cell or a 
delay in the differentiation process. As a conclusion the authors described HOXA 
proteins as rheostats that are necessary to adjust the complex haematopoietic 
differentiation depending on the varying environment. 
1.11 Telomerase 
The main function of telomerase is maintaining the chromosomal ends, the so called 
telomeres. The telomeres are a piece of double stranded DNA at the end of each 
chromosome. The telomeres harbour only non coding sequence of DNA and consist 
of nucleotide sequence TTAGGG repeats.  
Normal somatic mammalian cells have a limited rate of proliferation in vitro. The 
maximum number of cell divisions is called the Hayflick limit (Hayflick, 1979). As 
soon as this limit has been reached, critical shortened telomeres trigger a permanent 
growth arrest, also called senescence (Shay et al., 1991). To overcome the 
senescence, human cells must inactivate the RB and p53 signalling pathway. Cell 
populations that overcome senescence will continue to divide until a second 
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proliferation check point is reached, called crisis. This state is characterised by very 
short telomeres, chromosomal end to end fusions and anaphase bridges which results 
in the activation of apoptosis or programmed cell death. 
In very rare occasions cells are also able to overcome this stage by maintaining those 
short telomeres. Those cells are then termed immortal. Often it has been shown that a 
high telomerase activity is responsible for the telomere upkeep. Regulatory 
mechanisms behind this are still under investigation. In cells which have a telomere 
maintenance but no telomerase activity a second more uncommon way of telomere 
lengthening has been discovered, the so called ALT (alternative lengthening of 
telomeres) mechanism (Muntoni and Reddel, 2005, Bryan et al., 1997) where the 
telomeres are rebuild by complex recombination events. More than 90 % of all types 
of cancer show a high telomerase activity to keep the telomeres up, while the 
telomerase independent ALT mechanism was only found in approximately 10 %. 
(Kim et al., 1994) 
Only a few types of normal human cells show a high activity of telomerase. Those 
are stimulated lymphocytes, intestinal epithelium, basal keratinocytes, 
haematopoietic stem cells and germ cells in ovaries and testis (Kim et al., 1994, 
Hahn, 2005, Counter et al., 1995, Hiyama et al., 1995b). 
Telomerase as a diagnostic and prognostic marker is useful for a broad spectrum of 
cancer types (Hiyama and Hiyama, 2003, Ulaner, 2004, Shay and Bacchetti, 1997). 
As the telomerase activity rises during the onset of the disease it is possible to 
monitor the tumour tissue growth by its level of telomerase activity. Depending on 
the tumour the telomerase activity can be high from the beginning or increase during 
the disease. Increasing telomerase activity may reflect increased tumour progression. 
(Shay and Bacchetti, 1997, Hiyama and Hiyama, 2002) 
Also in cases when it is not possible to distinguish between benign and malignant 
cancer by morphological examinations, telomerase activity may aid in diagnosis. 
This group consist for example of brain tumours, adenocarcinoma, pancreatic 
endocrine tumours and intraepithelial neoplasms. In those tumours a correlation 
between telomerase activity and prognosis of the patient has been found. In 
neuroblastoma cells, a common tumour in children, high telomerase activity 
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correlated with a poor prognosis, while the outcome was much better when a low 
activity was determined (Hiyama and Hiyama, 2002, Hiyama et al., 1995a, Pearson 
et al., 2000, Falchetti et al., 1999, Poremba et al., 1999). 
The correlation of telomerase activity and cancer prognosis led to the fact that 
telomerase or its components could be a valuable drug target (Shay and Wright, 
2002). Multiple potential chemotherapeutic strategies based on telomere and 
telomerase biology are in development. This includes drugs that directly target the 
telomeres, the telomerase or telomerase associated regulatory mechanisms as well as 
telomerase immunotherapy and telomerase mediated tumour specific gene therapy. 
The telomerase consists of two major subunits. The protein subunit is named 
telomerase reverse transcriptase (TERT) and telomerase RNA component (TERC). 
The RNA component TERC is complimentary to the last telomeric repeat of the 
DNA, binds there and the reverse transcriptase (TERT) can add the complimentary 
nucleotides to the telomere DNA. DNA polymerases can then completely reconstruct 
the telomere. TERC will dissociate from the strand and target the next free 3’ DNA 
telomeric repeat. The telomerase core components hTERT and TERC have been 
shown to be preferable drug targets (Pendino et al., 2006).  
The RNA template or TERC was thought to be a good direct target as it is very 
important for the telomere lengthening (Corey, 2000). Inhibiting oligonucleotides 
targeting this template should have no difficulties in reaching the desired location. 
The challenge here is to establish a delivery system and to maintain the 
oligonucleotides stability meaning to protect the oligonucleotides until they reach 
their target without being degraded by endonucleases (Shay and Wright, 2006). Also 
antisense molecules have been tested to inhibit the RNA component. Those 
molecules do not target the template region. The most effective molecules were those 
which targeted sequences that are important for the formation of the telomerase 
enzyme. Another tested group of molecules were ribozymes which can induce 
telomere shortening and apoptosis in some cell line models (Yeo et al., 2005). 
Negative side effects in telomerase inhibitory therapy are the effects on telomerase 
positive proliferative cells like stem cells, germ cells or different types of 
regenerative epithelial cells. Those cell populations normally show much longer 
telomeres than malignant cell populations. Although those normal proliferative cells 
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have telomerase activity, they have a much slower rate of proliferation than 
malignant cells. Considering the differences in the rate of proliferation an anti-
telomerase therapy should affect the malignant highly proliferative cells much more 
than the slower proliferating normal cells.  
 
1.11.1 The reverse transcriptase of the telomerase, TERT 
Investigations in cancer biology and telomerase activation have shown that the 
protein subunit of the telomerase, TERT, plays a very important role (Nakamura and 
Cech, 1998). Over expression of TERT reactivated telomerase activity in various 
primary cell types but also immortalised those cells (Bodnar et al., 1998). TERC, the 
RNA component of the telomerase, was detected in malignant and normal cells 
equally (Feng et al., 1995, Yi et al., 2001). 
Although TERT expression alone is sufficient for inducing immortalisation, the 
event itself is rare. This suggests a strict regulation of the TERT promoter. The 
research team of Tanaka (Tanaka et al., 1999) has shown that the promoter is GC 
rich and inhibited by DNA methylation. This type of inactivation is often detected in 
differentiated or senescent cells (Lopatina et al., 2003, Shin et al., 2003). Inhibition 
of DNA methylation on the other hand leads in human teratocarcinoma (HT) cells to 
reactivation of TERT expression. Another regulatory mechanism that has been 
investigated in normal and malignant cells is the acetylation of histones (Annunziato 
and Hansen, 2000). By acetylation and deacetylation of histones the transition from 
euchromatin (transcription activation) to heterochromatin (repression of transcription) 
is regulated. Inhibition of histone deacetylases (HDAC) in normal telomerase 
negative cells leads to telomerase activation. 
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Table 4 Transcription factors for TERT 
factor role reference 
c-Myc activator (Wu et al., 1999, Bazarov et al., 2009) 
E2F1 repressor/activator (Crowe and Nguyen, 2001, Crowe et al., 2001) 
Mad1 repressor (Oh et al., 2000) 
Menin repressor (Lin and Elledge, 2003) 
p53 repressor (Toh et al., 2005, Kanaya et al., 2000, Shats et al., 2004) 
 
Various transcription factors for TERT expression have been identified. One of them 
is the oncoprotein C-MYC which is an activator. It forms a sequence-specific DNA-
binding protein complex with MAX and by binding of C-MYC to e-boxes which are 
short DNA sequences upstream of a gene in the promoter and binding sites for many 
transcription factors it activates the expression of TERT (Blackwood and Eisenman, 
1991, Bazarov et al., 2009). Furthermore the protein MAD-1 has been identified as 
an antagonist to C-MYC (Zhou and Hurlin, 2001). 
The transcription factor E2F1 has a dual role in the regulation of TERT. E2F1 is an 
important regulator of the cell cycle. Over expression of E2F1 is sufficient to initiate 
the expression of S-phase genes and stimulates proliferation of resting cells (Dimova 
and Dyson, 2005). E2F1 has a repressive role as complex E2F1-RB1-HDAC. (Dyson, 
1998). During the cell cycle and cell aging the tumour suppressor retinoblastoma 1 
RB1 is dephosphorylated and thereby active. Through RB1 activation formation of 
E2F1-RB1-HDAC complexes have a repressive effect on the expression of E2F1 
mediated transcription (Narita et al., 2003). In tumour cells E2F1 acts as 
transcriptional repressor for TERT (Crowe and Nguyen, 2001, Crowe et al., 2001) 
while it acts as activator in normal cells. 
The well-known tumour suppressor gene, p53 is also a potent suppressor of TERT. 
Over expression of p53 or activation of endogenous p53 results in a quick decrease 
of TERT expression levels. Further studies suggested that p53 interacts with the 
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transcription factor SP1 which binds to the TERT promoter and inhibits TERT 
expression (Kanaya et al., 2000). Additional studies indicate that p53 inhibits TERT 
expression via induction of the cyclin dependent kinase inhibitor p21 (Shats et al., 
2004). P21 also induces formation of the E2F-RB-HDAC complex via 
dephosphorylation of RB, repressing TERT expression by binding of E2F to the 
relevant binding site within the TERT promoter. Therefore p53 manages, next to 
inhibition of SP1, to suppress expression of TERT via induction of p21 (Shats et al., 
2004). 
 
1.12 RNA Interference 
In the beginning of 1990 two independent research teams made an unexpected 
discovery. They introduced genes into plants to give the blossoms a stronger colour. 
But the blossoms lost their colour in part or completely upon the gene over 
expression (van der Krol et al., 1990). A research group around Wassenegger 
published in 1994 that introducing genes into plant caused inactivation of the 
endogenous one resulting in loss of gene function (Wassenegger et al., 1994). 
Four years later in 1998, Craig Mellow and Andrew Fire showed in Caenorhabditis 
elegans, a nematode, that genes can be knocked out by treating the worms with 
complementary short double stranded RNAs (dsRNA) (Fire et al., 1998). 
Improvements and research in the following years provided a new and easy 
technique to investigate genes and their functions. With the newborn RNA 
interference or for short RNAi (Figure 1-10), it is possible to target every known 
gene and to silence it. 
In principle every cell has the RNAi machinery which marks a very important gene 
regulation mechanism. It is coded in different locations throughout the genome. 
Small RNAs, known as microRNAs (miRNA), are found in introns, exons and 
further regions, referred to as non-coding regions. The miRNAs are transcribed and 
then processed by a series of protein-complexes. Three main enzyme complexes are 
involved in miRNA processing: DROSHA, DICER and RNA induced silencing 
complex (RISC). The endonucleases DROSHA and DICER belong to RNaseIII 
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enzyme family. The exact function of DROSHA and DICER is still under 
investigation. DROSHA processes the primary-miRNA (pri-miRNA) in the nucleus 
by transforming the endogenous miRNA transcript into a hairpin structure, called 
precursor-miRNA (pre-miRNA). For exact cleavage DROSHA needs another protein 
called DGCR8 or PASHA in invertebrates. This protein determines the base of the 
dsRNA hairpins and DROSHA can produce the pre-miRNA. After the pre-miRNA 
has been exported to the cytosol, DICER further processes the miRNA, forming a 
double stranded RNA strand with a sense and antisense strand of about 21-25 
nucleotides of length. DICER then cleaves the hairpin and thereby creates the double 
stranded RNA (Figure 1-9). 
 
Figure 1-9 A model for dicer 
The DICER domain PAZ binds to the 2nt overhang of the 3’ end of the dsRNA. The 
RNaseIII domains form a pseudodimer and hydrolyse each strand of the dsRNA. (Hammond, 
2005) 
 
DICER consists of several domains but their functions still need to be fully 
investigated. An important domain is the PAZ domain which specifically binds to the 
3’ end of the dsRNA. The distance between the PAZ domain and the active cleavage 
site of the RNaseIII enzyme covers the distance of 25 nucleotides which is the final 
length of the dsRNA. It seems the domain structure of DICER is a molecular 
measuring tool that defines the length of the dsRNA by physical rather than 
biochemical aspects. In the next step the processed miRNA is loaded onto the RISC. 
For that two other enzymes are recruited, ARGONAUTE and a dsRNA-binding 
protein (TRBP) forming the RISC loading complex. The miRNA is transferred to the 
ARGONAUTE protein. The sense strand is removed and the antisense miRNA is the 
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guide for the RISC. Interestingly animal miRNAs are only partially complimentary 
to the target mRNA mainly in the 3’ untranslated region. As a consequence, the 
target mRNA is only silenced by blocking translation. In plants the mRNA is cleaved 
by RISC. Plant miRNA is also a 100 % match to the target sequence (Hammond, 
2005, Jinek and Doudna, 2009, Meister and Tuschl, 2004, Novina and Sharp, 2004). 
 
siRNA is an artificially created double stranded RNA molecule. siRNAs are 
designed to be fully complimentary to the target sequence to guarantee the silencing 
of the target mRNA and are normally transfected into the desired cells. For this 
purpose mainly two methods are in use. The electroporation on the one hand uses an 
electric field that punches holes into the cell membrane and thus the siRNA can enter 
the target cell. On the other hand, there are several transfection reagents available to 
guide the artificial dsRNAs through the cell membrane into the cytoplasm where 
they then can act, e.g. Lipofectamine. 
Currently in development are new forms of siRNA transfection methods such as 
nanotechnology or lipids. Thereby siRNAs are attached to nanoparticles or 
encapsulated into liposomes in order to change their charge and enhance the delivery. 
The uptake of these siRNA vehicles occurs then by the natural process of 
endocytosis. 
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Figure 1-10 The miRNA and siRNA pathway – the principle of RNAi 
Scheme of the siRNA and miRNA pathway. (1) The microRNAs gene is transcribed 
by RNA polymerase II and processed by DROSHA. After EXPORTIN-5 bound the 
pre-miRNA (2) it is exported to the cytosol where it is further processed by DICER 
(3). This is the status where transfected siRNA enters the RNAi machinery (red 
underlay). The interfering RNA (iRNA) antisense strand will be incorporated (4) by 
RISC and guides RISC to the target mRNA sequence (5). RISC hydrolyses the target 
mRNA (6) which is then further degraded. RISC will be recycled. (Hammond, 2005) 
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1.13 Preliminary work to this project 
The subject of this thesis is based on results, which have been published in 
November 2005 in Blood (Thomas et al., 2005). In this publication the t(4;11) 
positive cell line SEM expressing the MLL/AF4 fusion transcript was used. 
Treatment of the t(4;11) positive SEM cells with siRNA called “siMA6”, which is 
directed against the fusion gene transcript of der(11) MLL/AF4, led to a specific 
knockdown of the fusion gene transcript and protein expression (Figure 1-11, Figure 
1-12). 
 
Figure 1-11 The siRNA siMA6 causes depletion of MLL/AF4 mRNA. 
The diagram on the left side shows a significant  MLL/AF4 mRNA reduction after 96hours 
of sustained siRNA treatment. siMA6 is the active siRNA against the fusion gene transcript, 
siAGF1 the siRNA control. Significance was tested with an unpaired student t test (p<0.005). 
 
In qRT-PCR experiments MLL/AF4 mRNA was significantly reduced (p<0.005) 
upon application of active siRNA siMA6 to SEM cells compared to treatment with 
siRNA siAGF1, an active siRNA against the fusion gene transcript AML1/MTG8, not 
present in SEM cells. The 96 hours of sustained treatment with siMA6 caused a 70% 
knockdown out of 3 independent experiments at the mRNA-level of expression of 
MLL/AF4. Western Blot experiments showed diminished MLL/AF4 protein 
expression to confirm the successful inhibition of the MLL/AF4 protein biosynthesis. 
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In addition MLL/AF4 depleted SEM cells showed a strong inhibition of proliferation 
compared to mock and control siRNA treated cells (Figure 1-13). 
 
Figure 1-12 Western Blot against MLL/AF4 
The picture shows the MLL/AF4 protein. siMA6 treatment results in depletion of the protein 
level, compared to the controls Mock and siRNA control siMM. GAPDH is used as loading 
control. 
 
 
Figure 1-13 Proliferation curve of SEM cells after sustained siRNA treatment 
The graph shows the proliferation of SEM cells (y-axis) after sustained treatment in days (x-
axis) with active siRNA siMA6 (X) compared to Mock (♦) and control siRNA (*). 
 
Furthermore, induction of apoptosis was associated with MLL/AF4 depletion. The 
SEM cells were harvested after 96 hours of continuous siRNA treatment and were 
analysed for apoptosis by annexin-V staining. A three-fold increase of apoptosis was 
observed compared to mock and a control siRNA. This finding was validated by 
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immunoblotting against the anti-apoptotic protein BCL-XL and cleavage of caspase 
3 (CASP3), a clear induction of apoptosis pathway activation (Figure 1-14). 
 
 
 
 
Figure 1-14 Induction of apoptosis upon MLL-/AF4 depletion 
SEM cells were treated 96 hours with siRNA. The graph on the left side represents the result 
of an annexin-5 staining and shows a three-fold increase of apoptosis as consequence of 
MLL/AF4 depletion compared to mock and control siRNA treatment. The induction of 
apoptosis was further observed by western blot for cleaved CASP 3 and the anti-apoptotic 
protein BCL-XL. 
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1.13.1 Aim of this study 
 
The aim of the research presented in this thesis was to identify additional novel target 
genes for MLL/AF4. Preliminary studies and publications (Milne et al., 2002, 
Schraets et al., 2003, Thomas et al., 2005) suggested HOXA7, HOXA9 and HOXA10. 
The study was to examine other genes of the HOXA cluster. These genes are known 
to be regulators in early haematopoiesis so we hypothesised MLL/AF4 together with 
the HOXA genes play an important role in the stem cell character of the SEM cells. 
A secondary objective was to investigate the inhibition of telomerase activity as 
consequence of siRNA mediated MLL/AF4 knockdown. Preliminary results strongly 
suggested an effect on telomerase activity upon MLL/AF4 knockdown. Further to 
telomerase activity, the major subunits of the telomerase, TERT and TERC, should 
be investigated. 
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2 Results 
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2.1 Genes of the HOXA cluster as possible MLL/AF4 targets 
2.1.1 Introduction 
Genes of the HoxA cluster are important genes as they play a major role in 
controlling early haematopoiesis in both differentiation and maturation. Whether 
those genes play a role in leukaemia has also been investigated, although so far, their 
contribution towards the malignant transformation of haematopoietic cells is unclear. 
These genes have been especially investigated in leukaemic cells positive for a MLL 
rearrangement. The link here is that mll has been shown to regulate hox gene 
expression in mice and their homologues do the same in drosophila. In ALL and 
AML cell line models and patients the posterior genes of the HoxA cluster, HoxA7 
to HoxA10 in particular, have been shown to be alternatively regulated in the 
diseased cells. The other HoxA genes may have roles in early haematopoiesis but 
have not been investigated in a MLL rearranged leukaemia model. 
Initially the effect of MLL/AF4 knockdown on all genes of the HoxA cluster was 
first examined. For this purpose the t(4;11) positive cell line SEM was treated with 
an siRNA specifically designed against the fusion transcript as published(Thomas et 
al., 2005). The cells were treated twice with siRNA in the beginning and 48 hours 
after the first treatment. Cells were then harvested 48 hours after the second siRNA 
treatment and analysed by qRT-PCR for HoxA gene expression. In addition 
significantly altered expressed genes were examined for their protein levels by 
western blot. This first series of experiments should reveal possible new target genes 
of MLL/AF4 within the HOXA cluster. 
2.1.2 Real time PCR – important notes 
Real Time PCR data is acquired by measuring the fluorescent signal strength in each 
reaction cycle of the PCR with a total of forty cycles. According to the literature real 
time PCR reaction analysis is divided into four phases (Figure 2-1). The first one is 
the linear ground phase, where no PCR product is measured. In this phase there is not 
enough PCR product to produce a measurable fluorescent signal. Following the 
ground phase comes the early exponential phase, where the first PCR products can 
be detected. This phase switches over to the log-linear phase were, if optimal primer 
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binding occurs, the PCR product is doubled during every cycle. In this phase the so 
called cycle threshold (CT) is determined. This value is most important for the 
calculation of the amount of PCR product. The CT is the cycle number at which the 
fluorescent signal, generated during the PCR reaction, exceeds a predefined 
threshold. This threshold is arbitrary defined by the machine’s manufacturer and can 
be adjusted by the user. The optimum for setting the CT is the transition point 
between the early exponential phase and the log-linear phase. The starting point of 
the early exponential and log-linear phase very much depends on the gene of interest. 
In general it seems that highly expressed genes like GAPDH are measured during 
cycle 10 – 12. The log-linear phase is normally measured up to cycle 30. The final 
phase is the plateau phase. In this phase the PCR product is no longer doubled in 
every cycle. This might have various reasons, such as decreasing activity of the 
polymerase or exhausting reaction components. CT values determined within this 
phase must be considered with care as they might not reflect the real situation. CT 
values from cycle 30 onwards should only be considered as an approximate value. 
 
Figure 2-1 Phases of the PCR amplification 
This graph demonstrates the four phases of the PCR amplification curve. On the y-
axis, ∆RN describes the fluorescent signal, calculated from the signal of the 
fluorescent dye and a reference dye in the reaction. The x-axis shows the cycle 
numbers of the PCR reaction. The red line shows a typical amplification curve. The 
four phases are of the amplification are shown. Taken from http://www.dorak.info 
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2.1.3 General HOXA gene expression in SEM cells 
The first step was to determine basal mRNA expression levels of the HOXA genes in 
SEM cells, so relative gene expression of each individual HOXA genes was 
compared to internal GAPDH transcript control. 
SEM cells were taken, RNA was extracted and mRNA levels were analysed by qRT-
PCR. Results were analysed with SDS version 2.2 (Applied Biosystems) and Excel 
(Microsoft). Average ct cycle values were visualised as a bar chart (Figure 2-2) and 
relative HOXA gene expression levels were compared to the internal housekeeping 
gene GAPDH (Figure 2-3).  
 
Figure 2-2 HOX and GAPDH gene expression in SEM cells 
This bar chart shows the average CT cycle values of the HOXA genes. The error bars 
indicate average standard deviations of two (HOXA2 and 3) and four (HOXA4 – 10, 
GAPDH) independent experiments, respectively. The table shows the average CT 
cycle and standard deviation values of the according gene. 
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Figure 2-3 Relative expression of HOXA genes in SEM cells 
Relative mRNA expression levels of the HOXA genes compared to GAPDH internal control. 
 
The results show that HOXA1, HOXA11 or HOXA13 were not expressed. In contrast, 
HOXA7, HOXA9 and HOXA10 show the most abundant gene expression followed 
by the remaining HOXA genes A2-A6. MLL/AF4 is also expressed at a higher level 
comparable to the posterior HOXA genes. Remarkable is the high expression of 
HOXA9 which is about 4-fold compared to the other investigated HOXA genes and 
MLL/AF4. 
The present results reflect the expression level of the HOXA genes in a cell line. This 
might be completely different in primary human leukaemic cells. To achieve this 
goal, primary leukaemic cells from patients with ALL should be compared where the 
HOXA genes should compared to a suitable internal control, for example GAPDH. 
This data should be acquired from each patient and subsequently compared to the 
data from the other patients. This would results in a good overview of the HOXA 
gene activity in a cohort of ALL patients. 
  
 51 
 
2.1.4 siRNA mediated knockdown of MLL/AF4 affects HOXA gene 
expression 
Results of previous published work showed that the expression of at least two 
members of the HOXA gene cluster was influenced by MLL/AF4 knockdown, 
namely the genes HOXA7 and HOXA9 (Thomas et al., 2005). Further to these results, 
primers were designed to investigate the other members of the HOXA cluster. In 
qRT-PCR experiments the effect of MLL/AF4 knockdown on the HOXA genes. 
HOXA2, HOXA3, HOXA4, HOXA5, HOXA6 and HOXA10 were analysed. To support 
earlier results HOXA7 and HOXA9 were included in the experiments. 
The main goal of the HOXA cluster analysis was to determine the effect of siRNA 
mediated MLL/AF4 knockdown on the genes of the HOXA cluster. The siRNAs 
used were siMA6, which is targeted against the MLL/AF4 mRNA, and siAGF6 
which is a siRNA designed to target the fusion gene transcript AML1/ETO, a 
transcript that is present in AML cells with the t(8;21) translocation (e.g. SKNO cells 
or Kasumi-1 cells). This control was preferred over usual scrambled siRNA, as it 
successfully targets another fusion gene transcript (Heidenreich et al., 2003), thereby 
further demonstrating the specificity of the siRNA. 
SEM cells were cultured and electroporated twice with 500nM siRNA on day zero 
and day two of the experiment. Cells were harvested two days after the second 
electroporation, mRNA was isolated and quantified by qRT-PCR. Results were 
analysed using Excel. Relative fold change of mRNA expression of MLL/AF4 
depleted and siAGF1 transfected non-target control cells was compared to untreated 
mock control. As HOXA1, HOXA11 and HOXA13 did not show any mRNA 
expression, those genes were not included in the experiment. The mRNAs of HOXA2 
and HOXA3 were analysed in two independent experiments, but no knockdown was 
detected. HOXA4 showed a knockdown of about 70% upon MLL/AF4 depletion in 
two independent experiments, but due to the general very low expression levels 
(average CT value of 32) of HOXA4 it was decided to concentrate on the main 
candidates. HOXA5 was analysed in four independent experiment. No significant 
(student t test: p<0.9) differences in gene expression were observed with MLL/AF4 
depletion (Figure 2-4). 
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Figure 2-4 HOX gene expression after MLL/AF4 knockdown – part 1 
This picture shows the qRT-PCR analysis of relative HOXA mRNA levels (y-axis) after 96 
hours of sustained MLL/AF4 suppression by active siRNA siMA6 and siAGF6 control (x-
axis) in SEM cells. HOXA2, HOXA3 and HOXA4 were analysed in two independent 
experiments. The error bars represent standard deviation of two experiments. HOXA5 was 
analysed in four independent experiments. The error bars represent the standard deviation of 
four independent experiments. The result is not significant (p < 0.9), tested with student t test. 
 
The following results on HOXA6, HOXA7, HOXA9 and HOXA10 were obtained after 
SEM cells were treated twice with the MLL/AF4 fusion transcript specific siRNA 
siMA6 and control siRNA siAGF1. All experiments were performed at least three 
times each in triplicates (Figure 2-5). Upon depletion of MLL/AF4 mRNA levels of 
HOXA6 were significantly (p<0.005) reduced to about 70%. Western Blot analysis 
for the HOXA6 protein confirmed the mRNA results (Figure 2-3). HOXA7 and 
HOXA9 have been analysed in previous experiments and results have been published 
(Thomas et al., 2005). To confirm the HOXA7 knockdown, qRT-PCR analysis were 
repeated three times and western blot experiments were performed to confirm 
HOXA7 protein depletion. MLL/AF4 knockdown via siRNA caused a significant 
(p<0.02) depletion of HOXA7 mRNA of about 80% and a reduction of HOXA7 
protein expression (Figure 2-3). HOXA9 mRNA reduction after MLL/AF4 
knockdown was around 65% and protein analysis by immuno blotting reflects this 
substantial change (p<0.003) (Figure 2-3).The depletion of MLL/AF4 with the 
siRNA treatment led to a significant reduction (p<0.03) of HOXA10 mRNA around 
80%. However, western Blot on HOXA10 was not successful. 
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Figure 2-5 HOX gene expression after MLL/AF4 knockdown - part 2 
The qRT-PCR analysis of relative HOXA mRNA levels (y-axis) after 96 hours of sustained 
MLL/AF4 suppression by siRNA (x-axis) in SEM cells. The error bars represent the 
standard error of the mean (SEM) of three independent experiments. All experiments were 
performed in triplicate. All results are significant (HOXA6: p<0.005; HOXA7 p<0.02; 
HOXA9 p<0.003; HOXA10 p<0.03). Test of significance was performed by an unpaired 
student t test. 
 
 
Figure 2-6 Protein analysis of several HOX genes after MLL/AF4 depletion 
Protein analysis shows reduction of HOXA6 (~37kDa), HOXA7 (~25kDa) and HOXA9 
(~36kDa) after MLL/AF4 depletion. Protein was yielded after 96 hours of sustained siRNA 
treatment. GAPDH (~37kDa) served as a loading control. 
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2.1.5 Summary and discussion 
The first achievement during this thesis was the analysis of the HOXA cluster upon 
depletion of the MLL/AF4 fusion protein using a siRNA approach. The examination 
of the basal expression of the HOXA genes in the cell line SEM showed a low 
expression of the anterior HOX genes HOXA2 – HOXA5. Anterior HOXA genes are 
expressed in very early stages of the haematopoiesis and since may have already 
passed the stage where those genes are active. Expression of the posterior HOXA 
genes HOXA6, A7, A9 and A10 was stronger, especially HOXA7 and HOXA9. 
While HOXA9 has been described in the literature to be highly upregulated in 
haematopoietic malignancies involving the MLL gene, there is sparse literature 
available on HOXA7, HOXA6 and HOXA10. HOXA1, HOXA11 and HOXA13 were 
not detectable in the experiments. It is difficult to explain this finding. Since no 
positive control was used when testing the primers it is possible that the PCR did not 
work properly. It is also possible that expression of these HOXA genes may be 
silenced or deleted in SEM cells for unknown reasons. 
The knockdown experiments show a comparable result. The majority of the anterior 
HOXA genes did not show a change in gene expression upon MLL/AF4 knockdown. 
An exception is HOXA4 which did show a decrease in expression after siRNA 
treatment. Although this was a substantial knockdown of about 70% it was decided 
not to pursue those findings further, as the expression level of HOXA4 is very low 
with a CT cycle value of about 32. As a rule of thumb values above 30 should not be 
considered as significant result but more as approximate values. 
A new possible target of MLL/AF4 was found in HOXA6. A significant reduction at 
the mRNA level of about 70% was found and confirmed in western blot experiments 
which clearly demonstrated HOXA6 being affected by MLL/AF4 regulation. 
Knockdown of MLL/AF4 did also deplete mRNA levels of HOXA7 and HOXA9 
significantly. Furthermore to those results western blot experiments for HOXA7 and 
HOXA9 support the findings. Those results confirm already published results 
(Thomas et al., 2005). 
HOXA10 was also examined in three independent experiments. A significant 
knockdown of HOXA10 upon MLL/AF4 depletion could be detected at the mRNA 
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level however all attempts to detect HOXA10 on protein level were unsuccessful. 
Further establishment of the HOXA10 western blot is necessary to show the effect of 
MLL/AF4 knockdown on this member of the HOXA cluster. 
2.2 MLL/AF4 knockdown reduces telomerase activity 
2.2.1 Introduction 
A major hallmark of cancer cell lines is a high activity of the telomerase, a 
ribonuclear protein complex which is responsible for maintaining the telomeres. The 
telomerase is a complex consisting of two major sub units, the reverse transcriptase 
of the telomerase (TERT) and the RNA component (TERC). 
After knockdown of MLL/AF4 proliferation and self renewal of the affected cells 
were disrupted. The hypothesis was that depletion of MLL/AF4 also may have an 
effect on telomerase activity. To check telomerase activity after MLL/AF4 depletion, 
siRNA treated SEM cells were analysed with a qPCR based telomeric repeat 
amplification protocol (TRAP) assay (Wege et al., 2003). The advantage of this 
method in comparison to the classic TRAP assay is, it is easy and quick in handling. 
Briefly SEM cells were treated twice with the relevant siRNAs (siMA6 and siAGF1 
control). The SEM cells were lysed in a non-denaturing buffer to maintain protein 
activity after cell lysis. A protease inhibitor mix was added additionally. According 
to the literature, primers were designed, that mimic typical telomeric ends. Active 
telomerase would detect those “fake” telomeres and start to synthesise new telomeric 
repeats. With a second set of primers it is possible to perform real time PCR to detect 
those newly made telomeres. To compare telomerase activity of treated and untreated 
SEM cells a standard curve was created using a serial dilution of SEM cells. Using 
this standard curve, telomerase activity was determined after siRNA treatment. 
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2.2.2 Depletion of MLL/AF4 results in diminished telomerase activity 
For the standard curve SEM cells were harvested and lysed in non-denaturing, 
proteinase inhibitor supplied buffer. Telomerase activity was determined from        
50 000, 25 000, 10 000, 5 000 and 1 000 cells. Lysis buffer only was taken as zero 
control. From that data the correlation coefficient was calculated. It was 0.97 which 
is acceptable for the standard curve. For determination of telomerase activity in 
MLL/AF4 depleted cells, SEM cells were treated twice with siRNA siMA6 and 
siRNA control siAGF6, respectively. Cells were harvested and telomerase activity 
was determined from 25 000 cells. Based on the standard curve, telomerase activity 
in active siMA6 siRNA treated SEM cells was lowered to 30% due to MLL/AF4 
depletion compared to the control siRNA experiment. The experiment was 
performed once in triplicate (Figure 2-7) and confirms results previously done by 
Maria Thomas. 
 
 
 
Figure 2-7 Telomerase activity of MLL/AF4 depleted SEM cells 
The graph on the left side shows a standard curve created from a serial dilution of untreated 
SEM cells. On the right side a qRT-PCR analysis was performed on treated SEM cells. The 
amplicon cycle values (Ct) were compared with the standard curve Ct-values. 
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2.2.3 Effect of MLL/AF4 depletion on TERT and TERC 
Initial experiments showed a decreased telomerase activity upon MLL/AF4 depletion 
in SEM cells. To investigate the effect of MLL/AF4 knockdown on the telomerase in 
detail, experiments were designed to examine the two major components of the 
telomerase TERT and TERC. To investigate their involvement in the telomerase 
activity reduction upon MLL/AF4 depletion SEM cells were treated twice with 
active siRNA siMA6, mismatch control siRNA (siAGF1) and mock. Two days after 
the second electroporation the cells were harvested, RNA and protein were isolated 
and analysed for TERT and TERC expression by qRT-PCR and Western Blotting. 
 
Figure 2-8 MLL/AF4 depletion affects TERT but not TERC expression 
The upper row shows on the left side the result of three independent qRT-PCR experiments, 
performed in triplicate. A significant reduction (p<0.002) of TERT mRNA upon siMA6 
treatment of SEM cells was observed. Control siRNA siAGF1 and mock control show no 
effect. On the right sight, TERC mRNA levels were investigated. No significant differences 
were detected (p<0.8). The error bars represent the standard deviation of two independent 
experiments, performed in triplicate. The lower picture represents a western blot analysis of 
TERT. TERT protein is clearly reduced upon MLL/AF4 depletion. GAPDH serves as 
loading control. Test of significance was done by using an unpaired student t test. 
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A moderate but statistically significant (p<0.002) mRNA reduction of 40% was 
detected for TERT after MLL/AF4 knockdown by active siRNA siMA6 compared to 
siAGF1 and mock control. The experiment was performed three times in triplicate. 
This result was further analysed and confirmed in western blot experiments where a 
reduction of TERT protein was clearly detected upon depletion of MLL/AF4 (Figure 
2-8). TERC mRNA levels were investigated in two independent experiments also in 
triplicates. No significant differences were detected (p<0.8). 
 
2.2.4 Discussion 
The results in this section are an important finding for the whole thesis. Here it is 
shown, that the MLL/AF4 knockdown has also a negative effect on a mechanism 
which is of utmost importance for the survival of cells which are highly proliferative 
such as malignant haematopoietic cells. The importance of the telomerase has been 
discussed for nearly two decades. Since its description in the late 80’s numerous 
publications have shown, that maintenance of the telomeres by telomerase is one of 
the most important mechanisms for cell survival. Especially for fast proliferating 
cells like haematopoietic cells and stem cells, active telomerase and telomere 
maintaining is vital. This seems also to be the case for most malignant cells, where a 
high telomerase activity is found. Exact mechanisms of telomerase regulation in 
cancerous cells are still under investigation. 
The results of this chapter show a clear reduction of telomerase activity of roughly 
70% after knockdown of MLL/AF4 caused by siRNA treatment. This has been 
shown in the t(4;11) positive cell line SEM. To further investigate the effect of 
MLL/AF4 on telomerase, the subunits TERT and TERC were analysed after 
MLL/AF4 depletion. While TERC, the RNA component of the telomerase did not 
show any alterations in expression after MLL/AF4 knockdown, the reverse 
transcriptase of the telomerase, TERT, showed a significant knockdown of 40% at 
the RNA level which was in addition confirmed by protein analysis in western blot 
experiments. As described by others (Thomas et al., 2005) knockdown of MLL/AF4 
has a fatal effect on leukaemic cells. 
It has also been shown (unpublished data, PhD thesis Maria Thomas), that siRNA 
mediated knockdown of HOXA7 in MLL/AF4 positive cells also leads to reduction 
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of telomerase activity and downregulation of TERT. In the following experiments 
the aim was to investigate the effect of HOXA7 on TERT in detail. 
2.3 TERT is a downstream target of HOXA7 
2.3.1 Results 
To further investigate whether there is a direct connection between HOXA7 and 
TERT, siRNAs against the HOXA7 transcript (siHOXA7) were designed. SEM cells 
were electroporated twice with siHOXA7, siMA6 and siAGF1. siRNA mediated 
knockdown of MLL/AF4, HOXA7and TERT were investigated by qRT-PCR. To 
confirm previous data by others (PhD thesis Maria Thomas) the experiment was 
performed once in triplicate (Figure 2-9). siRNA mediated knockdown of MLL/AF4 
showed diminished levels of transcript for HOXA7 and TERT. Knockdown of 
HOXA7 mRNA using siHOXA7 had no effect on MLL/AF4 mRNA but reduced the 
TERT transcript to 60 %, comparable to results using siRNA against MLL/AF4. This 
finding confirmed previous results in the group done by Maria Thomas. 
 
Figure 2-9 HOXA7 knockdown reduces TERT but not MLL/AF4 transcript 
levels 
MLL/AF4 siRNA siMA6 reduces MLL/AF4 (dark gray bar), HOXA7 (light grey bar) and 
TERT (medium grey bar) transcript levels. siHOXA7 reduced TERT mRNA by 40 % but had 
no effect on MLL/AF4. Active non targeting siRNA siAGF1 did not have any effect. 
GAPDH was used as a housekeeping gene. 
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2.3.2 Discussion 
The effect of siRNA mediated MLL/AF4 knockdown on genes like HOXA7 and 
TERT give a valuable insight into the signalling mechanism of MLL/AF4. Both 
genes show a significantly decreased expression level at both the mRNA and protein 
level upon MLL/AF4 knockdown. Knockdown of HOXA7 does not influence 
MLL/AF4 expression but TERT mRNA expression was reduced by 40%, a 
comparable value to MLL/AF4 knockdown. Confirmation at the protein level was 
not done due to time constraints, but would be important to confirm those results. 
Those results suggest that MLL/AF4 has a direct effect on HOXA7 which in turn 
seems to have a regulatory effect on TERT. The loss of TERT is very likely the 
reason for the diminished telomerase activity. Publications show that telomerase 
activity is mostly dependent on the reverse transcriptase rather than on the RNA 
component (Wong et al., 2000) though this mechanism might be also active here. 
This could be further investigated by using siRNA against the TERT transcript. The 
aim here would be to investigate whether the loss of TERT does have a similar effect 
on MLL/AF4 positive cells as loss of MLL/AF4 or HOXA7. 
2.4 HOXA7 binds to the promoter of TERT 
2.4.1 Introduction 
The results obtained so far strongly suggest that HOXA7 regulates TERT activity. 
Whether this regulation is direct or indirect was the research question for the next 
chapter. To investigate this matter, chromatin immuno precipitation (ChIP) was used. 
With this method it is possible to investigate direct binding of a certain transcription 
factor to the chromatin, for example transcription factor binding to a region within 
the promoter region of a gene of interest. 
The critical point of this method is the choice of the right antibody. To receive good 
results the antibody must be very specific. As antibodies for HOXA7 are relatively 
rare and probably not specific enough for the ChIP, we used a plasmid that encoded 
for a murine hoxa7-flag protein. We then used antibodies which are specific for the 
flag sequence to perform the ChIP. Another more uncommon approach during the 
experiment was the use of inactivated bacteria particles for the pull down. Normally 
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beads covered with protein A are used for the pull down. Bacteria also have lots of 
protein A on their surface and gives a better pull down material with a larger surface 
thus produces a tighter pellet compared to the beads. 
Our hypothesis was that HOXA7 binds somewhere within the TERT promoter. By 
ChIP the aim was to identify this region.  
Briefly, SEM cells were transformed with a hoxa7-flag containing plasmid and 
incubated overnight. Cells were fixed with formaldehyde, lysed and chromatin was 
sheared by ultra-sonication. Flag-specific antibodies precipitated the hoxa7-flag 
construct together with bound chromatin. After removing the proteins by reverse 
crosslinking remaining DNA fragments were investigated by standard PCR. 
Before performing the ChIP experiments, primers had to be designed to cover most 
of the TERT promoter. The described core promoter of TERT was selected for the 
ChIP experiment (Takakura et al., 1999). To further get a first idea on possible 
binding sites for HOXA7 in the TERT promoter region, a protein database and a 
browser based program called MatInspector® was used. This program investigates a 
customised sequence for possible transcription factor binding sites. All transcription 
factors have specific binding sequences and MatInspector uses this information for 
estimating the possibility of transcription factor binding. Thus it is possible to predict 
possible binding sites for HOXA7 within the TERT promoter. 
2.4.2 Searching for HOXA7 binding sites in the TERT promoter region 
The observed TERT depletion caused by siRNA mediated HOXA7 knockdown led to 
the assumption that TERT is a direct target of HOXA. To investigate the possible 
connection between HOXA7 and TERT an in-silico experiment was performed. The 
browser based program MatInspector from Genomatix was used to investigate the 
promoter region of TERT for putative binding sites for HOXA7. After the sequence 
of the TERT promoter was analysed MatInspector identified several possible binding 
sites for HOXA7 (Figure 2-10). 
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Figure 2-10 Putative binding sites for HOXA7 in the promoter of TERT 
The schematic of TERT shows the promoter region from -2000bp upstream to +1500bp 
downstream of the start of transcription. The core promoter region has been defined by 
Takakura et al.(Takakura et al., 1999) and is illustrated by a black arrow. The black dots 
represent putative binding sites suggested by the MatInspector program from Genomatix. 
 
It is important to realise that this is only a prediction of binding sites as the program 
only identifies fragments and calculates a possibility for transcription factor binding. 
As the putative binding sites were spread over a region from roughly -750 to -2000 
base pairs (bp) primers were designed to cover the region from the start of 
transcription to -2000 bp. The program also revealed putative binding sites of other 
HOX proteins, mostly HOXA9 and HOX co-factors like MEIS and PBX proteins 
downstream of the transcription start site. Thus it was decided to include a region up 
to +1500 bp downstream of the transcription start into the analysis. 
2.4.3 Chromatin immune precipitation reveals HOXA7 binding in the 
TERT promoter 
Based on the suggestion of the MatInspector results for possible binding sites of 
HOXA7 in the TERT promoter (Takakura et al., 1999), several PCR primers were 
designed to cover a region from -2000bp to +1500bp for the start of transcription of 
TERT (Figure 2-11). For the experiment the plasmid pMSCVpuro-fhoxa7 (gift from 
Dr. R. Slany, University of Erlangen), expressing FLAG-tagged murine hoxa7 
protein, was transiently introduced into SEM cells. As a specificity control, 
pMSCVpuro-ffhl2 (gift from Dr. S. Raimundo, University of Tuebingen), expressing 
FLAG-tagged fhl2, was transfected into control SEM cells.  
16 hours after transcription the cells were harvested and the Chromatin-IP was 
performed (Figure 2-12). It showed that the FLAG-tagged hoxa7 transcription factor 
binds to a region between 1.0kb and 1.5kb upstream of the transcription start of 
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TERT, but not FLAG-tagged fhl2 which served as a specificity control. 6 % of total 
chromatin was used as input control. 
 
 
Figure 2-11 Scheme of the TERT promoter 
The gray bar represents a scheme of the TERT promoter and coding region. The red bars 
represent the approximate position of the PCR amplicons, while the table shows their exact 
position. Numbers represent the bp from the start of transcription. 
 
 
Figure 2-12 Chromatin IP reveals HOXA7 binding in the TERT promoter 
SEM cells were transiently transfected with either a plasmid coding a FLAG-tagged Hoxa7 
or a plasmid coding a FLAG-tagged FHL2 as a specificity control. The left box shows the 
results of the amplicons from the SEM cells transfected with the plasmid coding the FLAG-
tagged HOXA7 and the right box shows the results achieved with the specificity control. It 
can be clearly seen that the expressed fHoxa7 binds to the TERT promoter but not fFhl2. In 
both cases the negative controls without antibodies (-ab) did not show any binding and the 
input control of material in the Chromatin-IP was positive. 6 % of total chromatin was used 
as the input control. 
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2.4.4 Discussion 
In this section the aim was to investigate a possible direct regulation of the reverse 
transcriptase of the telomerase (TERT) by the HOXA7 transcription factor. Previous 
results have shown that knockdown of HOXA7 affects TERT but not MLL/AF4 
expression. This implies TERT being a downstream target of HOXA7. The 
investigation was performed in two steps. Firstly the core promoter sequence of 
TERT was analysed with a browser-based program called MatInspector. This 
program calculates putative transcription factor binding sites within a specified 
sequence by aligning the given sequence with a transcription factor database. 
MatInspector predicted multiple binding sites for HOXA7, HOXA9 and their co-
factors MEIS1 and PBX within a region spanning over 3500bp starting from -2000 
bp up to 1500 bp from the transcription start of TERT. Possible HOXA7 binding 
sites were only identified in the promoter region of TERT (Figure 2-10). Based on 
this prediction, primers were designed for the following chromatin immuno 
precipitation (ChIP) (Figure 2-11). The ChIP was performed by immunoprecipitation 
of a murine hoxa7-FLAG construct which was transiently transfected into SEM cells. 
The ChIP revealed direct binding of HOXA7 in the promoter region of TERT. This 
result was also confirmed by other group members investigating the same promoter 
region. 
To improve the performed experiments, it is necessary to establish a ChIP protocol 
which uses a human anti-HOXA7 antibody. Of course such a project relies either on 
the quality of commercially available antibodies or an antibody must be created by 
oneself. Further experiments should investigate also other HOX genes and their 
cofactors. HOXA9 would be a strong candidate, as it is also downregulated after 
MLL/AF4 knockdown. For the same reasons MEIS1 represents another important 
factor that needs to be investigated. 
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2.5 MLL/AF4 knockdown and mRNA expression of transcriptional 
target during caspase inhibition  
2.5.1 Introduction 
Results in the previous sections demonstrated that MLL/AF4 knockdown induced 
apoptosis. It was hypothesised that the induction of apoptosis by MLL/AF4 
knockdown might obscure molecular processes, thus knockdown was investigated 
whilst inhibiting apoptosis using zVAD, a cell permeable pan caspase inhibitor. The 
abbreviation zVAD stands for the chemical compound Z-Val-Ala-Asp(OCH3)-
Fluoromethylketone which acts as an irreversible, cell-permeable, broad-spectrum 
caspase inhibitor. This inhibitor binds irreversibly to the catalytic site of caspase 
proteases and inhibits activation of apoptosis.  
To investigate the effect of apoptotic inhibition in the context of siRNA mediated 
knockdown of MLL/AF4 a combined experiment was performed where SEM cells 
were treated with the active siRNA siMA6, control siRNA siAGF1 and mock 
together with the pan caspase inhibitor zVAD and compared untreated controls. The 
cells were harvested two days after two or three successive siRNA treatments, 
combined with or without zVAD treatment or untreated. As zVAD was prepared in 
DMSO which can be cytotoxic, a DMSO control was employed which followed the 
same protocol as the zVAD experiment but without the inhibitor itself. 
2.5.2 Results 
Using qRT-PCR, the mRNA levels of MLL/AF4, HOXA7 and TERT were 
investigated (Figure 2-13). While the addition of zVAD had no impact on the mRNA 
level changes of MLL/AF4 and HOXA7 after two and three electroporations of 
combined siRNA/zVAD treatment, TERT showed a prominent difference in the 
levels of reduction. Compared with the DMSO control, MLL/AF4 depletion and 
addition of zVAD reduced the mRNA level of TERT by 80%-90%. The decrease of 
TERT expression in the DMSO control was about 40%-50%. This effect was 
monitored in cells harvested after two and three electroporations. 
 66 
 
 
Figure 2-13 Inhibition of apoptosis by the pan caspase inhibitor zVAD  
Analysis of the mRNA level performed after 4 and 6 days of combined siRNA/zVAD 
treatment. Y-axis shows relative fold change compared to mock control. GAPDH was used 
as housekeeping gene. Analysis with qRT-PCR revealed stronger knockdown of TERT in 
zVAD treated cells upon treatment with siMA6 compared to control cells treated with 
siAGF1. MLL/AF4 and HOXA7 levels remained unaffected. 
To accompany these analyses the distribution of cells within the cell cycle was then 
determined using fluorescent activating cell sorting (FACS). During the cell cycle 
cells are distributed into four different stages which can be monitored by FACS. All 
living cells can be found in the G1/G0 phase, which is directly after cell divison, the 
S phase and the subsequent G2/M phase. Dead cells appear in a population which is 
called the sub G1/G0 phase (Figure 4-8). FACS analysis showed that after addition 
of zVAD no alteration of the cell cycle distribution after two, four or six days with 
combined siRNA/zVAD treatment was observed. To monitor the effect of zVAD the 
sub G1/G0 population, which represents the amount of dead cells in the cell cycle, 
was analysed. After two days control cells showed about 3.5 % of the cells in the sub 
G1/G0 phase. zVAD treated cells contained a population of 1 – 1.5 % in the sub 
G1/G0 phase. After 4 days, DMSO treated cells showed a typical sub G1/G0 
population for dead cells which is about 3%. Due to the siRNA treatment, the mock 
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and control siRNA treated cells also showed normal amounts of cells in the sub 
G1/G0 phase (~ 3-4%) while siMA6 treated cells showed 12% of dead cells. FACS 
analysis of the combined siRNA/zVAD treated cells showed a very low percentage 
of cells in the sub G1/G0 phase. Control cells had about 1% dead while the cells 
treated with active siRNA siMA6 showed only 2% dead cells. Interestingly, after 6 
days of zVAD treatment a high amount of dead cells was detected in the sub G1/G0 
population comparable with the DMSO control. In both samples MLL/AF4 depletion 
showed a subG1/G0 population of about 35% as. It was expected that zVAD would 
prevent the cells from dying by inhibiting the caspases (Figure 2-14). Experiments 
done in the group by Patricia Garrido Castro investigating this sub G1/G0 peak 
revealed that this population was not apoptotic as judged by Annexin-V staining or 
western blots against CASP3, CASP7 or PARP. 
 
Figure 2-14 FACS analysis of subG1/G0 cell population after combined 
siRNA/zVAD treatment 
SEM cells were treated with siRNA or mock together with either zVAD or DMSO. Cells 
were harvested after two (A), four (B) or six days (C) and analysed with FACS. The 
percentage of the cell population in subG1/G0 phase is represented on the y-axis, siRNA 
treatment on the x-axis. 
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2.5.3 Discussion 
MLL/AF4 depletion leads to an increase in apoptosis and to down regulation of 
certain genes like HOXA7 and TERT. In this section of the thesis the effect of 
MLL/AF4 knockdown on HOXA7 and TERT were analysed while supressing 
apoptosis by applying an anti-apoptotic agent called zVAD. zVAD in a pan-caspase 
inhibitor that blocks caspases by irreversible binding to their catalytic centre. As 
caspases are the main mediators of apoptosis their blocking results in apoptosis 
inhibition. 
The results showed an increase in TERT reduction upon siRNA mediated MLL/AF4 
knockdown with simultaneous apoptosis inhibition. The knockdown effect on 
HOXA7 was not altered which suggests an effect specific for TERT rather than a 
general one. It is also unlikely that it is a siRNA dependent effect as this should also 
be reflected in MLL/AF4 or HOXA7 knockdowns. One explanation could be that 
biologic processes during apoptosis might alter TERT expression. TERT has been 
reported to be anti-apoptotic so maybe during apoptosis cells try to survive by 
upregulating TERT. As apoptosis is not activated in zVAD treated cells, this 
hypothetical mechanism is also not active. As zVAD is targeting caspases, they 
could provide a target to further analyse this finding. 
2.6 Rescue experiments for HOXA7 and TERT 
2.6.1 Introduction 
As shown in the previous sections MLL/AF4 knockdown has dramatic effects on cell 
survival such as increased apoptosis, diminished self-renewal capability and 
inhibition of proliferation. Possible key players are HOXA7 and TERT. To 
investigate this, an artificial over-expression of HOXA7 or TERT should be realised 
in t(4;11) positive SEM cells. The hypothesis was that HOXA7 or TERT 
overexpression in the leukaemic cells would lead to a rescue of the cells after siRNA 
mediated knockdown of MLL/AF4. A lentiviral system was used to create a 
modified SEM cell line which over expresses either HOXA7 or TERT. To create 
HOXA7 overexpressing cells, a lentiviral vector was already available. The vector 
expresses a murine form of hoxa7 together with a FLAG and eGFP construct. The 
TERT containing lentiviral vector had to be created. 
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2.6.2 Generation of a lentiviral vector containing cDNA of human 
TERT 
In the basic lentiviral vector, pHR-SINcPPT-SIEW (pSIEW) (Figure 2-15) the 
sequence of the cDNA of TERT, the so called TERT fragment had to be integrated. 
The elements which are important for the lentivirus production are inserted between 
the 5’ long terminal repeat (LTR) and the 3’ LTR. The LTRs harbour several viral 
promoters and enhancers. During the integration of the wild type viral genome into 
the host genome, rearrangements of the LTRs take place which form a new element 
enabling viral reproduction, however for genetic engineering mutations within the 
LTR’s sequence prevent the formation of the self-reproducing signal (SIN = Self 
Inactivation). The pSIEW vector contains a SFFV promoter which should drive the 
expression of the integrated gene. The SFFV promoter is derived from the spleen 
focus-forming virus. An internal ribosomal entry site (IRES) follows the integrated 
gene. Usually, in eukaryotes the translation can only be initiated at the 5’ end of the 
mRNA molecule. The integration of the IRES allows for initiation of translation 
from a second open reading frame (ORF) of the mRNA molecule. Downstream of 
the IRES is a sequence coding for an enhanced green fluorescent protein (eGFP). 
The eGFP is a mutated form of the original GFP protein with brighter fluorescence. 
The function of the eGFP is to act as a reporter gene in the lentiviral background. 
Other integrated elements in the pSIEW vector are a woodchuck posttranscriptional 
regulatory element (WPRE) which enhances lentivirus-mediated transgenic 
expression. The WPRE element can form a RNA-protein complex which protects the 
freshly synthesised RNA from being degraded (Zufferey et al., 1999). Further to the 
WPRE, a rev responsive element (RRE) has been integrated into the pSIEW vector. 
Rev and RRE are necessary for the expression of different helper proteins and in 
addition rev is needed for transportation of full-length vector RNA. For security 
reasons, RRE and rev are found on different plasmids and can only work if 
transfected together in a packaging cell. Another element in the pSIEW vector is the 
central polypurine tract (cPPT) which improves the transduction efficiency by 
facilitating nuclear import of the vector's pre-integration complex in the transduced 
cells. The gag element encodes for a protein which is important for the encapsidation 
of the viral nucleic acid. The SL4 fragment is an element of the packaging sequence. 
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The TERT fragment was cut out of the plasmid pKS-TERT (Figure 2-16) and was 
then to be integrated into the BamHI site of pHR-SINcPPT-SIEW via blunt end 
ligation. To achieve this both the EcoRI/SalI-flanked TERT fragment and the BamHI 
linearised plasmid pHR-SINcPPT-SIEW were separated in an agarose gel and 
subsequently purified (QIAGEN, Qiaquick Gel Extraction kit). Afterwards, both 
sequences underwent a fill-in reaction with Klenow enzyme. 
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Figure 2-15 The basic lentiviral vector pHR-SINcPPT-SIEW 
The lentiviral target vector has been dephosphorylated with Calf Intestinal Alkaline 
Phosphatase (CIAP) to prevent self-ligation. After successful ligation, the final 
lentiviral vector was transformed via heat shock into DH5α E.coli bacteria. Unless 
otherwise stated, the bacteria strain DH5α of E.coli was used. 
The MiniPrep was cultivated in a shaking incubator at 37˚C. After 24 to 48 hours the 
E.coli cells were harvested and the plasmids isolated. These plasmids were then 
checked by restriction analysis for successful integration of the TERT fragment. 
After several cloning attempts no clones were isolated and the strategy was modified. 
Because the restriction enzymes BamHI and BglII create compatible sticky ends it is 
possible to insert artificial BglII sites into the pKS-TERT vector to flank the TERT 
fragment with BglII. Later, the TERT fragment could then be integrated in the unique 
restriction site of BamHI in the vector pHR-SINcPPT-SIEW. Therefore small 
oligonucleotides containing the BglII site were designed. The first step was to design 
two small BglII site containing oligo-linkers. They should insert the BglII restriction 
site between the flanking restriction enzymes XbaI/EcoRI at the beginning of the 
TERT fragment and SalI/Acc65I (KpnI) at the end (Figure 2-16). For each side 
flanking the TERT fragment in the pKS vector, two single oligo strands were 
designed which after being hybridised form the full BglII restriction site. The end of 
each double stranded oligo formed the sticky end of the relevant restriction site and 
so each double stranded oligo fragment was cloned into the pKS-TERT successively. 
Restriction analysis after integrating the first fragment XbaI-BglII-EcoRI resulted in 
nine positive clones out of nine picked. Restriction analysis was done with BglII and 
SalI. After integrating the second fragment SalI-BglII-Acc65I two positive clones 
were identified out of nine picked. Restriction analysis was performed by using BglII 
which should cut at each end of the TERT fragment and separate TERT. The new 
vector was named pKS-TERT-BglII. Hence, the TERT fragment was obtained with 
the help of the artificially integrated BglII restriction sites. So the transfer of the 
TERT fragment into the BamHI site of the plasmid pHR-SINcPPT-SIEW could then 
be performed as described before although the fill-in reaction was not necessary in 
this case. Several attempts were made but also in the case of this modified strategy, 
all clones were negative. Since it was not possible to obtain the needed vector for the 
insertion of the TERT fragment into the SEM cells, another strategy was attempted 
to induce overexpression. 
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Figure 2-16: The pKS-TERT vector and insertion of two BglII sites 
(A) The picture shows the TERT fragment in the pKS-bluescript vector (red arrow) where 
the artificial restriction site of BglII had to be integrated between the flanking restriction sites 
of XbaI and EcoRI at the beginning of the sequence of the cDNA coding for TERT and SalI 
and Acc65I/KpnI at the end of the sequence. The green restriction enzyme BamHI cuts two 
times in the vector, the enzymes in red cut the vector once. (B+C) Schemes to integrate the 
BglII site into the vector pKS-TERT. The oligo fragments were designed as shown above 
and after hybridisation inserted into the desired site. Red represents the XbaI sequence, green 
BglII, blue EcoRI. , dark red SalI and yellow the Acc65I/KpnI site. (D) Restriction control 
shows insertion of both BglII restriction sites; clone 3 and clone 5 were positive and used for 
further experiments. Restriction was done by using BglII.  
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The first step of the new strategy involved the restriction of lentiviral vector pHR-
SINcPPT-SIEW with the enzyme NotI at positions 8943 and 6676 to get a fragment 
which contains the BamHI restriction site. Restriction of the lentiviral vector 
revealed that the pHR-SINcPPT-SIEW vector did not contain an efficient NotI 
restriction site at position 8934bp despite the description in the plasmid, shown in 
Figure 2-15. 
This fragment was then supposed to self-ligate into a small intermediate vector. This 
first intermediate vector should be linearised using the unique restriction site BamHI. 
Secondly the modified pKS-TERT-BglII vector was meant to be digested with the 
enzyme BglII flanking the TERT fragment. As BglII and BamHI produce compatible 
ends the TERT fragment should be integrated into the BamHI site of the intermediate 
vector to for the new transfer vector. The transfer vector could then be linearised 
again with NotI and used for insertion into the available plasmid, pHR-SINcPPT-
SIEW.  
At this point with pressing time constraints it was decided to concentrate on the 
overexpression of HOXA7. 
  
 75 
 
2.6.3 Design of rescue experiments with HOXA7 
The lentiviral vector which contains the sequence coding for the cDNA of HOXA7 
combined to the FLAG-tag was already available. As a reporter gene, the hoxa7-
FLAG construct was connected to an EGFP construct via the IRES fragment. The 
control vector did not contain the hoxa7-FLAG construct. The experiment below 
describes the hoxa7-FLAG containing lentivirus. The control was treated the same 
way but will not be described separately. 
To get a lentivirus containing the HOXA7 over-expression cassette, the lentiviral 
vector with the integrated sequence encoding for the HOXA7 cDNA was transfected 
together with the packaging vector pCMVdeltaR8.91 and the enveloping vector 
pMD2.G into 293T cells. This was done by calcium precipitation. Three days after 
infection the 293Ts were examined with the fluorescence microscope for the 
expression of the enhanced green fluorescent protein (EGFP) which was used as 
reporter (Figure 2-17). EGFP expression was estimated by eye and showed an 
efficiency of almost 100% in both control and actual transfection experiments. 
 
Figure 2-17 Virus production in 293T cells 
293T cells three days after transfection of the lentiviral vector (+HoxA7, +GFP). The 
control vector (-HoxA7, +GFP) lacks the HOXA7 insert. 
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Figure 2-18 SEM cells after transduction with lentiviral particles 
SEM cells three days after transduction with lentiviral particles. 
 
On the fourth day after infection the lentiviruses were harvested and subsequently 
used for transduction of the SEM cells. Prior to the transduction the lentiviruses were 
concentrated by ultracentrifugation. Three days after the transduction the SEM cells 
were checked also for EGFP expression with a fluorescence microscope (Figure 2-
18). To measure the transduction efficiency several FACS analysis to detect EGFP 
were done (Figure 2-19). Since the hoxa7-FLAG construct was connected to an 
eGFP construct via IRES overexpression it was assumed eGFP expression correlates 
directly with hoxa7-FLAG expression. 
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Figure 2-19 FACS analysis of GFP positive SEM cells after lentiviral 
transduction 
Analysis of SEM cells after lentiviral transduction shows GFP positive cells in both cases. 
Blue bars represent transduced cells with HoxA7-FLAG containing lentiviruses, green bars 
represent HoxA7 lacking lentiviruses. The number of weeks after transduction is shown on 
the x-axis, percentage of GFP positive cells is shown on the y-axis. 
 
One week after transduction approximately 16% of the cell population transduced 
with HOXA7 positive lentiviruses showed an expression of the reporter protein EGFP 
measured with a FACS machine (FACSCalibur, Beckton Dickinson, UK). The 
control cells were almost 100% positive. This HOXA7 positive population remained 
stable at 16% until week five, when a sorting attempt was made. The attempt to 
culture sorted GFP positive cells had to be aborted, because after sorting the 
separated cells died while being cultured in standard conditions. The remaining 
mixed cell population was kept under optimum conditions (0.5x106 cells/ml culture 
medium) and was monitored over several weeks in incubation flasks using FACS 
analysis (Figure 2-19). It was observed that the amount of GFP positive cells 
decreased slowly over the cultivation period. As shown in Figure 2-19 the GFP 
positive control cells did not decrease at all. At this point of study it was decided to 
halt the experiment and to archive the remaining cells in cryo stocks. After thawing 
and re-culturing the HOXA7 positive cells FACS analysis showed no EGFP 
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expression. Control cells remained fine. As two of three cryopreserved stocks were 
negative the experiment was aborted. 
In another attempt, three different cell lines SEM, RS4;11 and MV4;11 were used as 
target cells for a similar lentiviral production and transduction using the pHR-
SINcPPT-SIEW lentiviral vector containing the hoxa7-FLAG cDNA. Shortly after 
the lentiviral transduction the cell numbers decreased rapidly. Interestingly also the 
control cells decreased rapidly but started growing after a few days. Finally the 
experiment had to be aborted as almost none of the pSIEW-HOXA7 transduced cells 
survived. The numbers of viable cells were determined by counting with the 
Neubauer cell counting chamber and the use of trypan blue. The number of trypan 
blue positive cells was not determined but clearly visible and rising during the time 
of the experiment. Figure 2-20 shows cell numbers at three different days. 
 
Figure 2-20 Different cell lines transduced with lentiviral particles 
Cell numbers on the y-axis and days after transduction on the x-axis show that in all cell 
lines HOXA7 transduced cells (red) decreased rapidly, while control cells (blue) start to 
grow after the second measurement. Shortly after the third measuring on day 5 the 
experiment had to be aborted as no more HOXA7 positive cells were available. 
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2.6.4 Discussion 
In this section the aim was to create a SEM cell line that overexpresses either TERT 
or HOXA7.  
The creation of a lentiviral vector that overexpresses TERT failed. Multiple cloning 
attempts were made but the final step to integrate the TERT containing cassette into 
the lentiviral vector failed. The likely problem is the size of vector and insert. The 
vector itself is about 10kb in size, and the TERT insert has 3kb. This size is too big 
for most bacteria as bacterial polymerases have difficulties to replicate vectors that 
are more than 10kb in size. Another problem was the inaccuracy of the only available 
map of the base vector pSIEW. Many cloning strategies were unsuccessful as 
predicted restriction sites detailed on the map were not present. For successful 
creation of a TERT containing vector, another lentiviral basal vector is needed. 
The creation of SEM cells that overexpress the murine hoxa7 was successful as 
judged by GFP expression. Unfortunately those cells were unstable and died. The 
reasons remain unclear. Hoxa7 overexpression seems to have a fatal effect on the 
cells. 
The method for creating these cells could not be fully established by the end of this 
thesis. Virus production must be monitored more closely by virus titer determination. 
Furthermore exact virus doses for transduction of target cells must be evaluated. This 
would also give information about the efficiency of the virus production itself and 
might help to improve it. Titration with known virus amounts could help to improve 
transduction efficiency and may lead to the creation of a cell line that overexpresses 
the target gene of interest. 
2.7 General expression of HOXA genes and TERT 
2.7.1 Introduction 
For this thesis, leukaemic cell lines were used to investigate changes in gene 
expression after siRNA mediated depletion of the fusion oncogene, MLL/AF4. To put 
this into context, the general expression level of the investigated genes within 
different leukaemic cell lines was investigated. The overall expression of certain 
genes of the HOXA cluster and TERT in different leukaemic cell lines was therefore 
investigated to reveal possible correlations. The following genes were chosen from 
the HOXA cluster: HOXA6, HOXA7, HOXA9 and HOXA10. Different leukaemic cell 
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lines were used to investigate the expression levels of the above mentioned genes by 
qRT-PCR. 293T cells were used as reference cell line, as it is a non leukaemic cell 
line. Table 5 gives a short overview of the cell lines used in this experiment. The 
experiment was performed once in triplicates. 
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Table 5 Cell lines for expression study 
SEM 
ALL cell line carrying the t(4;11) translocation with breakpoint at 
e9-e4 
RS4;11 
ALL cell line carrying the t(4;11) translocation with breakpoint at 
e10-e4 
MV4;11 
FAB M5 categorised AML cell line carrying the t(4;11) 
translocation with breakpoint at e9-e5 
REH 
ALL cell line carrying the t(12;21) translocation for TEL-AML1 
fusion gene 
697 
ALL cell line carrying the t(1;19) translocation for E2A-PBX 
fusion gene 
TK6 
Cell line carrying the BCR-ABL fusion gene t(9;22); no leukaemic 
phenotype 
NALM6 ALL cell line carrying the t(5;12) translocation 
K562 
CML cell line carrying the t(9;22) translocation for BCR-ABL 
fusion gene 
Kasumi-1 
FAB M2 categorised AML cell line carrying the t(8;21) 
translocation for AML1-MTG8 fusion gene. 
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2.7.2 Results 
As shown in Figure 2-7 HOXA6 and HOXA7 were only expressed in the t(4;11) 
positive ALL cell lines SEM and RS4;11. HOXA9 and HOXA10 were expressed in 
all investigated t(4;11) positive cell lines. Interestingly compared to the t(4;11) 
negative cell lines used in this experiment, HOX expression was relatively high in 
the t(4;11) positive cell lines but not in the other cell lines. 
The expression level of TERT was also analysed in this experiment. TERT mRNA 
levels were high in all cell lines but MV4;11 (Figure 2-21). The t(4;11) positive cell 
lines SEM, RS4;11 and MV4;11 revealed an interesting correlation between HOXA6, 
HOXA7 and TERT expression. In the ALL cell lines, a high expression of HOXA6 
and HOXA7, together with a high expression of TERT was detected. In the AML cell 
line MV4;11, HOXA6 and HOXA7 mRNA levels were very low, as was the mRNA 
level of TERT (Figure 2-22). Interestingly compared to the other cell line, the t(4;11) 
positive cell lines did not show the highest level of TERT expression. REH and 697 
cells showed a much higher TERT expression. All other cell lines had comparable 
expression levels to the t(4;11) positive cells. 
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Figure 2-21 Comparison of gene expression of the HOXA cluster and TERT 
Several leukaemic cell lines were used to determine the gene expression of HOXA6, HOXA7, 
HOXA9, HOXA10 and TERT relative to the gene expression in 293T cells. Genes where 
normalised against the housekeeping gene GAPDH. 
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Figure 2-22 Possible correlation between HOX and TERT expression levels 
A direct comparison of mRNA expression levels of HOXA6, HOXA7and TERT showed an 
interesting correlation. While TERT is expressed highly in SEM and RS4;11 cell lines, it is 
very low in MV4;11 cells. The expression pattern of HOXA6 and HOXA7 is comparable to 
TERT. 
2.7.3 Discussion 
The aim of this section was to determine the expression levels of several HOX genes 
(A6, A7, A9 and A10) and TERT within a range of leukaemic cell lines. It was of 
interest whether t(4;11) positive cell lines show a different gene expression compared 
to other leukaemic cell lines. 293T cells were used as a control cell line. 
Interestingly all t(4;11) positive cell lines showed HOXA9 and HOXA10 expression. 
HOXA6 and HOXA7 were only expressed in the ALL cell lines SEM and RS4;11. 
All the tested t(4;11) negative cell lines showed no or much lower expression of the 
investigated HOX genes. This strengthens the findings of others that HOX gene 
overexpression is a hallmark of MLL rearranged cells. 
It is interesting that MV4;11 cells do not have the HOXA6 and HOXA7 
overexpression. One reason could be that MV4;11 is an AML cell line and HOX 
gene expression is differently regulated in myeloid compared to lymphoid cells.  
TERT expression was also evaluated in all cell lines. It was present in all tested cell 
lines. The lowest expression was measured in MV4;11 cells, while the highest values 
were found in REH cells. All other cell lines had equal levels. There is an interesting 
correlation between TERT and HOX gene expression in the t(4;11) positive cell lines. 
In SEM and RS4;11 cells, HOXA6 and HOXA7 expression was found, together with 
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TERT. Interestingly in MV4;11 cells which show no HOXA6 and A7 expression, 
also TERT expression was lowest. This further strengthens the hypothesis that TERT 
may be regulated by HOXA7. Whether HOXA6 also plays a role in TERT 
expression needs to be further analysed. It would be of interest to see whether other 
MLL rearranged cells have a HOX-TERT pattern. This pattern could be evaluated in 
patient material and may lead to a biomarker for MLL rearranged leukaemia and 
better risk assessment of patients. 
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3 Discussion 
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3.1 MLL/AF4 has an effect on HOX gene expression 
Acute lymphoblastic leukaemia (ALL) is the most common leukaemia diagnosis in 
children, between 3 and 10 years. In general, ALL therapy results in an overall 
survival of nearly 80 % of all cases. Nevertheless, in some cases the prognosis is 
exceptionally poor. One of these high-risk ALL subgroups are infants of one year or 
younger. Although initial therapy achieves a remission rate of nearly 95 %, most of 
those infants relapse within the first year. The overall survival rate of those patients 
is 44 % (Stam et al., 2006). 
A hallmark of infant ALL is the occurrence of a translocation involving the MLL 
gene (11q23) found in 80 % of cases (Pieters et al., 2007). So far, over one hundred 
partner genes have been identified for this gene (Meyer et al., 2009). The most 
common partner is the AF4 gene, detected in about 50 % of the MLL rearranged 
patients (Pieters et al., 2007). This reciprocal translocation t(4;11) (q21;q23) leads to 
both the fusion MLL/AF4 as well as AF4/MLL (Domer et al., 1993). In our group we 
especially have addressed the role of MLL/AF4 by applying siRNA against the fusion 
site of this transcript (Thomas et al., 2005). Effects of the knockdown of the 
expression of MLL/AF4 were inhibition of proliferation, diminished self-renewal 
potential and a strongly increased rate of apoptosis for example in the cell line SEM. 
Furthermore, we showed that MLL/AF4 depletion also reduces the rate of 
engraftment of leukaemic cells in a severe combined immuno-deficient mice (SCID-
Mice) model.  
The overall aim of the study was to investigate the role of MLL/AF4 in t(4;11) 
positive B-ALL cells with regards to the interaction between MLL/AF4 and the 
genes of the HOXA cluster. As published data showed lethal consequences for t(4;11) 
positive cells upon siRNA mediated knockdown of MLL/AF4 together with a 
substantial decrease of HOXA7, HOXA9 and MEIS1 expression (Thomas et al., 2005) 
it was hypothesised that the MLL/AF4 – HOXA combination plays a key role for 
stemness and self-renewal potential.  
The first aim of this study was to investigate the effect of siRNA mediated MLL/AF4 
knockdown on all genes of the HOXA cluster. This cluster located on chromosome 7 
consists of 11 sequentially expressed genes, namely HOXA1, 2, 3, 4, 5, 6, 7, 9, 10, 11 
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and 13. These genes have been reported to be key transcriptional regulators for 
haematopoiesis (Sauvageau et al., 1994). Thus, during haematopoiesis HOXA genes 
play a role in differentiation. During early differentiation the so called 3’ or anterior 
HOXA genes (HOXA1 to A6) are active, while the ones located more at the 5’-end of 
the HOXA cluster, termed posterior HOXA genes (HOXA7 to A13) are active in more 
differentiated haematopoietic cells (Pineault et al., 2002). Therefore we investigated 
the effect of MLL/AF4 knockdown on these target genes. As some HOX gene 
primers had no positive controls, absent expression must be viewed with caution as 
this may be due to inefficient primer design. 
The results showed a distinctive pattern between the group of anterior and posterior 
HOX genes. With two exceptions, HOXA4 and HOXA6, the anterior HOX genes 
showed very similar behaviour upon MLL/AF4 depletion in that they did not show a 
substantial alteration in their expression. 
In two recent publications, the anterior HOXA genes were studied. In a study by 
Bach and colleagues murine bone marrow cells (MBMC) were transduced with 
MLL/ENL and murine Hox gene expression was analysed. They found that with the 
exception of Hoxa2 all other anterior Hox genes were substantially upregulated. 
Transducing the MBMCs with each individual anterior HOXA gene resulted in 
transformation of the cells, with the exception of HOXA2 and HOXA5. If each 
individual HOXA gene was cotransfected with the HOX cofactor MEIS1, with the 
exception of HOXA5, all other anterior HOX genes showed transforming ability. 
When trying to establish permanent cell lines from those experiments, only HOXA1, 
HOXA4 and HOXA6 transformed cells, with or without MEIS1, survived and 
expanded permanently in culture. The three permanent HOXA+MEIS1 cells were 
subsequently transplanted into mice and all three transplanted mice groups developed 
an AML phenotype where the combination HOXA4+MEIS was most and 
HOXA6+MEIS1 the least aggressive combination (Bach et al., 2010). 
In the study by Guenther and colleagues, t(4;11) positive SEM cells were 
investigated for the binding of MLL/AF4, wildtype MLL, wildtype AF4, H3K4 and 
H3K79 to the locus of the anterior HOXA genes with global ChIP-on-chip 
microarrays. There was no direct binding of MLL, AF4 or the fusion protein to any 
of the anterior HOXA genes detected. In the case of HOXA1 H3K4 binding was 
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detected and HOXA5 and HOXA6 were found to be bound by H3K79 (Guenther et al., 
2008). This signature suggests transcriptional active genes (Jones et al., 2008). 
In this thesis HOXA1, HOXA2, HOXA3 and HOXA4 were investigated in two, 
HOXA6 in three and HOXA5 in four independent experiments. While there was no 
HOXA1 expression detected, HOXA2, A3 and A5 were analysed but showed no 
substantial change in the level of expression upon MLL/AF4 depletion. HOXA4 and 
HOXA6 show a substantial decrease of 70 % in two and three experiments 
respectively. For HOXA4 only the transcript level was investigated and more 
experiments are necessary on both mRNA and protein level to confirm these 
preliminary data. However, HOXA6 was analysed on mRNA as well as on protein 
level. Both methods demonstrated a substantial knockdown which in the case of the 
transcript level statistically significant. 
HOXA1 and HOXA2 have been described to be active during myeloid differentiation 
(Zhang et al., 2009). In MLL knockout mice (MLL-/-) an increase of HOXA1 has 
been reported (Schraets et al., 2003). However, this was investigated in murine 
fibroblasts and does not necessarily represent the situation in human haematopoietic 
cells. Nevertheless H3K4 methylation was found within the HOXA1 locus(Guenther 
et al., 2008) which implies transcriptional activity, although this was not detectable 
during this project. The results of the Bach study indicate a role of a MLL fusion 
protein, MLL/ENL, in HOXA1 regulation as well as the potential of HOXA1 to 
induce an AML phenotype in mice (Bach et al., 2010). Assessment of HOXA2 in the 
lymphoid t(4;11) SEM cell line showed expression, hence it would be of interest to 
investigate whether the AML t(4;11)-positive cell line MV4;11 has a higher HOXA2 
expression, and whether there might be an effect caused by MLL/AF4 knockdown in 
this cell line. However, the MV4;11 cell line was established from AML cells which 
were classified as FAB M5, meaning that the differentiation process is more 
advanced; but expressions of HOXA1 and HOXA2 are suspected in earlier 
differentiation phases. Despite this, it would be worthwhile to investigate MV4;11 
cells for HOXA2 and also HOXA1 expression as MLL/AF4 can influence those 
genes. Although no direct link between MLL and HOXA2 can be found, this 
demonstrates the oncogenic potential and thereby the potential contribution to 
leukaemogenesis of HOXA2. 
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HOXA3 showed similar results like HOXA2 in the Bach study as well as in the 
Guenther study (Bach et al., 2010, Guenther et al., 2008).  
The role of HOXA5 in leukaemia is still widely unknown and controversial results 
have been published. On the one hand it has been reported that overexpression of 
MLL/AF9 or CALM/AF10 in bone marrow cells results in upregulation of HOXA5 
(Argiropoulos and Humphries, 2007, Okada et al., 2006). ALL patients with a MLL 
rearrangement were analysed for HOXA gene expression and amongst others HOXA5 
was clearly upregulated compared to ALL patient without MLL rearrangements 
(Armstrong et al., 2002). On the other hand, in studies by Strathdee and colleagues 
methylation assays revealed strong hypermethylation, a sign of inhibition of 
transcription, of CG-rich regions, so called CpG islands, in the promoter regions of 
HOXA4 and HOXA5 (Strathdee et al., 2007a, Strathdee et al., 2007b) in childhood 
acute leukaemia. The data presented here shows expression of HOXA5 but as it did 
not show substantial gene expression alteration upon MLL/AF4 knockdown, we 
conclude that HOXA5 together with HOXA3, HOXA2 and HOXA1 do not play a 
substantial role in our study. 
 
Two independent MLL/AF4 knockdown experiments were done and HOXA4 
expression analysed. A reduction of HOXA4 upon MLL/AF4 knockdown could be 
observed on mRNA level. Although the HOXA4 signal was detected quite late during 
the qRT-PCR (around cycle 33), hence it was assumed that HOXA4 is expressed but 
at very low level. The literature supports these findings. It has been reported that 
there is an indicative correlation between HOXA4 and other members of the four 
HOX clusters which may play a role in the overall HSC development (Bijl et al., 
2006). The decrease of HOXA4 expression as a consequence of MLL/AF4 depletion 
suggests that HOXA4 is a target for MLL/AF4 but possibly indirectly as in the 
Guenther study HOXA4 was not detected to in the ChIP-on chip study in SEM cells. 
The results of Bach (Bach et al., 2010) plus the data here suggest that MLL fusions 
have an effect on HOXA4 expression which itself seem to be a potent contributor to 
acute haematopoietic malignancies. This is supported by the findings of Armstrong 
and colleagues who detected HOXA4 upregulation in an ALL patient cohort with 
MLL rearrangement (Armstrong et al., 2002). They compared this result to ALL 
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patients without MLL rearrangement and found that HOXA4 expression to be 
exclusive to MLL rearranged patients. More studies regarding the role of HOXA4 in 
t(4;11) positive cells are necessary to explore HOXA4 contribution to this kind of 
disease. Confirmation of HOXA4 knockdown upon MLL/AF4 depletion would be the 
first step in this direction. It would be interesting to clarify whether HOXA4 plays a 
role in ALL onset or is more important for myeloid malignancies. 
In this study a new downstream target of MLL/AF4, HOXA6, was identified. A 
statistical significant reduction of expression on mRNA level of about 70 % after 
siRNA mediated MLL/AF4 knockdown experiments in SEM could clearly been 
demonstrated. This together with confirmatory western blot results showed that 
HOXA6 was affected by MLL/AF4. In the literature, HOXA6 has been shown to be 
important in the early phase of haematopoietic differentiation (Dickson et al., 2009). 
HOXA6 was also demonstrated to have an influence on colony forming and self-
renewal. Therefore the interaction between MLL/AF4 and HOXA6 is another 
indication for HOXA genes playing a central role in the stem cell behaviour of 
malignant haematopoietic progenitor cells. Whether HOXA6 plays an important role 
in the development and maintenance of ALL still needs to be investigated. Direct 
interaction of MLL, AF4 or MLL/AF4 was not reported in the Guenther 
study(Guenther et al., 2008). However H3K79 binding to the HOXA6 locus was 
reported which indicates involvement of the DOT1L methyltransferase complex. In 
this study, HOXA6 showed similar expression levels as HOXA3 or HOXA5 in SEM 
cells. In contrast, HOXA6 expression was clearly affected by MLL/AF4 knockdown. 
Examination of HOXA6 expression in the cell lines SEM, RS4;11 MV4;11 and the 
Kasumi-1 showed that AML cell lines MV4;11 and Kasumi-1 did not have a 
substantial HOXA6 expression while it was detectable in all in the ALL cell lines 
RS4;11 and SEM. In the ALL cell lines REH, 697 and NALM6 HOXA6 expression 
was comparably low to the aforementioned AML cell lines. It is also worth noting, 
that HOXA6 showed a similar expression level and MLL/AF4 knockdown pattern as 
HOXA7. This has to be investigated further. Knockdown experiments with siRNA 
specially against HOXA6 should be performed to clarify whether HOXA6 plays a 
functional role in t(4;11) positive leukaemia. By using AML and ALL cell lines it 
should be possible to see if HOXA6 has an influence on lineage determination. 
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As already briefly mentioned above the knockdown of MLL/AF4 on mRNA level 
resulted in depletion of HOXA7 (Thomas et al., 2005) which was confirmed on 
protein level by western blot in this study. Furthermore it was shown that siRNA 
treatment against HOXA7 of SEM cells had a similar effect as MLL/AF4 knockdown. 
These data were produced by qRT-PCR which showed an 85 % knockdown of 
HOXA7. In the literature, HOXA7 has been described as acute lymphoblastic 
leukaemia associated although it is not clear so far if HOXA7 expression is vital for 
leukaemic development involving rearranged MLL (Armstrong et al., 2002, 
Rozovskaia et al., 2001). The Bach study demonstrated induction of HOXA7 
expression in murine haematopoietic cells by transfection with a MLL/ENL construct. 
Moreover they showed a transforming ability of HOXA7 but which was less potent 
than HOXA6. The coexpression of MEIS1 increased HOXA7 transforming potential. 
From those cells it was possible to establish a permanent cell line (Bach et al., 2010). 
In global ChIP-on-chip studies HOXA7 was clearly detected as a target of MLL/AF4 
and showed epigenetic involvement of H3K4 as well as H3K79 at the HOXA7 locus 
(Guenther et al., 2008). The data presented here therefore proves that in the SEM cell 
line model, HOXA7 is clearly necessary for the upkeep of the leukaemic cells as 
HOXA7 depletion leads to rapid onset of apoptosis. When comparing HOXA7 
expression levels in several leukaemic cell lines, a high expression of HOXA7 in the 
t(4;11) positive ALL cell lines SEM and RS4;11 was detected but no HOXA7 
expression was measurable in MV4;11, the t(4;11) positive AML cell line. Also in 
three other ALL cell lines e.g. REH, 697 and NALM6 no HOXA7 expression was 
detected. This suggests a role of HOXA7 in the two t(4;11) positive ALL cell lines. 
Interestingly those cell lines were all obtained from patients at relapse (Greil et al., 
1994, Stong and Kersey, 1985), whereas MV4;11 was derived from a patient with de 
novo t(4;11) AML (Lange et al., 1987). In a publication from Bertrand and 
colleagues another t(4;11) positive cell line BLIN-3 was reported to be HOXA7 
negative. BLIN-3 was established from an infant with de novo ALL (Bertrand et al., 
2003, Bertrand et al., 2001). These results, although only observed in cell lines so far, 
indicate a role of HOXA7, and maybe also of HOXA6, in the onset and also the 
severity of relapse resulting in t(4;11) ALL, because the expression of these HOXA 
genes was only detectable in cell lines established from relapsed patients. In contrast 
to this, are the findings of two research group who investigated ALL patients 
carrying t(4;11) translocations (Stam et al., 2009, Trentin et al., 2009). They found 
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that not all t(4;11) positive ALL patients showed upregulation of HOXA7 as well as 
HOXA3, HOXA5, HOXA9 and HOXA10. Those lacking HOXA overexpression had a 
very high risk of relapse compared to the patient cohort with up regulated HOXA 
genes (Stam et al., 2009). This still needs to be clarified whether the genetic 
phenotype of de novo ALL’s matches the relapse genotype and if HOXA gene 
expression plays an important role in relapse. Nevertheless, as in this study, HOXA7 
knockdown had lethal consequences for the cell lines, thus HOXA7 and HOXA6 
could be potential targets for ALL relapse therapy. 
To further investigate the role of HOXA7 the t(4;11) positive cell lines SEM, RS4;11 
and MV4;11 were transduced with a lentiviral construct expressing a murine FLAG 
tagged Hoxa7 combined with eGFP as an expression marker. The cell line SEM was 
transduced twice and RS4;11 as well as MV4;11 once, but did not result in a stable 
HOXA7 over expressing cell line. The transduced cells from RS4;11 and MV4;11 
died within five days after transduction while SEM cells in the first experiment 
survived for several weeks but the eGFP expression decreased constantly. An 
attempt to sort and cultivate eGFP positive cells failed in the first instance. In the 
second transduction experiment the eGFP positive SEM cells also died rapidly within 
five days post transduction. The reasons for these results are not clear. One reason 
could be that HOXA7 overexpression would need the often discussed additional 
MEIS1 coexpression although this does not explain the high apoptosis rate of cells 
with overexpressed HOXA7. Control cells, transduced with a construct which only 
lacks the Hoxa7 FLAG tag showed no signs of apoptosis or any other negative 
effects. This rules out the posiibility of toxicity of the lentiviral construct integration 
or the eGFP. During the first transduction experiment with SEM a decreasing eGFP 
fluorescence could be monitored over time by fluorescence microscopy. This 
indicates that cells with high Hoxa7 overexpression died earlier than cells with 
moderate or low Hoxa7 overexpression. It is also possible that the virus 
concentration plays a major role in the successful transduction of a cell line. A 
weakness of this study was not to determine a virus titer. One suggestion at this point 
is to always determine the virus titer which would help to standardise these 
transduction experiments. For future work it is important to determine the virus titer 
to use a median virus concentration for each transduction which was not done in 
these experiments. To avoid time consuming titer determinations it is possible to use 
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at least a dilution series of the concentrated virus to determine cell viability and 
eGFP expression. As virus production is not equal every time the dilution series 
cannot be a standard procedure but would be helpful as a starting experiment to 
collect the first data. Figure 3-1 illustrates the hypothesis of the correlation between 
cell viability and HOXA7-eGFP expression in SEM cells. This model can also be 
used for other cell lines as well. 
 
 
Figure 3-1 Viability model of transduced SEM cells 
This diagram illustrates the model for the survival of cells transduced with a Hoxa7-eGFP 
expressing cassette. The eGFP expression is a marker for Hoxa7 expression as both genes 
are driven by the same promoter. Cells which show the highest expression of Hoxa7/eGFP 
have the lowest viability. With decreasing Hoxa7/eGFP expression, depending on the 
number of integration sites, viability of the cells increases. Further experiments should reveal 
the optimal concentration of virus particles to create a permanent Hoxa7/eGFP 
overexpressing cell line. 
 
Discussions about the HOXA gene cluster and their interactions in ALL, especially 
MLL/AF4, HOXA9 will be described in the next chapter. Our own results show that 
HOXA9 mRNA expression is decreased after MLL/AF4 knockdown. This result was 
confirmed by western blot. Comparison of several leukaemic cell lines (SEM, 
RS4;11, MV4;11, REH, 697, TK6, NALM6, K562 and Kasumi1) showed HOXA9 
expression only in t(4;11) positive cells but low or abundant expression in others. 
This would support the argument that HOXA9 contributes to MLL rearranged 
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leukaemias. There exist a large number of studies describing the role of HOXA9 in 
leukaemogenesis. HOXA9 upregulation is detected in most t(4;11) related leukaemias 
(Armstrong and Look, 2005, Armstrong et al., 2002). In animal models it was 
demonstrated, that HOXA9 overexpression leads to increased proliferation and to a 
leukaemic phenotype (Thorsteinsdottir et al., 2002). More recent work shows that 
HOXA9 is necessary for MLL rearranged leukaemia. It was shown, that HOXA9 
depletion in MLL rearranged cells led to inhibition of proliferation and caused 
apoptosis (Faber et al., 2009). In contrast to this, it was reported that transformation 
of haematopoietic HOXA9 negative precursor cells with MLL/GAS7 led to colony 
forming blasts but which were less potent than after restoring HOXA9 expression. 
This indicates the importance of HOXA9 contribution to the rapid development of the 
leukaemic phenotype (So et al., 2004). Bertrand and colleagues also reported a lack 
of HOXA9 expression in the already mentioned t(4;11) positive cell line BLIN-3 
(Bertrand et al., 2003). The studies of the Bach group demonstrated an induction of 
HOXA9 expression by transfection of murine haematopoietic cells with MLL/ENL as 
well as the transforming potential of HOXA9. The transfection of murine primary 
bone marrow cells with HOXA9 led to a differentiation block and onset of 
proliferation which was further increased by coexpression of the HOXA cofactor 
MEIS1. Those cells were taken into permanent cell culture and cell lines were 
established. Transplantation of those cells then led to rapid onset of an acute myeloid 
leukaemia phenotype in recipient mice and a quick death of the animals (Bach et al., 
2010). Global ChIP analyses revealed the binding of MLL/AF4 to HOXA9 and of 
H3K4 and H3K79 to the HOXA9 locus (Guenther et al., 2008). 
The MLL/AF4 knockdown effect on HOXA10 was investigated in three independent 
experiments on mRNA and protein level. The detection of HOXA10 in several 
western blot experiments failed. MLL/AF4 depletion led to a significant 80 % 
reduction of the transcript level in SEM cells. Similar to HOXA9, HOXA10 was 
expressed in three t(4;11) positive cell lines (SEM, RS4;11 and MV4;11) but was 
less expressed in other leukaemic cell lines (REH, 697, TK6, NALM6, K562 and 
Kasumi1). HOXA10 has been described to play an important role in transforming 
myeloid progenitors. The overexpression of HOXA10 leads to onset of acute myeloid 
leukaemia in murine haematopoietic cells (Thorsteinsdottir et al., 1997). HOXA10 
was also reported to impair haematopoiesis (Buske et al., 2001) and is a critical 
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regulator for development of haematopoietic stem cells, and erythroid and 
megakaryocyte development (Magnusson et al., 2007). There is sparse literature 
available on the role of HOXA10 in acute lymphoblastic leukaemia. By transfecting 
murine bone marrow cells with HOXA10 a differentiation block and induction of 
proliferation could be observed. Further experiments showed colony forming ability 
which was pronounced by coexpression of HOXA10 with MEIS1. From both types of 
transfected cells, HOXA10 with or without MEIS1, it was possible to generate 
permanent cell lines (Bach et al., 2010). This result underlines the potency of 
HOXA10 in leukaemic transformation. HOXA10 was also found to be upregulated in 
a subset of T-cell acute leukaemia bearing an inversion within chromosome 7 
(Speleman et al., 2005). In global ChIP-on-chip analysis MLL/AF4 was found to 
bind to HOXA10 and also epigenetic involvement at the HOXA10 locus was found 
(Guenther et al., 2008). Together with the presented results here, this suggests that 
HOXA10 has an important role in leukaemogenesis. 
It was not possible to detect expression of HOXA11 and HOXA13 in two independent 
MLL/AF4 knockdown experiments. As for HOXA1, primers were not tested for 
specificity or with a positive control. HOXA11 like HOXA10 has been reported to be 
upregulated in inv(7) positive T-cell acute lymphoblastic leukaemia (Speleman et al., 
2005). However, HOXA13 has been reported to be essential for the onset of T-Cell 
leukaemia (Su et al., 2006). Bach and colleagues showed upregulation of HOXA11 as 
well as HOXA13 in MLL/ENL transfected murine haematopoietic cells. HOXA11 and 
HOXA13 transformed murine bone marrow cells were able to form colonies and 
enhanced colony formation was detected with coexpression of MEIS1. Nevertheless 
it was not possible to form a permanent cell line from those cells (Bach et al., 2010). 
ChIP-on-chip studies revealed that H3K4 trimethylation was detected within the 
HOXA11 and HOXA13 locus which suggests involvement of the MLL methylation 
complex (Guenther et al., 2008). Unlike genes like HOXA7 or HOXA9, HOX11 and 
HOXA13 did not show any noticeable dysregulation in microarray studies which 
could mean that HOXA11 and HOXA13 do not play an important role in infant acute 
leukaemia. 
 
 97 
 
In summary, the whole HOXA cluster was investigated for changes in HOXA gene 
expression as a consequence of MLL/AF4 depletion. HOX genes have been reported 
to play important roles during haematopoiesis and development of leukaemia 
(Argiropoulos and Humphries, 2007) but also at least partly in cell cycle control 
(Mishra et al., 2009). A significant reduction of HOXA gene expression for HOXA6, 
HOXA7 and HOXA9 on both mRNA and protein level was found which could 
indicate possible target genes in MLL rearranged ALL cases. HOXA10 only showed 
a significant reduction at the mRNA level but it was not detected at the protein level. 
Another possible target gene, HOXA4, was found although more experiments need to 
be done to confirm this result. HOXA7, HOXA9 and HOXA10 were also 
downregulated and are genes which are strongly correlated with acute leukaemia, 
thus the findings are not very surprising. These genes have been shown to be induced 
by MLL fusion genes like MLL/ELL, MLL/AF6, MLL/AF9, MLL/AF10 and 
MLL/ENL (Ayton and Cleary, 2003, Bach et al., 2010). HOXA6 activation by a MLL 
fusion was recently reported by Bach and colleagues(Bach et al., 2010). Furthermore 
HOXA7 and HOXA9 have been reported to be essential for the maintenance of 
leukaemia (Ayton and Cleary, 2003, Faber et al., 2009). Key cofactors for HOXA 
genes have been found in MEIS1 and PBX1 (Bach et al., 2010, Mamo et al., 2006, 
Wang et al., 2006, Zeisig et al., 2004). MEIS1 and PBX1 can alter HOX-DNA 
binding specificity, increase HOX-DNA binding affinity and enhance gene 
transcription activity (Argiropoulos et al., 2007). MEIS1 has been found to form 
trimeric complexes with HOXA9 and PBX1 (Shen et al., 1997, Shen et al., 1999). 
MEIS1 has been found to play a major role in MLL leukaemia stem cell potential by 
regulating self-renewal, the differentiation arrest and also the in vivo generation of 
LSCs from myeloid progenitors (Wong et al., 2007) Also MEIS1 has been reported 
to be downregulated as a consequence of MLL/AF4 knockdown (Thomas et al., 
2005). The Guenther study showed that MEIS1 was bound by MLL/AF4, H3K4 and 
H3K79 in SEM cells. All these data indicate the importance of MEIS1 and PBX1 in 
leukaemogenesis. Another common signature of HOXA7, HOXA9 and HOXA10 has 
been found during global ChIP-on-chip studies. All three genes show binding to 
MLL/AF4 as well as binding of H3K4 and H3K79 to the locus of the genes 
(Guenther et al., 2008). Thus, in summary, all direct binding of MLL/AF4 to the 
HOXA genes seems to be a key mechanism in MLL rearranged leukaemia. The 
question remains as to how MLL exactly effects their gene expression. Evidence in 
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the literature suggests that binding of MLL to the CpG cluster within the HOXA9 
promoter protects it from methylation by DNA methyl transferases (DNMT). DNA 
methylation would inhibit the transcription of the gene (Erfurth et al., 2008). Thus 
one assumes that an uncontrolled permanent binding of MLL/AF4 via the DNA 
methyltransferase domain to the promoter leads to permanent transcription of the 
HOXA9 gene and presumably the same mechanism contributes to HOXA7 and 
HOXA10 gene activation. Knockdown of MLL/AF4 could then allow DNMT 
binding, DNA methylation and thereby gene transcription inhibition. As it has been 
shown that at least HOXA7 and HOXA9 are vital for survival this could explain the 
fatal effect of the MLL/AF4 knockdown. siRNA directed against HOXA7 confirmed 
the critical role of this gene. The cells show a similar phenotype on lack of HOXA7 
expression as they do when MLL/AF4 is depleted. Targeting HOXA6, HOXA9 and 
HOXA10 with siRNA could provide further insights into this matter and thus may 
clarify if the other HOXA genes also have critical roles in the survival of MLL/AF4 
positive cells. An interesting correlation was found when comparing expression 
levels of HOXA7 of four t(4;11) positive cell lines SEM, RS4;11 and MV4;11 and 
BLIN-3 (Bertrand et al., 2001). HOXA7 expression was found in the t(4;11) positive 
ALL cell lines SEM and RS4;11 but not in the AML cell line MV4;11. This may 
suggest that HOXA7 is exclusively expressed in ALL. However, gene expression 
studies of the BLIN-3 cells, a cell line established from an infant diagnosed with 
ALL, also did not show HOXA7 expression. This is supported by further findings 
that not all t(4;11) positive infant leukaemias show overexpression of HOXA7 (Stam 
et al., 2009, Trentin et al., 2009). Interestingly HOXA-negative patients had a worse 
prognosis than HOXA-positive ones. Interestingly SEM and RS4;11 are cell lines 
established from patients in relapse. MV4;11 and BLIN-3 had their origins in 
patients with de novo development of t(4;11) positive leukaemia. Whether HOXA7 
overexpression is important for relapse has yet to be revealed. If HOXA7 can be 
identified as a key player in the development of aggressive relapse leukaemia, it may 
provide a possible target for treatment. 
Another point of discussion about the expression pattern of HOXA6, HOXA7, 
HOXA9 and HOXA10 at the mRNA level in t(4;11) positive cell lines (SEM, RS4;11 
and MV4;11) is that these cell lines had high expression of HOXA genes compared to 
other cell lines which showed very low gene expression. Whereas the ALL cell lines, 
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SEM and RS4;11, showed expression of all four mentioned HOXA genes HOXA6 
and HOXA7 were exclusively expressed in the ALL cell lines. Atkinson and 
colleagues investigated epigenetic marking of the HOX genes during differentiation 
of pluripotent cells (Atkinson et al., 2008). They showed that during differentiation 
of pluripotent cells the HOXA genes (HOXA4 to HOXA11) are epigenetically 
marked by di- and trimethylation and these methylations suggest gene activation. As 
MLL fusion genes are thought to be constantly bound at the HOXA7 to the HOXA10 
sites in t(4;11) positive ALL cells, this would support the hypothesis that 
differentiation is blocked due to the constant activity of HOXA genes in malignant 
haematologic diseases, driven by MLL fusion gene expression (Slany, 2009). In the 
B-cell precursor cells from SEM and RS4;11 it seems that HOXA6 and HOXA7 
drove the cells towards the lymphoid lineage. This may indicate that these genes are 
important for the lineage determination in the process of differentiation. Both 
HOXA6 and HOXA7 activation could drive the cell towards the lymphoid lineage, 
while the inactivation of those genes may lead to the myeloid lineage. Because 
HOXA genes are expressed in transcriptional cascades it is difficult to argue with this 
theory. The activation of a certain HOXA gene activates the transcription of the next 
HOXA gene in a 5’ direction and represses transcription of the 3’ HOXA gene, 
although this sequential gene activation cascade is discussed controversially in the 
literature.  
In the lymphoid development there is also activation of HOXA9 expression but this is 
transient and a specific stage of development. The following picture visualizes the 
expression of the HOXA genes in a cascade and the involvement of MLL/AF4 
expression as an interrupter of differentiation in the affected cell (Figure 3-2). 
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Figure 3-2 Halt of differentiation by MLL/AF4 
Illustration of how MLL/AF4 expression could affect progression of the HOXA gene 
transcription cascade. Atkinson and colleagues (Atkinson et al., 2008) showed a 
correlation between epigenetic marking and activation of HOXA genes in pluripotent 
human stem cells. Here this model is translated to haematopoietic stem cells (HSCs). 
Differentiation of HCSs can progress until the appearance of MLL/AF4 (RED) 
which blocks further differentiation by constant stimulation of HOXA7/HOXA9 
expression via mechanisms yet not fully understood. 
 
Differentiation is a tightly controlled process and the HOXA genes play an important 
role. Howeve,r the way a haematologic stem cell differentiates is not known in detail. 
Often there are agonists and antagonists for certain groups of genes. For example, the 
trithorax group (trx-G), of which MLL is a member, are agonists for HOXA gene 
expression and antagonists of genes of the polycomb group (PcG). PcG genes have 
been shown to be crucial in the development of mice and are implicated in 
leukaemogenesis. Both trx-G and PcG are groups of histone methyltransferases. 
While the genes of the trx group activate gene expression by methylation of H3K4, 
PcG genes silence gene expression by methylation of H3K27 (Schuettengruber et al., 
2007). A role in leukaemia has been reported for PcG proteins which are deregulated 
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in AML. Interestingly, this is associated with deregulation of the PcG target genes 
HOXA4, HOXA9 and MEIS1 (Grubach et al., 2008). The PcG gene BMI1 for 
example has been found to be crucial for the development of human leukaemia CD34 
positive cells as BMI1 knockdown impaired self-renewal and induced apoptosis of 
the cells (Rizo et al., 2009). Their particular role in the development in MLL 
rearranged forms of leukaemia has not been fully investigated yet.  
 
3.2 A correlation between MLL/AF4, HOXA7 and TERT 
Over the past years a considerable amount of literature has been published on the 
involvement of the enzyme complex telomerase and its subunits in cancer biology. 
These subunits are TERT, the reverse transcriptase of the telomerase, and TERC, the 
RNA component of the telomerase. In these publications an elevated telomerase 
activity has been demonstrated in a substantial number of cancer types (Hahn, 2005, 
Shay and Bacchetti, 1997). In the present study telomerase activity was investigated 
after depletion of MLL/AF4 by siRNA mediated knockdown in the t(4;11) positive 
cell line SEM. TRAP assays showed that depletion of MLL/AF4 was associated with 
a 70 % reduced telomerase activity in these cells. A high activity of telomerase and a 
therefore assumed permanent occurring prolongation of the telomeres in the cell 
override the activation of apoptosis and can lead to a malignant cell. The data 
presented here suggest MLL/AF4 is involved in processes which are very important 
for the stem-like behaviour of the malignant cells. More detailed investigations on 
the subunits of the telomerase namely TERT and TERC revealed a knockdown effect 
on TERT but not on TERC upon depletion of the fusion transcript MLL/AF4. 
Treatment of SEM cells with siRNA against MLL/AF4 or HOXA7 showed in both 
cases moderate but significant TERT depletion of about 40 % (p < 0.002). As a 
consequence of MLL/AF4 knockdown, not only the transcripts of HOXA7 but also 
TERT were affected. Applying siRNA against HOXA7 revealed that only TERT but 
not MLL/AF4 was affected. This shows that HOXA7 is downstream of MLL/AF4 and 
so is TERT. Furthermore it was demonstrated that TERT is a downstream target of 
HOXA7. As knockdown of HOXA7 diminished TERT expression, a direct regulation 
was hypothesised. The simplified model to this hypothesis is shown in the picture for 
the MLL/AF4 signalling pathway Figure 3-3. HOXA7 has been reported to 
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transform haematopoietic pluripotent cells into colony forming blasts thereby 
suggesting contribution to self-renewal potential (Bach et al., 2010). TERT also has 
been reported to immortalise cells by bypassing the p53 and Rb apoptosis pathway 
(Chapman et al., 2006). The interaction between MLL/AF4, HOXA7 and TERT 
could be a key mechanism in the self-renewal potential of the SEM cells, and thus 
for HOXA positive t(4;11) ALL. These experiments suggest the possible signalling 
order shown in figure 3-3 but direct gene regulations have not been shown so far. 
 
 
 
 
 
Figure 3-3 Model of MLL/AF4 target genes 
Knockdown experiments showed HOXA7 being influenced by MLL/AF4. In 
knockdown experiments it also showed HOXA7 is a downstream target of MLL/AF4 
and TERT being a downstream target of HOXA7. The dashed line illustrates that 
there is no clear evidence whether MLL/AF4 directly influences TERT expression. 
Both HOXA7 and TERT are correlated with the potential of self-renewal and 
regulating cell death. 
 
A direct effect of MLL or MLL/AF4 on TERT also has not been detected in the global 
ChIP analysis from the group of Guenther. Epigenetic modifications such as histone 
methylation of the TERT promoter by MLL or MLL/AF4 is possible as H3K4 and 
H3K79 have been found to bind within the TERT locus(Guenther et al., 2008). This 
indicates that gene activation involves the MLL methyltransferase complex. In 
addition to MLL there are also other histone methyltransferases like MLL2, MLL3, 
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MLL5, SET1a, SET1b and ASH1L (Slany, 2009) which could all be involved in the 
H3K4 methylation. 
To investigate the promoter of TERT for possible binding sites of HOXA7 an in 
silico approach was used as a first step. 
In this study an internet browser based program called MatInspector© (Genomatix 
Software GmbH, Germany) was used to investigate the promoter of TERT for 
potential HOXA7 binding sites. After providing the sequence of the core TERT 
promoter the program suggested several possible binding sites for HOXA genes or 
their cofactors such as PBX1 and MEIS1.  
After selecting the most suitable sites primers were designed for the designated 
promoter sequences. Using these specifically designed primers, a chromatin immuno 
precipitation assay (ChIP) was carried out. The ChIP assays revealed direct binding 
of Hoxa7 to the promoter of TERT. The binding position is about 1kb upstream of 
the transcription start of TERT. While the software MatInspector predicted this, it is 
the first time that direct binding of a HOXA transcription factor to TERT has been 
demonstrated. Further investigations should point out whether this binding is crucial 
or to what extent it contributes to the leukaemic phenotype of MLL/AF4 positive 
cells. As the MatInspector program also suggested general HOX binding to the TERT 
promoter it is likely that also other HOXA transcription factors can bind such as 
HOXA6 or HOXA9. In addition MEIS1 or PBX1 binding was also suggested. As the 
experiments were performed with FLAG-tagged Hoxa7, endogenous HOXA7 
binding to the TERT promoter has not been demonstrated. The data presented here 
show direct binding of murine hoxa7 to the promoter of TERT. TERT overexpression 
leads to a constantly active telomerase which maintains the telomeres, thus leading to 
a high proliferation rate without telomere shortening and cells are immortalised. 
 104 
 
 
Figure 3-4 Mechanism for TERT activation 
TERT over-expression is regulated by HOXA7, which is constantly overexpressed by 
MLL/AF4 binding. TERT maintains a constant telomerase activity which contributes 
to the immortality of the cells. 
To what extend this mechanism contributes to the stem cell potential of the 
leukaemic cells is not clear. We have shown so far, that knockdown of MLL/AF4 or 
HOXA7 leads to the onset of apoptosis and diminished colony forming rate. As 
MLL/AF4 and HOXA7 knockdown also result in TERT reduction it is likely that 
TERT contributes to the stem cell potential of the investigated leukaemic cells. In the 
literature there are reports of TERT overexpression in normal cells which leads to 
immortalisation of these cells (Chapman et al., 2006). Also, the high telomerase 
activity in a high variety of cancer, including haematopoietic malignancies, indicates 
that TERT is playing a central role in tumour maintenance (Shay et al., 1996, 
Hiyama et al., 1995b, Kim et al., 1994). 
 
On the one hand, the protein MLL alone is known to generally methylate lysine 4 of 
the protein histone 3 (H3K4) in the promoter regions of genes and thereby activates 
their transcription. On the other hand, AF4 is known to form a complex with the 
elongation factor DOT1L and is involved in modifying methylation of histone 3 
lysine 79 (H3K79) which also modulates gene transcription activity. In addition the 
literature describes MLL/AF4 fusion proteins having a striking impact on gene 
activity via abnormal H3K79 methylation (Krivtsov et al., 2008). Global ChIP-on-
chip analysis revealed gene activating H3K4 and H3K79 signature on the promoter 
of TERT in t(4;11) positive cells but also in t(4;11) negative REH cells suggesting 
that the involvement of MLL/AF4 in the epigenetic marking of TERT is unlikely 
(Guenther et al., 2008). 
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Figure 3-5 MLL/AF4 knockdown consequences 
MLL/AF4 regulates TERT expression via HOXA7. (A) Direct binding of HOXA7 in 
the promoter region of TERT was identified suggesting an indirect link between 
MLL/AF4 and TERT via HOXA7. (B) siRNA mediated knockdown (red) of 
MLL/AF4 causes a reduction of HOXA7 thereby a diminished TERT expression and 
consequently a lowered telomerase activity. The loss of telomerase activity thus 
causes shortening of the telomere length and consequently damage of the coding 
chromosomal region which may trigger apoptosis.  
 
The consequence of MLL/AF4 knockdown (Figure 3-5) is the direct depletion of 
HOXA7 in the affected cells. Direct HOXA7 binding to the TERT promoter explains 
the diminished TERT expression which results in reduction of telomerase activity. 
Thus the telomeres are not maintained anymore and will be reduced to a critical point 
where damage of coding regions of the DNA occurs. This DNA damage may then 
trigger the DNA-damage p53 response and finally induction of apoptosis. 
 
Using siRNA against MLL/AF the knockdown of TERT at the mRNA level was 
twofold and a considerable knockdown of the TERT protein 4 was observed (Figure 
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2-6). During analyses of these effects in SEM cells, an increasing number of 
apoptotic cells was observed when the time duration of siRNA treatment increased. 
By inhibiting apoptosis with the pancaspase inhibitor zVAD the aim was to rescue 
the cells and investigate them. The TERT knockdown was much stronger upon 
MLL/AF4 depletion after combined zVAD treatment compared to a control 
experiment without inhibitor. The level of mRNA of TERT was reduced to about 10% 
in siRNA/zVAD treated cells compared to only 50 % in siRNA/control cells. FACS 
analyses showed the effectiveness of apoptosis inhibition by zVAD (Figure 2-14). 
Interestingly after 144 hours of constant combined siRNA/zVAD treatment a 
subG1\G0 population of dead cells was observed. Closer investigations done by 
Patricia Garrido Castro in the group showed that this population did not consist of 
apoptotic cells, as key apoptotic markers were not seen however, there was evidence 
of necroptosis. This would lead to the assumption that the knockdown of MLL\AF4 
leads to inevitable cell death. Ongoing experiments further investigate this matter. 
Reports in the literature show that TERT has alongside its role in telomerase 
maintenance also an anti-apoptotic effect (Lee et al., 2008, Zhang et al., 2003). One 
reason for the resistance of the disease regarding many forms of treatment may be 
the high TERT expression in the surviving cells. As most anti-cancer agents block or 
damage crucial functions for cells like inhibition of DNA structure modification 
which normally induces apoptosis a high TERT expression might be sufficient to 
survive those treatments. The remaining problem in cancer therapy is not the blast-
crisis itself but the complete removal of malignant cells from the haematopoietic 
system of the individual. Thus a small residual population of TERT-induced 
apoptosis resistant cells may be enough to induce a relapse. 
 
When apoptosis is not suppressed by pancaspase inhibitors most cells die upon 
MLL/AF4 depletion. So far, there is no obvious reason that some cells do survive. 
Whether TERT plays a role in this resistance to apoptosis needs to be further 
investigated.  
Since MLL/AF4 knockdown results in HOXA7 depletion which then has a negative 
effect on TERT expression, it is perplexing that qRT-PCR results from zVAD treated 
cells do not correlate with the HOXA7 and MLL/AF4 results. One would expect 
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MLL/AF4 and HOXA7 to show an increased knockdown effect in apoptosis inhibited 
cells similar to TERT, assuming that there is a direct regulation of TERT by HOXA7. 
It may be that there is a mechanism which restores TERT expression during the 
knockdown and a small subpopulation of cells recovers from the siRNA mediated 
knockdown. HOXA7 may not be the only regulator of TERT expression (Wu et al., 
1999, Toh et al., 2005) and rescue mechanisms may be activated during the 
knockdown experiments. Those rescue mechanisms could depend on pro-apoptotic 
caspase activation as this is the only major change in the experimental setup (Figure 
3-6). With inhibition of the caspases by zVAD, this rescue mechanism does not take 
place and TERT expression remains low. As TERT has been reported to act in an 
anti-apoptotic way (Zhang et al., 2003, Lee et al., 2008) this rescue mechanism 
would clearly contribute to the survival and immortality of the cancer cells. This 
rescue mechanism may be present only in therapy resistant t(4;11) positive relapse 
acute lymphoblastic leukaemias. 
With regard to the HOXA genes, this mechanism would be HOXA independent. With 
the reports on HOXA negative and HOXA positive ALLs (Stam et al., 2009, Trentin 
et al., 2009) together with the poor outcome of HOXA negative patients, 
investigations regarding the TERT expression might show existence of a mechanism 
of TERT expression independent of the HOXA genes and more resistant to apoptosis. 
In our cell line comparison of HOXA7 and TERT expression, it was shown that TERT 
expression in MV4;11 cells is much lower compared to HOXA7-positive SEM or 
RS4;11 cells. However, this HOXA7 independent TERT expression might have a 
higher impact on chemotherapy resistance than the HOXA7 dependent TERT 
expression. Investigations into this matter might provide new insight into the 
mechanisms of t(4;11) positive leukaemias. 
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Figure 3-6 TERT is modulated by two independent mechanisms 
TERT regulation by MLL/AF4 is mediated via HOXA7. An alternative caspase 
dependent regulation may also exist. 
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3.3 Summary 
The overall aim of the study was to investigate the role of MLL/AF4 in t(4;11) 
positive B-ALL cells with regard to the interaction between MLL/AF4 and the genes 
of the HOXA cluster. The hypothesis was that MLL/AF4 – HOXA played a key role 
in both stemness and self-renewal potential.  
Acute lymphoblastic leukaemia (ALL) is the most common form of leukaemia in 
children of five years and under. In infants with ALL up to the age of 12 months 
rearrangement of the MLL gene is detected in more than 80 % (Pieters et al., 2007). 
More than 100 partner genes have been identified so far for MLL (Meyer et al., 
2009). The most common is AF4, detected in nearly 50 % of MLL rearranged infant 
leukaemias (van der Linden et al., 2009). This translocation t(4;11) marks a very 
aggressive form of leukaemia with a poor prognosis. The role of MLL/AF4 was 
investigated by applying siRNA against the fusion gene transcript. Knockdown of 
MLL/AF4 in the t(4;11) positive cell line SEM led to diminished proliferation, 
increased rate of apoptosis. Two homeobox genes, HOXA7 and HOXA9 along with 
HOX cofactor MEIS1 were also reported to be depleted upon MLL/AF4 knockdown 
(Thomas et al., 2005). 
The first goal was to investigate the whole HOXA cluster for altered expression upon 
MLL/AF4 knockdown. During the study it became clear that HOXA7 is vital to the 
survival of MLL/AF4 positive malignant cells. In knockdown experiments with 
HOXA7 its central role in maintaining the viability of MLL/AF4 positive SEM cells 
could clearly be shown. Beyond that, HOXA7 binding to the promoter of TERT, the 
reverse transcriptase that maintains the telomeres, was found and thereby contributed 
to the immortality of the malignant cells. Interestingly over expression of HOXA7 in 
t(4;11) positive cells turned out to be lethal. The reason for this remains unclear. 
There is still the question as to whether HOXA7 by itself could transform HSCs into 
their malignant form. 
While HOXA7, HOXA9 and HOXA10 knockdown was concomitant with previous 
data, a new target gene was identified in HOXA6 and another possible target gene in 
HOXA4. The HOXA genes have been recently described as bearing transforming 
potential in haematopoietic pluripotent cells (Bach et al., 2010) and to be directly 
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associated to the MLL complex (Guenther et al., 2008), especially HOXA7 and 
HOXA9. In addition, the important HOX co factor MEIS1 was demonstrated to be 
essential for leukaemic survival and greatly improves the transforming potential of 
malignant haematopoietic cells (Ayton and Cleary, 2003, Faber et al., 2009, Mamo et 
al., 2006, So et al., 2004). The exact role of the HOX genes in leukaemogenesis is 
still unclear. Their contributing characteristics are widely discussed in the literature. 
Comparing cell lines from de novo patients (MV4;11 and BLIN-3) and relapse 
patients (SEM and RS4;11) it appears that HOXA7 may play a role in the relapse 
patients which suffer from a more aggressive and therapy resistant form of leukaemia. 
One must be careful as this is data based on cell lines and may not reflect the data 
from primary patient material. Here the question rises as to why t(4;11) positive ALL 
patients with positive HOXA status have a better prognosis than HOXA negative 
patients (Stam et al., 2009, Trentin et al., 2009). More investigations in the genomic 
expression pattern of de novo patients compared with relapse patients would clarify 
this situation. 
 
A common finding in most forms of cancer is a high activity of the telomerase, an 
enzyme complex that maintains the telomeres, thereby contributing to the 
immortality of the malignant cells (Davison, 2007). The question was addressed as to 
whether the telomerase activity is affected by MLL/AF4 knockdown. A decrease in 
telomerase activity of about 70 % was found upon MLL/AF4 depletion. Further 
analyses were performed to see whether the protein subunit TERT or the RNA 
component TERC was affected by MLL/AF4 knockdown. We identified TERT, the 
reverse transcriptase of the telomerase, as being affected by MLL/AF4 knockdown. 
Further experiments showed that TERT was also depleted by siRNA mediated 
knockdown of HOXA7 which suggested TERT being a target of HOXA7. TERC did 
not show any changes upon MLL/AF4 depletion. Subsequently the question was 
asked as to whether TERT is a direct target of HOXA7. In first instance, in silico 
experiments were performed and several putative binding sites for HOXA7 in the 
promoter region of TERT were found. Primers were designed for several regions in 
the TERT promoter and ChIP experiments were performed to investigate the matter. 
Binding of HOXA7 directly to the promoter of TERT was detected. Epigenetic 
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marking of TERT has been previously reported by others (Guenther et al., 2008). In 
our scenario it looks like the binding of HOXA7 is crucial for TERT expression. 
Comparing t(4;11) cell lines SEM, RS4;11 and MV4;11, a correlation was shown 
between HOXA6, HOXA7 and TERT expression. Both ALL cell lines SEM and 
RS4;11 showed HOXA6, HOXA7 and TERT expression while the AML cell line 
MV4;11 did not. Whether this difference is dependent on the lineage AML vs. ALL 
or relapse vs. de novo disease has to be confirmed in further experiments. 
Application of siRNA against TERT could also lead to results which show the 
importance of TERT. As TERT is a key component in the telomerase and thereby for 
telomere maintenance, the loss of TERT would have result in telomere shortening 
and induction of apoptosis as a consequence. The t(4;11) positive cell line SEM 
showed an increased apoptosis rate upon MLL/AF4 depletion whereupon TERT 
depletion is a consequence. Whether TERT depletion is decisive for apoptosis 
induction needs to be investigated. 
The function of TERT being an inhibitor for apoptosis is currently discussed in the 
literature (Lee et al., 2008, Zhang et al., 2003). SEM cells were treated with siRNA 
against MLL/AF4 and additionally with or without zVAD, a pancaspase inhibitor 
which inhibits apoptosis induction. zVAD treated cells showed lower TERT 
expression after MLL/AF4 depletion than cells without zVAD. This leads to the 
assumption that cells with low TERT expression die faster than cells with high TERT 
expression. Here it is possible that TERT inhibits apoptosis by a mechanism so far 
not fully understood. This mechanism involves a family of proteins called 14-3-3 
which may shuttle TERT to the mitochondrion and prevents cytochrome c release 
thus inhibiting apoptosis (Seimiya et al., 2000). 14-3-3 proteins or even their genes 
are also possible targets to be investigated for treatment in leukaemia. These proteins 
are involved in many processes like signalling, cell cycle and apoptosis (van Hemert 
et al., 2001). 
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3.4 Future work 
Knockdown of MLL/AF4 causes depletion of HOXA6, HOXA7, HOXA9 and 
HOXA10. Furthermore HOXA4 seems to be affected but needs to be validated in 
more MLL/AF4 knockdown experiments and at the RNA as well as at the protein 
level. To investigate the function of HOXA4, HOXA6, HOXA9, HOXA10 and also 
TERT, siRNAs must be designed and knockdown experiments in t(4;11) cell lines 
performed. The inclusion of the cell line BLIN-3 to the already available cell lines 
SEM, RS4;11 and MV4;11 would allow the influence of HOXA genes on the 
malignant cells to be further investigated. Initial comparison experiments should be 
performed to investigate overall expression of the HOXA genes and TERT in all cell 
lines, including other AML and ALL cell lines. One could also think of adding 
primary patient material and carefully distinguish between de novo and relapsed 
patients.  
Another important step would be the generation of leukaemic cell lines that stably 
over express one of the candidate HOXA genes or TERT or both, using the existing 
cell lines such as SEM, RS4;11 and MV4;11. MLL/AF4 knockdown experiments 
could give then further insight into the importance of HOXA genes. Overexpression 
of TERT and knockdown experiments targeting the HOXA genes would clarify the 
importance of TERT. Attempts done in this thesis did not lead to the establishment of 
such cell lines. 
To investigate HOXA7 binding to the TERT promoter, luciferase assays could be 
established. As a starting point, the already published sequence of the TERT core 
promoter could be used (Takakura et al., 1999). Attempts could be made to clone this 
promoter into a luciferase gene harbouring vector and to express the protein under 
control of the TERT promoter to measure the binding of recombinant HOXA7 in an 
overexpressing cell line. Investigating truncated versions of the TERT promoter 
could then finally lead to the exact position of the HOXA7 binding site. 
Another subject for further studies could be the 14-3-3 proteins and their role in the 
TERT localisation in the malignant cell. It is possible that investigation of the role of 
these proteins in the regulation of cellular processes in leukaemia may give rise to 
further studies or even lead to targets for treatment. Firstly, it should be investigated 
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if they are aberrantly expressed in leukaemic cells. Following this, the effects of 
MLL/AF4 downregulation on 14-3-3 proteins could be investigated. Several forms of 
the 14-3-3 genes have been identified to be affected by MLL and AF4. Epigenetic 
modification of H3K4 and H3K79 at the locus of those forms has also been reported 
(Guenther et al., 2008). One of these forms is 14-3-3zeta which is already associated 
with TERT nuclear localisation (Seimiya et al., 2000, Zhang et al., 2003). This form 
would be the primary target for further analyses. 
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4 Materials and Methods 
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4.1 Materials 
 
All details and specifications are standard unless stated otherwise. 
General lab equipment is from Scientific Laboratory Supplies (Nottingham, UK), 
VWR (Lutterworth, Leicestershire, UK) or Fisher Scientific (Loughborough, 
Leicestershire, UK). 
4.1.1 Devices 
ABI 7000 Real Time detection system   Applied Biosystems, Darmstadt, 
Germany 
ABI 7500 Fast Real-Time PCR system  Applied Biosystems, USA 
ABI 7000 SDS program    Applied Biosystems, USA 
ABI 7900HT Sequence detection system  Applied Biosystems, USA 
ABI SDS 2.2      Applied Biosystems, USA 
Agarose gel electrophoresis unit   BIO-Rad, Hemel Hempstead, 
Herts., UK 
Electroporation-Impulsegenerator EPI 2500  Heidelberg, Germany 
FACSCalibur       Beckton Dickinson, Heidelberg, 
Germany 
FACScan       Beckton Dickinson, Oxford, UK 
FACSCanto       Beckton Dickinson, Oxford, UK 
FujiFilm Luminescent Image Analyser LAS-300 FujiFilm Microdevices Co., Ltd., 
Japan 
Fuji X-Ray Film processor RG11   Fuji Photo Film Co. Ltd., Tokyo, 
Japan 
 116 
 
MINI-PROTEAN II electrophoresis cell  BIO-Rad, Hemel Hempstead, 
Herts., UK 
MINI Trans-Blot Electrophoretic transfer cell BIO-Rad, Hemel Hempstead, 
Herts., UK 
MSE Soniprep 150 plus sonicator   MSE (UK) limited, London, UK 
ND-1000 spectrophotometer    Nanodrop technologies Ltd., 
USA 
Spectramax 250 multiwell plate reader  Molecular devices, Crawley, UK 
 
Centrifuges 
Centrifuge 5415C     Eppendorf, Hamburg, Germany 
Centrifuge 5415R     Eppendorf, Hamburg, Germany 
L870M Ultracentrifuge    Beckman, High Wycombe, UK 
Allegra® X-12 benchtop centrifuge   Beckman Coulter, High 
Wycombe, UK 
 
 
 
 
 
 
 117 
 
4.1.2 Buffers and solutions 
All standard chemicals were purchased either from SIGMA (Poole, Dorset, UK), 
Fisher Scientific (Leicestershire, UK) or BDH (Dorset, UK). 
Protein extracts and western blotting 
Urea Buffer      9 M Urea 
4 % CHAPS 
1 % DTT 
pH 5.0 
stored at –20˚ C 
 
Bradford Reagent Concentrate Bio-Rad Protein Assay BIO-Rad, Hemel 
Hempstead, UK 
 
2x SDS Loading buffer   100 mM Tris, pH 6.8 
2.5 mM EDTA, pH 8.0 
25 % Glycerin 
0.05 % Bromphenolblue 
4 % sodium dodecyl sulphate (SDS) 
100 mM DTT 
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Separating Gel: 
 
7 %  8 %  10 %  12 %  15 %  
H2O  5.75 ml  5.5 ml  5 ml  4.5 ml  3.7 ml  
4x separation gel-
buffer  
2.5 ml  
40 % PAA  1.75 ml  2 ml  2.5 ml  3 ml  3.8 ml  
Mix well 
10 % APS  100 µl  
TEMED  10 µl  
 
Stacking Gel: 
3.9 ml   H2O 
5 ml  2x stacking gel buffer 
1 ml  40 % PAA (Sigma, 19:1) 
Mix well 
100 µl  10 % APS 
10 µl  TEMED 
10x Tris – Glycine buffer   14.4 % Glycine 
3 % Tris 
1x electrophoresis buffer  1/10 vol. 10x Tris-Glycine buffer 
     0.1 % SDS 
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1x blotting buffer   1/10 vol. 10x Tris-Glycine buffer 
     10 % Methanol 
TST      10 mM Tris, pH 7.5 
100 mM NaCl 
0.1 % Tween20 
1 mM EDTA, pH 8.0 
Blocking solution    TST buffer + 10% skim milk 
ECL Plus Western Blotting   Amersham Biosciences, Freiburg, Germany 
Detection Reagents  
Immobilon Western    Millipore, Watford, Hertfordshire, UK 
Chemoluminescent HRP solution 
Immobilon-P Membrane, PVDF Millipore, Watford, Hertfordshire, UK 
 
Stripping Buffer    100 mM β-Mercaptoethanol 
2% SDS 
62.5 mM Tris, pH 6.7 
E.coli transformation 
LB-Medium     10 g/l Bacto-Trypton (Applichem, Darmstadt) 
      5 g/l Yeast Extract 
10 g/l NaCl 
pH 7.4 
sterilized by autoclaving 
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LB-Agar     10 g/l Bacto-Trypton 
5 g/l Yeast Extract 
10 g/l NaCl 
15 g/l Agar 
pH 7.4 
sterilized by autoclaving 
 
 
Molecular Cloning 
Restriction Enzymes (Fermentas or New England Biolabs NEB): 
BamHI 
AscI 
PvuI 
EcoRI 
XhoI 
SalI 
NcoI 
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Modifying Enzymes 
Klenow Fragment 
Calf intestinal alkaline phosphatase, CIAP 
Chromatin Immunoprecipitation (ChIP) Assay with Staphylococcus aureus 
Cell lysis buffer    5mM  PIPES, pH8 
      85mM  KCl 
      0.5%  NP40 
 
Nuclei lysis buffer    50mM  Tris-Cl, pH 8.1 
      10mM  EDTA 
      1%  SDS 
      + Complete, 1 tablet (right before use) 
IP dilution buffer    0.01%  SDS 
      1.1%  Triton X100 
      1.2mM EDTA 
      16.7mM Tris-Cl, pH 8.1 
      167mM NaCl 
      + Complete, 1 tablet (right before use) 
 
1x Dialysis buffer    2mM  EDTA 
      50mM  Tris/HCl, pH 8 
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IP Wash buffer    100mM Tris/HCl, pH 9 
      500mM LiCl 
      1%  NP40 
      1%  deoxycholic acid 
 
IP elution buffer    50mM  NaHCO3 
      1%  SDS 
 
5x PK buffer     50mM  Tris/HCl, pH 7.5 
      25mM  EDTA 
      1.25%  SDS 
 
- 37% Formaldehyde 
- 1.25M Glycine 
- Complete™ Mini, EDTA-free, REF 11 836 170 001, 25 tablets, Protease 
Inhibitor cocktail tablets, Roche, Basel, CH 
- PBS (+ Complete™) 
- RNaseA (10mg/ml) 
- 5M NaCl 
- 100% EtOH 
- TE Buffer 
- 1:1 mixture of Phenol and Chloroform/Isoamyl alcohol (24:1) 
- Chloroform/Isoamyl alcohol (24:1) 
- 3M NaAc 
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Hybridization of siRNAs 
SiRNA Hybridization buffer   100 mM NaCl 
25 mM Tris-HCl, pH7.5 
Cell cycle analysis 
Citrate buffer     0.25 M Saccharose 
40 mM Natriumcitrate, pH 7.6 
DNA-staining    PBS 
and lysis buffer    20 µg/ml PI 
0.5% NP-40 
0.5 mM EDTA 
Cell cycle wash buffer  PBS 
0.5% BSA 
FACS-buffer     PBS 
2 mM EDTA 
0.1% BSA 
Telomerase activity assay 
Roche Complete™ Protease   Chymotrypsin, 1.5µg/ml 
Inhibitor Cocktail Tablets   Thermolysin, 0.8µg/ml 
Papain, 1mg/ml 
Pronase, 1.5µg/ml 
Pancreatic extract, 1.5µg/ml 
 124 
 
Trypsin, 0.002µg/ml 
Telomerase lysis buffer   10 mM Tris/HCl, pH 7.5 
1 mM MgCl2 
1 mM EGTA 
5 mM β-Mercaptoethanol 
0.5% CHAPS 
10% Glycerol 
+Complete ™, 1 tablet 
Real Time RT-PCR 
SYBR Green QCR Supermix w/ROX   Invitrogen, Paisley, UK 
RevertAid™H Minus First Strand cDNA Synthesis Kit Fermentas, York, UK 
 
Electroporation 
Cuvettes 4mm par 50 sans pipet    Eurogentec, 
Southampton, UK 
4.1.3 Kits 
RNeasy Total RNA Isolation Kit   Qiagen, Crawley, West Sussex, 
UK 
QIAquick PCR Purification Kit    Qiagen, Crawley, West Sussex, 
UK 
QIAquick Gel Extraction Kit     Qiagen, Crawley, West Sussex, 
UK 
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Miniprep Plasmid Isolation Kit    Qiagen, Crawley, West Sussex, 
UK 
Maxiprep Endofree Plasmid Isolation Kit  Qiagen, Crawley, West Sussex, 
UK 
AMAXA Nucleofection Kit     Lonza 
Nucleofector solution R     
 
4.1.4 Antibodies 
 
Primary 
Anti HOXA6 Antibody #H00003203-M01  Abnova Cooperation, UK 
Anti HOXA7 Antibody #ab-70027-100  Abcam, Cambridge, UK 
Anti HOXA9 Antibody #07-178   Millipore/Upstate, Watford, UK 
Anti hTERT Antibody #1531-1   Epitomics/BIOMOL, Hamburg, 
Germany 
Anti glyceraldehyde-3-phosphate dehydrogenase HyTest Ltd. Turku, Finland 
(GAPDH) Antibody #5G4 
 
Secondary HRP conjugated 
Anti rabbit IgG #P0217    Dako, Ely, Cambridgeshire, UK 
ECL™ Anti mouse IgG #NA931V   GE Healthcare, Bucks, UK 
Anti goat IgG #SC-2020    Santa Cruz, USA 
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4.1.5 Synthetic Oligonucleotides 
Oligonucleotides were purchased from Purimex (Grebenstein, Germany), Alnylam 
Europe (Kulmbach, Germany), VHBio (Gateshead, UK), Eurofins-MWG-Operon 
(London, UK) or Qiagen (Crawley, UK) 
siRNA 
MLL/AF4 siRNA “siMA6”  
sense; 5´-AAG AAA AGC AGA CCU ACU CCA-3´ 
antisense; 5´-UGG AGU AGG UCU GCU UUU CUU UU-3´ 
siRNA control siMM  
sense; 5´-AAA AGC UGA CCU UCU CCA AUG-3´ 
   antisense; 5’-CAU UGG AGA AGG UCA GCU UUU CU-3’ 
siRNA control siAGF1  
sense; 5´-CCUCGAAAUCGUACUGAGAAG-3´ 
antisense; 5´- UCUCAGUACGAUUUCGAGGUU -3´ 
 
HOXA7 siRNA “siHOXA7”  
sense; 5’ - CCGUUCCGGGCUUAUACAAUG - 3’ 
antisense; 5’ - UUGUAUAAGCCCGGAACGGUC – 3’ 
 
hTERT siRNA “siRNA-5 TERT” 
sense; 5’ AAC ACG GUG ACC GAC GCA CUG 3’ 
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antisense; 5’ UUC AGU GCG UCG GUC ACC GUG 3’ 
hTERT siRNA “siRNA-41 TERT” 
sense; 5’ AAA AGA GGG CCG AGC GUC UCA 3’ 
antisense; 5’ UUU GAG ACG CUC GGC CCU CUU 3’ 
Primers for RealTime-PCR 
HoxA1 forward 5’-ACC CCG CCA GGA AAC G-3’ 
HoxA1 reverse  5’-GGA ACG CAG GGC GAA GA-3’ 
HoxA2 forward 5’-AGA ACT GTG GAG CTG GCC TAA AC-3’ 
HoxA2 reverse  5’-GAA AAC GCT AAA GTC CTG CAA AGA-3’ 
HoxA3 forward 5’-CCA ATC TGC TGA ACC TCA CTG A-3’ 
HoxA3 reverse  5’-GCA TGC CCT TGC CCT TCT-3’ 
HoxA4 forward 5’-GGT GTA CCC CTG GAT GAA GAA G-3’ 
HoxA4 reverse  5’-CTT AGG CTC CCC TCC GTT ATA AC-3’ 
HoxA5 forward 5’-CGC CCA ACC CCA GAT CTA C-3’ 
HoxA5 reverse  5’-GGC CGC CTA TGT TGT CAT G-3’ 
HoxA6 forward 5’-CGG TTT ACC CTT GGA TGC A-3’ 
HoxA6 reverse  5’-GCC CAT GGC TCC CAT ACA C-3’ 
HoxA7 forward 5’-GAG GCC AAT TTC CGC ATC TA-3’ 
HoxA7 reverse  5’-GCG GTT GAA GTG GAA CTC CTT-3’ 
HoxA9 forward 5´-CCA CCA TCC CCG CAC A-3´ 
HoxA9 reverse  5´-AAC AGG GTT TGC CTT GGA AA-3´ 
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HoxA10  forward  5´-CAG GCC ACC TCG TGC TCT T-3 
HoxA10  reverse  5´-TTT GTC CGC CGA GTC GTA G-3´ 
HoxA11 forward 5’-TCG TCT TCC GGC CAC ACT-3’ 
HoxA11 reverse  5’-TCT CGG ATC TGG TAC TTG GTA TAG G-3’ 
HoxA13 forward 5’-CCA AAT GTA CTG CCC CAA AGA-3’ 
HoxA13 reverse  5’-AGA CCA CGT CGG GCA GAG T-3’ 
TERC  forward 5’-GCT GTT TTT CTC GCT GAC TTT CA-3’ 
TERC  reverse  5’-GCA GCT GAC ATT TTT TGT TTG C-3’ 
TERT  forward 5’-GGA GAA CAA GCT GTT TGC GG-3’ 
TERT  reverse  5’-AGG TTT TCG CGT GGG TGA G-3’ 
GAPDH forward 5´-TGG CAT GGC CTT CCG T-3´ 
GAPDH reverse  5´-TCT CCA GGC GGC ACGT T-3´ 
HPRT  forward 5´-TGA CAC TGG CAA AAC AAT GCA-3´ 
HPRT  reverse  5´-AGC TTG CGA CCT TGA CCA TC-3´ 
RPLP01 forward 5’-TCT GAT TGG CTA CTT TGT TGC C-3’ 
RPLP01 reverse  5’-CCT TCC ACG AGG ACG CCT-3’ 
28S  forward 5’-AAG CAA GGC CTC TGG AAA AC-3’ 
28S  reverse  5’-ATG CAG TAT GTC TTA GCC TTA A-3’ 
RPLP0M forward 5’-TGG GCA AGA ACA CCA TGA TG-3’ 
RPLP0M reverse  5’-AGT TTC TCC AGA GCT GGG TTG T-3’ 
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Plasmid Maps: 
 
 
 
 
Figure 4-1pCMV_dR8.91 
Plasmidmap of the pCMV_dR8.91 packaging vector 
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Figure 4-2 pMD2.G 
Plasmidmap of the pMD2.G enveloping vector 
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4.2 Methods 
4.2.1 Cell lines and Cell culture (Sources: DSMZ, Germany) 
Leukaemic cell lines (immunology and cytogenetics from DSMZ, Germany): 
MV4;11 (AML): 
Original cells were obtained from a 10 year old boy with acute monocytic leukaemia 
(AML FAB M5). The MV4;11 cell line was established in 1987 by Lange and 
colleagues (Lange et al., 1987). 
 
Immunology: CD3 -, CD4 +, CD5 -, CD8 -, CD10 -, CD13 +, CD14 -, CD15 +, 
CD19 -, CD21 -, CD25 -, CD33 +, CD37 -, CD68 +, CD138 -, HLA-DR + 
Cytogenetics:  human hyperdiploid karyotype - 48(46-48)<2n>XY, +8, +18, +19, -
21, t(4;11)(q21;q23) 
 
RS4;11 (ALL): 
Original cells were obtained from a 32 year old woman with acute lymphoblastic 
leukaemia in first relapse. The cell line was established by Stonge and colleagues in 
1985 (Stong and Kersey, 1985) 
Immunology: CD3 -, CD10 -, CD13 -, CD19 +, CD20 -, CD34 (+), CD37 -, 
cyCD79a +, CD80 -, CD138 -, HLA-DR +, sm/cyIgG -, sm/cyIgM -, sm/cykappa -, 
sm/cylambda – 
Cytogenetics: human hyperdiploid karyotype - 47/48<2n>X/XX, +8, +18, 
t(4;11)(q21;q23), i(7q) - sideline without +8/18 - carries MLL-AF4 fusion gene - 
resembles published karyotype 
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SEM (ALL): 
Original cells were obtained from the peripheral blood of a 5 year old girl at relapse 
of acute lymphoblastic leukaemia (ALL). The cell line was established by Greil and 
colleagues (Greil et al., 1994) 
Immunology: CD3 -, CD4 -, CD13 +, CD14 -, CD15 +, CD19 +, CD33 +, CD34 -, 
HLA-DR +, sm/cyIgG -, sm/cyIgM -, sm/cykappa -, sm/cylambda – 
Cytogenetics: human hypodiploid karyotype with 1.5% polyploidy - 45(40-
46)<2n>XX, -13, t(4;11)(q21;q23), del(7)(p14) - carries t(4;11) with breakpoints at 
AF4 and MLL - matches published karyotype 
 
Other cell lines: 
293T  
Human embryonic kidney cell line, modified with human adenovirus type 5 (Graham 
et al., 1977). The SV 40 large T-antigen was introduced into the cells which makes 
them a perfect host for virus production. The SV 40 large T antigen allows for 
replication of transfected episomes that contain the SV 40 origin of replication. An 
episome is a piece of plasmid DNA which is located in the nucleus but not integrated 
into the genome of the host cell. 
Cytogenetics: human flat-moded near-triploid karyotype; 61-73<3n>XXX, 
add(1)(p32), add(1)(q44)x1-2, der(4;10)(q10;q10), del(8)(p12), t(9;9)(p24;q21), 
der(13)t(6;13)(q21;q32), der(14)t(13;14)(q32;q32), del(17)(p11), 
der(22)t(17;22)(q21;q22) 
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4.2.2 Cell culture 
Cells from the cell lineages SEM, RS4;11 and MV4;11 were cultured in RPMI1640 
Medium (SIGMA, HEPES Modification, #R5886) supplemented with 10% FCS 
(SIGMA, #F7524) and 2mM L-Glutamine (SIGMA, #G7513). The 293T cells were 
cultured in DMEM (SIGMA, #D6171) and also supplemented with FCS and 2mM L-
Glutamine. All cells were incubated at 37°C, 5% CO2 and 95% air humidity. SEM, 
RS4;11 and MV4;11 cells were split every two days to a final concentration of 
5x105cells/ml. 293T cells were split at a ratio of 1:10 when their confluence reached 
about 80%. 
 
4.2.3 Freezing and thawing of cells 
Cells were frozen in 800 µl of medium, containing 40% FCS and 10% DMSO. A 
typical total cell number for freezing was 5x106 cells. The cells were put into cryo-
vials (Nunc) and frozen at -80°C for 24 hours. After that time the cells were put into 
liquid nitrogen for long term storage. 
For thawing, the cells were quickly thawed at 37°C and pre-warmed medium was 
added to the thawed solution. The cells were pelleted by centrifugation and 
subsequently resuspended in pre-warmed medium to dilute the cells to the desired 
concentration. 
 
 
4.2.4 Determination of cell concentration 
To determine the cell concentration in a culture flask a hematocytometer was used 
(Figure 4-3). The hematocytometer is a counting chamber called “Neubauer 
improved Counting Chamber”.  
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Figure 4-3 Cell counting using a Neubauer counting chamber 
The picture shows the counting grid on a improved Neubauer counting chamber. Cells in the 
four red highlighted were counted as illustrated in the picture (green lines); taken from 
www.carl-roth.de . 
 
After counting all squares, the following equation gave the concentration of cells per 
ml medium: 
 
			


∗ 10

 = cells/ml medium 
 
4.2.5 Treatment of SEM cells with zVAD 
zVAD or zVAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- 
fluoromethylketone) is a pan caspase inhibitor (pan = Greek meaning “all”) which 
binds irreversibly to the catalytic centre of the major caspases and by this blocks 
apoptosis. zVAD inhibits all caspases except CASP2. 
The substance was dissolved in DMSO following manufacturer’s protocol, resulting 
in a 20 mM stock solution. As DMSO is cytotoxic, the stock dilution was pre-diluted 
10-fold in medium, yielding a second stock solution with concentration of 2 mM. 
Just before seeding the electroporated or otherwise treated cells, the 2mM stock 
solution was added to the cell culture medium to get the desired concentration. Cells 
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were cultured as described in section 4.2.2. The end concentration in medium was 50 
µM. 1mg of zVAD was diluted in 107 µl DMSO to get 20 mM stock solution. 
Frozen at -20° C, the solution is stable for about a month. Before use, the DMSO 
stock solution was diluted 1:10 in medium (no additives) (2mM end concentration). 
The final dilution was 1:40 in cell culture medium. 
4.2.6 Hybridisation of siRNA 
siRNA sense and antisense strands were diluted in hybridization buffer to a final 
concentration of 20 µM, placed into a thermal block and incubated at 95° C for 30 
seconds. Subsequently the heat-block was cooled down to room temperature. When 
the thermal block reached this temperature, the siRNA solution was aliquoted (in 
order to avoid unnecessary handling of the sample) and frozen at -20° C. 
4.2.7 Molecular Cloning 
Restriction of plasmid DNA 
The restriction of plasmid DNA was performed for three purposes: Either to cut a 
plasmid for a following cloning step, to check the size of a certain plasmid or to 
separate and isolate a specific fragment of the plasmid. 
The plasmid DNA was digested according to the manufacturer’s specifications. 
Normally 1 µg to 2 µg of plasmid DNA were used for digestion. The reaction mix 
contained 1x concentration of the enzyme specific reaction buffer, normally 5 units 
of enzyme and was filled to the desired volume with ddH2O. The reaction was 
incubated for 1 hour at 37°C if not otherwise stated. For double digestion the 
reaction buffer was chosen after using the Fermentas Double digest program 
(http://www.fermentas.com). The restriction enzymes were inactivated by the 
addition of EDTA followed by incubation at 65°C for 20 minutes. 
Isolation of plasmid DNA fragments 
To isolate the desired DNA fragment, the digested plasmid DNA solution was 
separated on a 1 % agarose gel by electrophoresis. After addition of DNA loading 
dye the solution was pipette into the loading pockets of the gel and run with 120V for 
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one hour or until the bromophenol blue marking has reached the lower quarter of the 
gel. 
After electrophoresis, the gel was stained with ethidium bromide (EtBr) for at least 
30 minutes. The ethidium bromide bath contained 200ng EtBr diluted in one litre 
water. Subsequently the gel was placed onto a UV table and the desired band was cut 
out with a scalpel. The fragments were then isolated by using the QiaQuick Gel 
Extraction Kit. Briefly the gel slice was weighed and dissolved in buffer QG. After 
adding one gel volume of isopropanol, the solution was transferred to a QiaQuick 
column. After several washing steps the fragments were eluted with water or EB 
buffer. 
Modification of plasmid DNA 
For molecular cloning it is sometimes necessary to modify the linearised vector to 
avoid religation in following steps or to fill in sticky ends to perform a blunt end 
ligation. 
For some cloning reactions a blunt end ligation seems to be the optimal way. If the 
plasmid DNA was cut with enzymes which produce sticky ends these have to be 
altered to blunt ends. To perform this fill-in reaction the Klenow fragment was used 
according to the manufacturer’s protocol. The Klenow fragment is part of the 
polymerase I enzyme and has endonuclease activity, but no exonuclease activity. 
For the fill-in reaction 20 µl of the digested plasmid solution was mixed with 1 µl 
EcoPol buffer (10 mM Tris-HCl at pH 7.5; 5 mM MgCl2; 7.5 mM DTT), 1 µl 10mM 
dNTPs, 1 µl Klenow (5u/ µl) and filled with 7 µl of water. The reaction was 
incubated for 15 minutes at room temperature and subsequently deactivated by 
heating to 95°C for 3 minutes. The plasmid DNA was isolated by agarose gel 
electrophoresis and extracted by using the QiaQuick gel Extraction Kit. 
 To avoid religation of the linearised vector, the digested plasmid was treated with 
calf intestinal alkaline phosphatase (CIAP) according to the manufacturer’s protocol. 
CIAP dephosphorylates the ends of an open vector. Without a free phosphate-group 
the ends of the opened vector cannot religate. For dephosphorylation the desired 
plasmid fragments were mixed with 10xCIAP buffer (50mM Tris-HCl (pH 9.3 at 
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25°C), 1mM MgCl2, 0.1mM ZnCl2 and 1mM spermidine), 2 µl CIAP (1u/ µl) and 
water. The dephosphorylation was performed for 30 minutes at 37’C. For 
inactivation the solution was incubated at 95°C for 3 minutes. 
Ligation 
For the ligation, the insert fragment and the vector were mixed in a 3:1 ratio based on 
their molecular weight. The ligation mix contained the insert-vector mix, 10% v/v 
ligase buffer (400 mM Tris-HCl, 100 mM MgCl2, 100 mM DTT, 5 mM ATP (pH 7.8 
at 25°C), 1 µl of T4 ligase (4u/ µl) and was filled to 20 µl with water. The reaction 
was incubated for 4-6h at room temperature. The reaction was inactivated by adding 
EDTA and incubation at 65°C for 20 min. The complete ligation was then used for 
the transformation. 
Transformation of bacteria 
For transformation of expression and cloning vectors the E. coli strain DH5α was 
used. All lentiviral vectors were replicated by transforming the E. coli strain Stbl3 
from Invitrogen (One Shot ® Stbl3™ chemically competent E. coli; Genotype: F- 
mcrB mrr hsdS20 (rB-,mB-) recA13 supE44 ara-14 galK2 lacY1 proA2 rpsL20(StrR 
xyl-5 λ-leu mtl-1). 100 µl of the desired competent bacteria were mixed with the 
whole ligation solution and incubated on ice for 20 minutes. The mixture was then 
incubated for exactly 90 seconds in 42° C warm water and put back on ice for 
another 5 minutes. After addition of 400 µl of warm LB-buffer the mixture was 
incubated for 30 minutes at 37°C while constantly shaking. Thereafter the mixture 
was plated onto agar plates containing ampicillin as the selection marker. The plates 
were then incubated at 37°C overnight. 
Isolation of plasmid DNA from bacteria 
MiniPrep: For preparation of a MiniPrep, one single colony from was picked from a 
selective plate and inoculated in 3ml LB Medium overnight at 37°C on a shaking 
platform. The next day, the bacteria were harvested by centrifugation at 6800g for 3 
minutes. The pellet was resuspended in buffer P1 (50 mM Tris-Cl, pH 8.0; 10 mM 
EDTA; 100 µg/ml RNaseA) and transferred to a micro centrifuge tube. Lysis buffer 
P2 (200 mM NaOH; 1% SDS w/v) was added subsequently and the tube was 
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inverted several times. After complete lysis of the bacteria, the neutralisation buffer 
P3 (3.0 M potassium acetate, pH 5.5) was added and the tube again was inverted. 
The tubes were then centrifuged for 10 minutes at 17 000 g to pellet the debris. The 
supernatants were transferred to a QiaPrep Spin Column and centrifuged at 17 000 g 
for 1 minute followed by two washing steps with buffer PB. The plasmids were 
eluted by adding 50 µl water to the column and centrifugation for one minute at  
17 000 g. 
 
MaxiPrep (optional endofree): For the MaxiPrep, 2ml of cultured plasmids 
(remaining culture of the MiniPrep pre-culture) were added to 100 ml – 150 ml LB 
medium and cultured overnight at 37° C on a shaking platform. The next day, the 
bacteria were harvested by centrifugation with 6000 g at 4° C for 20 minutes. The 
pellet was resuspended in buffer P1 and lysed by addition of buffer P2 followed by a 
5 minute incubation at room temperature. The lysis was neutralised by addition of 
buffer P3 and incubation on ice for 20 minutes. The mixture was then applied to a 
QiaFilter cartridge and filtered into a new 50ml tube. Where required an endotoxin 
removal step was performed at this point by adding buffer ER to the filtered lysate. 
During the incubation, the QiaTip 500 columns were equilibrated by applying buffer 
QBT to them. The neutralised mixture was then centrifuged for 30 minutes with 20 
000 g at 4° C. The supernatant was applied to the equilibrated Tip500 and washed 
twice with buffer QC. The plasmids were eluted with buffer QF. 
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4.2.8 Typical setup for transfection experiment 
 
Figure 4-4 Overview of a typical transfection experiment 
The flowchart shows the typical setup for the transfection of a target cell line with siRNAs 
and procedures for subsequent analysis.  
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Figure 4-4 shows briefly how a typical transfection experiment was performed. On 
day 0 target cells were electroporated with according siRNAs and cultured for 48h at 
optimal cell line specific conditions. Depending on the experimental setup cells were 
harvested on day 2 and analysed or electroporated for a second time. This procedure 
was repeated on day 4. On day 6 all remaining cells were harvested and analysed. A 
range of analytical methods was used included fluorescent activating cell sorting 
(FACS), protein analysis in form of western blots and mRNA quantification by 
quantitative reverse transcriptase polymerase chain reaction. 
4.2.9 Electroporations 
The standard method for the transfection of siRNAs was the electroporation with the 
pulse generator EPI2500 (Dr. L. Fischer, Heidelberg), shown in figure 4-5. Cells 
were electroporated in 100 – 800 µl culture medium in 4mm cuvettes at a 
concentration of 1x107cells/ml. If not indicated otherwise, the final siRNA 
concentration was 500 nM diluted from a 20 µM stock. The electroporation 
conditions varied between the different cell lines. SEM and MV4;11 cells were 
electroporated at 350V with a 10ms pulse. For RS4;11 cells, 370V and a 10ms pulse 
was used. After siRNA treatment, the cells were left in the cuvettes for 15 minutes at 
RT and subsequently diluted twenty-fold into culture flasks. 
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Figure 4-5 The Fischer EPI2500 electroporator 
(A) Picture of the EPI2500 electroporator used during this study. (B) represents the 
advantage of the square pulse, generated by the EPI2500. The advantage compared to older 
methods is the constant upkeep of the voltage during the electroporation time (red line). 
Taken from www.electroporation.eu  
 
For nucleofection, the transfection of plasmid DNA directly into the nucleus, the 
procedure was performed according to the protocol for the AMAXA Nucleofection 
kit. Cells were electroporated in cuvettes provided with the kit at a concentration of 
1x106cells/100 µl. As suggested by the protocol, 2 µg of plasmid DNA was added 
and immediately electroporated with a 15ms pulse at 250V. Subsequently the cells 
were cultured in the according medium at the optimum cell concentration. 
4.2.10 Isolation of total RNA and protein 
For the isolation of total RNA and protein, the Qiagen RNeasy Kit was used and the 
method was performed according to the protocol. Basically cells were harvested and 
washed once with PBS. After centrifugation, the cell pellet was lysed in RLT buffer 
supplemented with β-Mercaptoethanol (10 µl/1ml RLT). The lysate was transferred 
A 
B 
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onto a Qiagen Shredder column and spun for 2min at full speed (~13000 rpm, 
depending on the centrifuge) in a table centrifuge at room temperature (RT). After 
adding 350 µl of 70% ethanol to the flow through, the lysate was transferred to a 
QIAGEN RNeasy column and spun for 1min at full speed. The flow through was 
collected for further protein isolation, the RNA was further isolated according to the 
manufacturers protocol. The total RNA yield was determined by 
spectrophotometrical measuring with a ND-1000 UV-Vis Spectrophotometer. 
The flow through with the protein was transferred to a 2 ml Eppendorf tube and filled 
up with 100% acetone. The tubes were closed and kept on ice for 30 minutes. 
Subsequently the protein lysates were centrifuged at full speed in a table centrifuge 
for 15 min at RT. The supernatant was discarded, the pellet briefly air dried and then 
solubilised in urea buffer. The protein concentration was determined by Bradford 
protein assay. 
4.2.11 cDNA synthesis – reverse transcriptase PCR (RT-PCR) 
To analyse the mRNA it has to be converted to cDNA which is then used in the real 
time PCR. For the cDNA synthesis, the RevertAid™H Minus First Strand cDNA 
Synthesis Kit from Fermentas was used according to the manufacturers protocol. In a 
PCR tube, one microgram of RNA was mixed with random hexamers and the total 
volume was adjusted to 12 µl. The mixture was incubated at 70° C for 5min. After 
the incubation, 4 µl of reaction buffer, 2 µl of dNTP mix, 1 µl of RiboLock RNase 
inhibitor and 1 µl of MuMLV reverse transcriptase polymerase were added. The tube 
was incubated in a PCR machine with the following conditions: 
10min 25°C 
60min 42°C 
10min 70°C 
After the synthesis was done, 30 µl of RNase-free water was added to the mixture. 
The cDNA was then stored at -20°C. 
 143 
 
4.2.12 Quantitative real time polymerase chain reaction (qPCR) 
The real time PCR was performed in two different real time PCR machines. The 
qPCR analysis is made by calculating the cycle threshold (CT) values and plotting 
them to a graph. The earlier a signal is detected, the more substrate was present in the 
sample. This can then be correlated with the amount of mRNA extracted from the 
cells and so levels of expression can be determined. 
The following procedure was performed when using the ABI PRISM 7000 Sequence 
Detection System from Applied Biosystems:  
The end concentration for each standard primer except the MLL-AF4 primers is 375 
nM. Standard primers were pre diluted to 100 µM each.  
Each MLL-AF4 primer was used at an end concentration of 62.5 nM. The MLL-AF4 
primers were pre diluted to 5 µM each. 
For the real time PCR on this machine the following mix was prepare in a 96-well 
plate: 
 
 
Master-mix using standard PCR primers: 
SYBR©Green (2x)   7.5  µl 
Primer fw  (100µM 375nM) 0.05  µl 
Primer rev (100µM 375nM) 0.05  µl 
dH2O     4.4  µl 
    ∑ = 12  µl 
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For MLL/AF4 primers the following mix has been prepared: 
SYBR©Green (2x)   7.5 µl 
Primer fw (5µM62.5nM) 0.15 µl 
Primer rev (5µM62.5nM) 0.15 µl 
dH2O     4.1 µl 
    ∑ = 12 µl 
Each sample was prepared in triplicate. 
In a 96-well plate 12 µl qPCR-Mix + 3 µl RT-PCR cDNA were mixed. 
After preparation, the plate was sealed, short-spun and put into the real time PCR 
machine (ABI PRISM 7000 Sequence Detection System, Applied Biosystems). 
 
The following program was used: 
 
50°C  2min   1 cycle 
95°C  10min____________________________________________ 
95°C  15sec  40 cycles 
60°C  1min 
 
The data were analysed with the programs ABI 7000 SDS and Microsoft Excel. 
For broader analysis of mRNA the ABI 7900HT Sequence detection system was 
used. This machine uses 384 well plates and therefore the units for each well 
changed. Primer concentrations remained the same as for the ABI PRISM 7000 
system. Each sample was prepared in triplicate. 
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Master-mix for all standard primers (except MLL-AF4) 
SYBR©Green (2x)   5  µl 
Primer fw  (100µM  375nM) 0.03  µl 
Primer rev  (100µM  375nM) 0.03  µl 
dH2O     2.94 µl       
     ∑ = 8 µl 
Master-mix for MLL-AF4 primers only: 
SYBR©Green (2x)   5  µl 
Primer fw (5µM  62.5nM) 0.1 µl 
Primer rev  (5µM  62.5nM) 0.1 µl 
dH2O     2.8 µl 
    ∑ = 8 µl 
 
In a 384 well multi-plate 8 µl master-mix together with 2 µl cDNA were prepared in 
triplets. Acquired data were analysed with the program SDS version 2.2 from 
Applied Biosystems. Additional to the data from the cDNA amplification, a 
dissociation curve was acquired. This curve shows at which temperature the 
amplicons dissociates and the curve shows specificity of the primer and detects 
unspecific products and primer dimers. 
4.2.13 Bradford assay 
Before analysing the protein, the protein concentration had to be determined. This 
was done by using the Bio-Rad protein assay. This assay uses colorimetry to quantify 
the amount of protein in a certain solution based on the Bradford method. The assay 
uses Coomassie Brilliant Blue G-250. During the assay, the red form of Coomassie 
interacts with the protein and denatures it. During the process the blue form of 
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coomassie becomes stable and the absorption shifts from 465 nm to 595 nm 
determined with a spectrometer. Briefly a standard curve was created using BSA (0 – 
10 µg/ µl). All samples were measured in triplicates. 10 µl of diluted samples and 
standards were mixed with 190 µl Bradford reagent in a 96-well plate and measured 
in a Spectramax 250 multi-well plate reader using the SOFTmax PRO analysis 
software (Molecular Devices).  
4.2.14 SDS Gel Electrophoresis and Western Blot 
For protein separation a SDS-PAGE (sodium dodecyl sulphate – polyacrylamide gel 
electrophoresis) was performed. For western blotting 20 - 30 µg protein were diluted 
with SDS-loading dye and separated on a polyacrylamide (PAA) gel. 
To get the right PAA solution, the two components acrylamide and bis-acrylamide 
had to be mixed in the ratio 19:1. While acrylamide forms long polymers, bis-
acrylamide cross-links the long polymers. The addition of 
tetramethylethylenediamine (TEMED) and ammonium per-sulphate (APS) starts the 
polymerisation. 
The loading dye contains SDS and DTT to denaturise the protein and to give it a 
negative charge. The protein was loaded into pockets in the gel and first run through 
the stacking gel to concentrate and even the protein distribution. After passing the 
stacking gel, the proteins were separated according to their size in the separation gel. 
Gels were run at 80V for 10 minutes and 120V for one hour or until the bromophenol 
blue band has reached the end of the gel. 
 
During the western blot procedure the proteins were transferred from the PAA gel to 
a Millipore Immobilon PDVF membrane. For this, a mini trans-blot system from 
BIO-RAD was used. The proteins were blotted for one hour at 400mA. Subsequently 
the membrane was incubated in Ponceau red for two minutes to check the blotting 
procedure for loading and possible bubbles. Ponceau red stains reversibly proteins 
and the membrane can be destained with TST or water. The gel was stained in 
colloidal coomassie overnight to visualise remaining proteins as a loading control. 
For blocking, the membrane was incubated in a 5% or 10% milk-TST solution for 
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one hour, depending on the experimental setup. Blocking a membrane can lower the 
risk of unspecific antibody binding. After blocking the membrane was briefly rinsed 
with TST and subsequently incubated with the primary antibody at 4°C overnight on 
a shaking or rolling platform. The next day, the membrane was washed three times 
for five minutes in TST and subsequently incubated with the secondary antibody for 
one hour at room temperature. After a repeating washing procedure the membrane 
was incubated with the detection solution (Millipore Immobilon Chemoluminescent 
HRP substrate) for five minutes. Signal detection was done by using x-ray films 
(Kodak) and an automatic film developer. 
 
4.2.15 Telomerase activity assay 
The PCR based telomerase assay (TRAP assay) was described elsewhere (Wege et 
al., 2003) and is a modified version of the classical TRAP assay published by Kim 
and colleagues in 1997 (Kim and Wu, 1997). The sample cells were lysed with a 
non-denaturising buffer. A PCR mix was prepared containing SYBR©Green and two 
primers ACX and TS. Those two primers mimic the telomere end and active 
telomerase binds to the primers and elongate them. The amplicons can be analysed 
with real time PCR. The amplicon cycle values (Ct) were compared with standard 
curve Ct-values generated from untreated cells. Figure 4-6 illustrates the basics of the 
qPCR based TRAP assay. 
 
For the standard curve 1x105 untreated cells were collected and pelleted by spinning 
at 250 g for 5 minutes at room temperature. Cells were washed once with 1 ml PBS. 
Cells were lysed in telomerase lysis buffer to an equivalent of 25 000 cells/µl lysis 
buffer. The cells were incubated on ice for 30 minutes. After successful lysis, the 
lysed cells were spun for 30 minutes at 4° C at full speed in a table top centrifuge (> 
10 000 g). 
Untreated cells were used for standard curve and the cell lysate was diluted 
corresponding to 50,000, 25,000, 10,000 and 5,000 cells. 
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25,000 treated cells were used for the analysis of the telomerase activity. 
 
The following mix was prepared. The protocol shows the mixture for a single well. 
Each sample was prepared in triplets: 
Primer Sequences (Kim and Wu, 1997): 
TS:  5'- AAT CCG TCG AGC AGA GTT -3’ 
ACX:  5’- GCG CGG [CTTACC]3 CTA ACC -3’ 
 
0.4 µM telomerase primer TS 
0.1 µM  anchored return primer ACX 
1x   SYBR Green master mix 
2 µl  lysate 
Ad 15 µl H2O 
 
RealTime PCR program: 
1 cycle: 
25°C  20min 
95°C  10min 
40 cycles: 
95°C  30sec 
60°C  90sec 
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Figure 4-6 Scheme of the TRAP assay 
This illustration shows the principle of the telomeric repeat amplification protocol (TRAP). 
Cells of interest are lysed in non-denaturising lysis buffer. After lysis the cell debris are 
removed and the lysate is transferred to a real time PCR 96-well plate. The transferred lysate 
volume is equivalent to the desired number of cells. Additionally to the lysate, a qPCR mix 
is added including primers TS and ACX. TS is designed so that the telomerase in the lysate 
recognises TS as telomere end and elongates it to “fake-telomeres”. After an elongation time 
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the qPCR starts and TaqPol amplifies the “fake-telomeres” with ACX as secondary primer. 
Results are then analysed with qPCR program SDS2.2 (Wege et al., 2003). 
4.2.16 Fluorescent activated cell sorting (FACS) 
FACS analysis was mainly used for analysing the cell cycle and monitoring GFP 
expression. 
During the cell cycle a cell divides into two. The cell cycle consists of four major 
phases which are the M phase, the G1 phase, the S phase and the G2 phase (Figure 4-
7). During the M phase (M for mitosis) the mitosis takes place which is the 
segregation of the chromosomes and finishes with the cytokinesis, the division of the 
cytoplasm. Following the M phase is the G1 phase. During this phase, the cell grows 
and starts to express the needed proteins. Next comes the S phase (S for synthesis), 
where the DNA is replicated in preparation for the next M phase followed by the G2 
phase which is like the G1 phase used to express proteins and cell growth. 
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Figure 4-7 The cell cycle 
The phases of the cell cycle. In the M phase mitosis and subsequently the cytokinesis take 
place. In the following phases continuous cell growth happens. During the S phase the DNA 
is being replicated. During G1 and G2 phase increasing cell growth and protein expression 
takes place. Some cells enter the G0 phase either temporarily or permanent. During this 
phase the cell cycle is on hold or completely switched off. Protein expression continues. 
During the G0 phase repair mechanisms also can also take place (Alberts, 2002). 
 
With DNA staining it is possible to monitor the distribution of cells within the cell 
cycle. As DNA content of each cell is increasing during the cell cycle, the analysis 
gives a typical result (Figure 4-8). 
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Figure 4-8 Typical distribution of cells within the cell cycle 
The picture represents SEM cells after 96 hour of continuous mock treatment. The y-axis 
represents the cell count and the x-axis shows the DNA content. Cells in the G1/G0 phase 
have a haploid set of chromosomes and thereby represent the population of viable cells with 
lowest DNA content. During the S phase the genome is replicated therefore the DNA content 
increases. In the G2/M phase the cells bear a diploid set of chromosomes and this is visible 
on the diagram as the peak for G2/M has the highest amount of DNA. When cells die the 
DNA degrades into smaller fragments. Therefore dying cells are represented in the Sub 
G1/G0 phase which has the lowest DNA content of all cells analysed during a FACS/Cell 
cycle experiment. During this representative experiment the cells were distributed as 
followed: 48.75% in G1/G0 phase, 35.33% in S phase, 15.92% in G2/M phase and 3.95% in 
the sub G1/G0 phase which represents the dead cells. Analysis was done with Mod Fit LT ™ 
(© Varity Software House) 
 
For cell cycle analysis 50,000 – 100,000 cells were harvested, washed in PBS once 
and resuspended in 100 µl citrate buffer. In a FACS tube 400 µl propidium iodide 
solution together with 3 µl RNaseA were prepared. The cells in the citrate buffer 
were added and incubated for 5 minutes. The cells were then analysed in a FACS 
machine (ABI FacsCalibur) using the programs CellQuest, Mod Fit and WinMDI. 
The green fluorescent protein (GFP) was first discovered in the jellyfish Aequora 
victoria and described by Osamu Shimomura and colleagues in 1962 (Shimomura et 
al., 1962). Over the years many mutants were biologically engineered which 
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increased the intensity of the emitted fluorescent light and also changed the 
excitation peak for better use in commonly used FACS machines. Today GFP is 
broadly used in cell biology as it is possible to combine the GFP gene to a gene of 
interest and so to receive an expressed fusion protein with an attached GFP signal. 
Thus it is possible to monitor protein expressing directly in a cell, for example the 
distribution during certain cell events. 
For eGFP expression, 100000 cells were harvested, washed with PBS once and 
resuspended in 500 µl PBS. The expression of eGFP was analysed in FacsCalibur 
machine using the programs CellQuest and WinMDI. 
 
4.2.17 ChIP – chromatin immuno precipitation 
 
The ChIP protocol was established in the Lab of P. Farnham (Weinmann and 
Farnham, 2002). 
 
Figure 4-9 The chromatin immuno precipitation (ChIP) 
The chromatin IP presented as an illustration. (A) A plasmid containing an expression 
cassette for FLAG tagged HOXA7 was transiently transfected into the nucleus of SEM target 
cells via nucleofection (Amaxa™ Nucleofection Kit®). (B) The FLAG tagged HOXA7 
protein binds to the DNA. (C) The protein-chromatin bindings are cross-linked and by 
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sonication the DNA is sheared into fragments between 500bp and 1000bp. (D) By incubation 
with an anti-FLAG antibody and subsequently performing a immuno precipitation reaction it 
is possible to isolate the cross-linked protein-chromatin complex. (E) After removing the 
protein by reverse cross-link reaction and purifying the DNA it is possible to analyse the 
DNA fragments with PCR. As a specificity control a plasmid expressing a FLAG tagged 
FHL2 protein was used. 
SEM cells were taken and transfected with 2 µg plasmid of pMSCVpuro-fHOXA7 or 
pFHL2-FLAG per 106 cells. The plasmids were transfected by electroporation with 
the Nucleofection Kit from AMAXA. 
One litre of Staphylococcus aureus (StaphA) bacteria (Cowan 1 strain, kindly 
provided by Prof. Andreas Peschl from the University of Tuebingen) were cultured 
overnight. When they reached an optical density of about 0.6 the bacteria were spun 
down and the pellet was resuspended in 10ml dialysis buffer followed by a 
centrifugation step with 5600g for 5min at 4°C. This step was done twice. The 
bacteria were then resuspended in 3ml of 1xPBS with 3%SDS and 10% β-
Mercaptoethanol and boiled for 30min. The bacteria were then again twice 
centrifuged and resuspended in 10ml dialysis buffer. In a final step the bacteria were 
resuspended in 4ml dialysis buffer and divided into 100 µl aliquots, quickly frozen in 
liquid nitrogen and stored at -80°C. 
For one ChIP assay a single vial of StaphA cells was thawed. 10 µl of herring sperm 
DNA (10mg/ml) and 10 µl of BSA (10mg/ml) were added to preclear the bacteria 
overnight at 4°C on a rotating platform. The next day the precleared bacteria cells 
were centrifuges for 3min at full speed (> 10000g) and the supernatant was discarded. 
The pellet was washed twice with 1x dialysis buffer and was then resuspended in 100 
µl 1x dialysis buffer. 
Cross linking the chromatin was done by incubating the transfected SEM cells with 
formaldehyde (1% end concentration) for 10min at 37°C. The reaction was stopped 
by adding 1/10 vol. of 1.25M glycine. The cells were spun down, washed once with 
PBS and resuspended in the cell lysis buffer. After 10min incubation on ice, the 
nuclei were collected by spinning the cell lysate at 5000rpm for 5min at 4°C. The 
supernatant was discarded; the pellet was resuspended in nuclei lysis buffer and 
incubated on ice for 10min. Each sample was subsequently sonicated 5 times 
alternately with a two minute break in between for 10 seconds (= 10 pulsed) with the 
following settings: Duty cycle 50, output 5. After sonication the samples were 
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centrifuged at 10000g for 10min at 4°C. The lysates were then incubated with 15 µl 
pre blocked StaphA cells for 15min at 4°C. The lysates were spun down and the 
supernatants collected. To the precleared lysates 1 µl of anti-FLAG antibody or no 
antibody (control) was added and incubated on the rotating platform at 4°C overnight. 
On the following day to each lysate 15 µl of precleared bacteria cells were added and 
rotated for 15min at 4°C. Subsequently all samples were centrifuged at 10 000g for 
3min. The supernatant of the antibody control was collected as chromatin input 
control, the other supernatants were discarded. For washing the pellets, 1.4ml 
dialysis buffer was added to the samples, rotated for 3min and subsequently 
centrifuged at 10000g. The supernatants were discarded. This washing step was 
performed 5 times. The whole washing process was then performed using IP wash 
buffer. After the last wash, the pellets were resuspended in 150 µl IP elution buffer 
and vortexed strongly. The samples were centrifuged at 10,000g for 3min at room 
temperature and the supernatants collected in new tubes. The elution step was then 
performed a second time with the bacteria pellets and the supernatants were merged. 
The reverse cross linking was performed by adding NaCl (200 mM end 
concentration) and 10 µg RNaseA followed by 5 hour incubation at 67°C. The 
samples were then precipitated overnight by adding 2.5 volume of absolute ethanol at 
-20°C. On the next day, the samples were centrifuged at 10 000g at 4°C for 20min 
and resuspended in 100 µl TE buffer. Subsequently 25 µl of 5x proteinase K buffer 
and 5 µl proteinase K was added and incubated for 1 hour at 45°C. The chromatin 
was then isolated with phenol-chlorophorm-isoamyl alcohol extraction (25:24:1) 
followed by chloroform-isoamyl alcohol extraction (24:1). After precipitation with 
1/10 vol. of 3M NaAc and 2.5 vol. absolute ethanol the chromatin pellets were air 
dried, resuspended in 30 µl of water and analysed by PCR. 
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4.2.18 Production of recombinant pseudotyped lentivirus 
The process of the lentiviral production is based on a protocol from D. Trono’s 
Laboratory of Virology and Genetics (EPFL, Lausanne, Switzerland). The protocol 
was modified by Vasily V. Grinev from the University of Minsk (Department of 
Genetics, Biology Faculty, Belarusian State University, Minsk, Belarus). 
The cell line 293T was used as lentivirus producer cell line. One day before 
transfection, 2-3x106 viable 293T cells were seeded in a 100mm Tissue Culture dish 
in 10ml DMEM medium, completed with 10%FCS and 2mM L-Glutamine and 
cultured overnight in an incubator (5% CO2, 37°C, 95% air humidity).  
On the day of transfection the cells had a confluence of about 30%. The method for 
transfection was by calcium precipitation. For each lentiviral plasmid the following 
mix was prepared. In an Eppendorf tube, 5 µg of the pMD2.G envelope plasmid, 15 
µg of the pCMVdeltaR8.91 packaging plasmid and 20 µg of the third generation 
lentivirus transfer plasmid were mixed with special water (125µl of 1M pH 7.3 
HEPES solution dissolved in 50 ml water) and 0.5M CaCl2 solution to an end 
volume of 500 µl. This solution was then mixed very slowly with 500 µl 2xHeBS. 
The prepared mix was then incubated for 30min at RT so that the precipitates can 
form. Subsequently the mix was added slowly; drop wise on the 293T cells. The 
plate was gently stirred and placed back in the incubator and cultivated overnight. On 
the next day, a fine, sandy precipitate was visible all over the plates but not in the 
surroundings of the cells. A very careful medium change was done to minimize any 
damaging to the cell monolayer. The cells were then incubated under standard 
conditions for 3 more days. On the third day the medium was collected and spun 
down (500g, Beckman Coulter Allegra® X-12 benchtop centrifuge) to get rid of any 
cells. The supernatant was again collected and filtered through a 0.45µm filter to 
remove any remaining cell debris. To concentrate the virus, the solutions were 
transferred into Beckman Instruments Inc thickwall-style polyallomer conical tubes 
(ref. 358126) with Derlin PKGED’1 adapters (ref. 358156). The tubes were filled up 
to 30ml with medium and then put into a SW 28 swinging bucket rotor and spun at 
26,000 rpm (120,000 g) for 120 min at +4°C in a Beckman ultracentrifuge. The 
supernatant was discarded and the virus pellet was resuspended in medium according 
to the experimental design. Figure 4-10 gives an overview about the process. 
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4.2.19 Lentiviral transduction of suspension cells 
One day prior to the transduction, 2x106 cells per lentiviral transduction were seeded 
to a well of a 6-well plate in 2 ml complete medium. On the day of transduction, 1ml 
containing the recombinant virus particles was added to each well, according to the 
experimental setup. The virus titer was not determined. The plates were sealed with 
parafilm, wrapped in cling film and centrifuged at 1500g for 2h at 32°C. The cells 
were then put into an incubator at standard conditions overnight. The next day the 
cells were collected, washed with PBS once and resuspended in 3ml of fresh medium 
to remove any unbound lentiviral particles. Then the cells were treated under 
standard conditions. 
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Figure 4-10 Illustration of lentivirus creation and transduction of target cells 
In this scheme the production of the lentiviruses followed by the transduction of target cells 
is demonstrated. 293T cells are being transfected with three plasmids containing all genetic 
information for creating a virus with the gene of interest. In those 293T cells, the viruses is 
produced and secreted into the medium. The lentiviruses are harvested and concentrated for 
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the transduction which is the last step for the successful transduction of genetic material into 
a target cell. 
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5.2 List of abbreviations 
 
AD  transcriptional activation domain 
AF4  ALL-1 fused gene on chromosome 4 
ALL  acute lymphoblastic leukaemia 
ALT  alternative lengthening of telomeres 
AML  acute myeloblastic leukaemia 
APS  ammonium persulphate 
AT-H  AT Hook 
ATP  adenosine triphosphate 
BCR  breakpoint cluster region 
bp  Base pair 
BSA  bovine serum albumin 
CD  cluster of differentiation 
cDNA  complementary desoxyribonucleic acid 
CHAPS 3[(3-Cholamidopropyl)dimethylammonio]-propanesulfonic acid 
CHD  C-terminal homology domain 
ChIP  chromatin immunoprecipitation 
CIAP  calf intestinal alkaline phosphatase 
CLL  chronic lymphoblastic leukaemia 
CML  chronic myeloblastic leukaemia 
cPPT  central polypurine tract 
CR  complete remission 
DMSO  demethylsulphoxide 
DNA  desoxyribonucleic acid 
dsRNA double stranded ribonucleic acid 
DTT  Ditiotreitol 
EDTA  Ethylene diamine tetraacetic acid 
EFS  event free survival 
eGFP  enhance green fluorescent protein 
EGTA  ethylene glycol tetraacetic acid 
FACS  fluorescent activated cell sorting 
Fw  forward 
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GAPDH glycerine aldehyde 3 phosphate 
GFP  green fluorescent protein 
H3K4  histone 3 lysin 4 
H3K79 histone 3 lysin 79 
HDAC  histone deacetylase 
HOX  homeobox 
HRP  Horse radish peroxidase 
HSC  hematopoietic stem cell 
IRES  internal ribosomal entry site 
LTR  long terminal repeat 
MEF  murine embryonic fibroblast 
miRNA micro ribonucleic acid 
MLL  mixed lineage leukaemia 
MT  methyltransferase domain 
NHD  N-terminal homology domain 
NLS  nuclear localisation sequence 
NOD/scid nonobese diabetic severe combined immunodeficiency 
NP40  nonyl phenoxylpolyethoxylethanol 
ORF  open reading frame 
PAA  poly acryl amide 
PAGE  polyacrylamide gel electrophoresis 
PBS  phosphate buffered saline 
pcG  polycomb group 
PCR  polymerase chain reaction 
PHD  plant homeodomain 
PI  propidium iodide 
PIPES  piperazine-N,N′-bis(2-ethanesulfonic acid) 
Pol II  RNA polymerase II 
pSer  proline-serine rich region 
PVDF  Polyvinyliden flouride 
qPCR  quantitative polymerase chain reaction 
qRT-PCR quantitative reverse transcription polymerase chain reaction 
RB  retinoblastoma 
Rev  reverse 
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RISC  ribonucleic acid induced silencing complex 
RNA  Ribonucleic acid 
RRE  rev responsive element 
RT  room temperature 
RT-PCR reverse transcription polymerase chain reaction 
SDS  sodium dodecyl sulphate 
SET  Su(var)9-3, Enhancer of Zeste and trithorax histone methyltransferase 
domain 
SFFV  spleen focus forming virus 
SL-IC  scid leukaemia – initiating cell 
SIN  self inactivation 
siRNA  small interfering ribonucleic acid 
t(4;11)  reciprocal translocation between chromosome 4 and chromosome 11 
TEMED tetramethylethylenediamine 
TERC  telomerase ribonucleic acid component 
TERT  reverse transcriptase of the telomerase 
TRAP  telomeric repeat amplification protocol 
trxG  trithorax group 
WPRE  woodchuck posttranscriptional regulatory element 
zVAD-FMK carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone 
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5.3 Abstract 
The t(4;11) fusion protein MLL/AF4 regulates TERT expression 
About 50% of all infants suffering from acute lymphoblastic leukaemia (ALL) show 
the translocation t(4;11)(q21;q23) which creates the fusion genes MLL/AF4 and 
AF4/MLL. This reciprocal translocation identifies a therapy resistant form of 
leukaemia with a poor prognosis. In order to gain a better insight into the molecular 
mechanisms of t(4;11) leukaemias we used the two ALL cell lines SEM and RS4;11, 
both harbouring the t(4;11) translocation, however with different fusion sites. 
Specific small interfering RNAs (siRNAs) against the two fusion site variants of the 
MLL/AF4 fusion transcript were designed and transfected into the respective cells via 
electroporation, using very mild conditions. Serial electroporations at two-day 
intervals resulted in sustained depletion of the MLL/AF4 transcript up to 70-80%, and 
depending on the experimental setup, cells were analysed after two or three 
electroporations. Knock-down of MLL/AF4 resulted in strong inhibition of 
proliferation and clonogenicity in the two t(4;11)-positive cell lines SEM and RS4;11, 
along with induction of apoptosis. MLL/AF4 depletion resulted in a 65% decrease in 
telomerase activity in both SEM and RS4;11 cells, with telomerase reverse 
transcriptase (TERT) expression being reduced twofold on both transcript and protein 
levels. Notably, TERT reduction was even stronger (90% depletion) when apoptosis 
caused by MLL/AF4 knock-down was suppressed with the caspase inhibitor zVAD. 
In contrast, levels of the RNA component of the telomerase, TERC, were not affected 
by MLL/AF4 knock-down. Additionally, MLL/AF4 knock-down was associated with 
reduced expression of several members of the HOXA gene cluster, HOXA6 (65% 
reduction), HOXA7 (85% reduction), HOXA9 (60% reduction) and HOXA10 (75% 
reduction). Interestingly, siRNA-mediated knock-down of the MLL/AF4 target gene 
HOXA7 also induced apoptosis and resulted in a 70% decrease of TERT levels in two 
t(4;11) positive cell lines without affecting MLL/AF4. Chromatin 
immunoprecipitation assays revealed HOXA7 binding to the promoter of TERT. 
Therefore, MLL/AF4 regulates TERT expression, at least in part, via HOXA7. These 
data suggest that t(4;11) positive cells with substantially lower TERT expression 
undergo apoptosis, and that TERT may play an antiapoptotic role in t(4;11) positive 
ALL. Furthermore, these studies identify TERT as a putative new therapeutic target 
in this therapy-resistant infant leukaemia.  
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